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Abstract 
The calcium activated cysteine protease calpain-I has a pivotal role in a variety 
of physiological processes within the human body. In particular calpain-I 
enables the cell spreading and subsequent chemotaxis behaviour of neutrophils 
in response to tissue damage. Neutrophils are linked to the pathological 
condition rheumatoid arthritis and so calpain-I is considered be a valuable 
therapeutic target. Many inhibitors of calpain-I are highly non-selective with the 
exception of two small molecule synthetic inhibitors. A phenyl and an indole-
based α-mercaptoacrylic acid have shown a slight selectivity towards calpain-I 
over other cysteine proteases. 
In this work 24 novel monohalogenated α-mercaptoacrylic acid inhibitors were 
prepared based on these lead structures using Vilsmeier-Haack chemistry 
followed by Knoevenagel condensation of the resulting aromatic aldehydes as 
key steps. The thiols within the α-mercaptoacrylic acid moiety demonstrated a 
tendency to form disulfide bridges in solution. Analysis of this disulfide 
formation through 1H NMR spectroscopy, UV-Vis spectrophotometry and HPLC 
showed that the monomeric form was active under the reducing conditions 
used in subsequent assays. 
The analogues were tested as inhibitors of calpain-I revealing that bromoindole 
based inhibitors were the most potent. Selected compounds showed ~10 fold 
selectivity towards calpain-I versus calpain-II. In live neutrophils they were 
capable of slowing the cell spreading process by up to 70%. When live 
neutrophils containing the inhibitor were irradiated with 410 nm light, the cells 
completely lost the ability to spread.  
To show that these compounds were allosteric inhibitors the calcium binding 
domain PEF(S) was expressed in E. coli and purified using anion exchange 
chromatography and size exclusion chromatography. Solution of X-ray co-
crystal structures of the calpain PEF(S) domain with two different inhibitors 
revealed that they bind to the protein in a similar fashion as an α-helical domain 
of calpastatin, the endogenous inhibitor of calpain. 
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1.1 Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is one of the most common forms of inflammatory 
arthritis and one of the most prevalent autoimmune diseases.1 It is an 
autoimmune condition where the body’s natural defence mechanism becomes 
over stimulated and attacks the body itself.2 Though the exact causes of RA are 
unknown, there are links to both genetics3 and environmental factors such as 
smoking.4 The damage that occurs through RA causes severe pain and disability 
to the patient and through development of secondary conditions, such as 
cardiovascular disease and pulmonary fibrosis, leads to an increased mortality 
rate.5, 6  The condition is known to affect approximately 1% of the world’s 
population and in the UK alone costs the economy almost £8 billion each year 
(2010 figures).6, 7  
In RA, the joints are attacked at the synovial membrane by a number of 
leukocytes and lymphocytes (white blood cells). This process is thought to be 
initiated via a specific subset of lymphocytes known as T cells, more specifically 
T-helper cells.8  T-helper cells are activated in response to antigen presenting 
cells found within the synovium.8 The presence of these cells causes an influx of 
macrophages,9 a form of leukocyte, into the synovial lining. As a consequence 
the release of cytokines is stimulated.8, 10, 11 These pro-inflammatory cytokines, 
such as TNFα and interleukin-1, act as signalling molecules for the attraction 
and activation of other leukocytes and lymphocytes to the area, such as 
neutrophils, chondrocytes and fibroblasts12 The activated chondrocytes and 
fibroblasts secrete metalloproteases and reactive oxygen species that damage 
the cartilage and tissue within the surrounding area.8 The constant 
bombardment of white blood cells eventually causes the formation of granular 
pannus tissue, which grows over the articular cartilage.6, 13 This pannus tissue is 
composed of synovial fibroblasts and mononuclear cells and leads to further 
destruction of the cartilage and bone due to the high concentration of 
metalloproteases (Figure 1.1).13-15 In addition the synovial fluid within the joint 
increases in volume and decreases in viscosity leading to the loss of lubrication 
within the joint and further damage (Figure 1.1). Synovial fibroblasts within the 
arthritic joint can also spread to other previously unaffected joints.16 
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The role of the neutrophil, a polymorphonuclear granulocyte, is generally 
forgotten within rheumatoid arthritis.17 Neutrophils, the most abundant form of 
white blood cells, are found within the joint, with the highest populations found 
within the synovial fluid.15, 18, 19 Neutrophils contain granules that release their 
toxic contents into the surrounding area and therefore can cause severe damage 
to the cartilage and bone (Section 1.2).17, 20, 21 
  
Figure 1.1: Image depicting the damage caused to a hand afflicted with rheumatoid arthritis 
(top) in comparison to a normal hand (bottom). A diagram representing a joint with one side 
afflicted with rheumatoid arthritis (right) and the normal joint (left).1 
1.2 Neutrophils 
Neutrophils are a granular leukocyte and are the most abundant group in the 
immune system making up 40-65% of all white blood cells.22 They are typically 
the first cells to reach the site of infection or inflammation.22 Granular 
leukocytes are so called as they contain cytoplasmic granules, the contents of 
which are highly toxic towards foreign bodies (e.g. microbes).22 These granules 
contain a wide variety of proteinases and hydrolases as well as proteins that 
have the capability to generate reactive oxygen species (ROS).21 Upon normal 
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activation at the site of action, the cells are phagocytic and encapsulate the 
foreign bodies in a vacuole. Neutrophils are 12-15 µm in circumference and are 
capable of encapsulating up to eight separate zymosan particles, which are 1-2 
µm in circumference.23 The cell then releases the contents of the granules into 
the vacuole formed; it is these contents that destroy the foreign body (Figure 
1.2).21, 24, 25 Neutrophils have a relatively short lifetime of 5-7 days within the 
body.22 Once a cell has reached the end of its life cycle it undergoes apoptosis 
and the remnants of the neutrophil are taken up by macrophages.25 
 
Figure 1.2: A neutrophil undergoing phagocytosis and upon consuming the microbe releasing 
granules into the vacuole containing the microbe, these granules contain proteases, hydrolases 
and reactive oxygen species (ROS).21, 22 
To reach a site of damage or infection neutrophils must migrate across several 
tissue barriers beginning with blood vessel walls. Initially neutrophils detect 
small molecule chemoattractants, for example N-formyl peptides and 
interleukin-8, which are released by cells in the damaged area.22, 26, 27 Through 
detection of these chemoattractants the neutrophils are triggered to migrate 
towards the site and stimulate the activation of integrins, cell adhesion 
molecules.27 Migration of neutrophils from the bloodstream occurs after the 
cells have undergone a rapid shape change to adhere to the endothelium of the 
Introduction 
5 
 
blood vessel and extrude themselves across the tissue barrier.23, 28 In the 
bloodstream neutrophils are roughly spherical in shape with the cell surface 
membrane comprised of numerous wrinkles all along the surface, these 
wrinkles are held together through two different protein scaffolds.23 L-selectin 
and β2-integrin are bound in the membrane and are localised upon the peaks 
and valleys of the wrinkles in the cell membrane,  respectively (Figure 1.3).28 It 
is postulated that the glycoprotein L-selectin is bound to the intracellular 
protein actin through a protein ‘bridge’ ezrin.23, 29 Actin is bound to the 
membrane bound protein β2-integrin through talin. This model is based upon 
what has been reported for the wrinkles found within lymphocytes (Figure 
1.3).23, 29 In response to the chemoattractants calcium (Ca2+) is released. The 
release of calcium leads to the activation of the cystolic cysteine protease 
calpain-I (Section 1.5) at the plasma membrane.30, 31 The activated protease 
then cleaves the proteins holding the wrinkles in place (talin and ezrin) 
allowing the cell membrane to spread and flatten (Figure 1.3).23, 32-34 Once the 
neutrophil has spread the L-selectins and β-integrins are capable of interacting 
and adhering to membrane bound proteins on the endothelial wall.22 The 
neutrophil then undergoes chemotaxis, whereby the cell migrates towards an 
ever increasing concentration of chemoattractants.35 In order to move the 
neutrophil forward the actin filaments below the cell membrane are used as 
protrusions that push the membrane forward.22, 36 Detachment at the rear of the 
neutrophil occurs via the recycling of β-integrins towards the ‘front’ of the cell 
with the aid of calcium and calcineurin.37 The process of chemotaxis occurs until 
the site of damage is reached.35 
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Figure 1.3: The structure of a neutrophil in the bloodstream with wrinkles on the cell surface 
membrane. Detailed structures of the individual wrinkles with L-selectin/β2-integrin bound to 
ezrin/talin which is bound to the intracellular protein actin (peak of the wrinkle/‘valley’ of the 
wrinkle).23  
1.3 The Calpain Family  
The calpain family is a group of calcium activated cysteine proteases within the 
papain super-family.38, 39 As well as calpains the papain superfamily consists of 
bleomycin hydrolases and papains.38, 40 The calpain family has 15 known 
isoforms which all contain the catalytic active site known as the CysPc domain 
(Section 1.6.2).41 Some of these isoforms are ubiquitously expressed throughout 
the human body, such as the two most studied members calpain-I and calpain-
Introduction 
7 
 
II;42 others are tissue specific, such as calpain-III (p94), which is found in the 
skeletal muscle.43 This family comprises two subsets; the classical calpains, of 
which there are nine known isoforms that are solely activated by calcium and 
are structurally similar. The second subset are the non-classical calpains, these 
isoforms possess calcium binding properties but also feature other activation 
methods such as zinc finger domains.44 Calpains are modulator proteases 
meaning that instead of hydrolysing a protein substrate to destroy it, such as 
caspases and proteasomes, they modify and repurpose proteins to alternate 
functions within the body.41 
1.4 Cysteine Protease – The mechanism of action 
 
Figure 1.4: General mechanism of the hydrolysis of a peptide bond within the active site of a 
cysteine protease.45 
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To catalyse the hydrolysis of the target proteins, cysteine proteases use a 
cysteine residue within a catalytic triad that is completed with a histidine and 
an asparagine residue.46 The asparagine is utilised to manoeuvre the histidine 
residue into the correct position to act as a base for deprotonation of the 
sulfhydryl of the cysteine residue (Figure 1.4).45 The nucleophilic thiolate then 
attacks the carbonyl group of the target peptide bond (Figure 1.4).45 The 
incorporation of water then completes the hydrolysis and the peptide bond is 
cleaved and the cysteine residue is regenerated to carry out further hydrolysis 
(Figure 1.4).45 
1.5 Calpain-I and calpain-II 
Calpain-I and calpain-II are heterodimeric proteins composed of a large subunit, 
known as CAPN1 and CAPN2 respectively, and a small subunit known as 
CAPNS1.44 CAPN1 comprises 714 amino acids (MW 81,889)47 which is 14 more 
than CAPN2 (MW 80,005).48 The sequence similarity between the large 
subunits of these two isoforms of calpain is 62%.48 CAPNS1, also known as the 
regulatory subunit, is composed of 268 amino acids (MW 28,316) and is 
identical in both calpain-I and calpain-II.49 The large subunit comprises four 
domains and the small subunit two (Figure 1.5).50  The N-terminal domain is the 
anchor α-helix (Section 1.6.1), this is followed by the proteolytic core of the 
enzyme known as the CysPc domain. The CysPc domain is divided into two 
halves, known as PC1 and PC2 (Section 1.6.2).41, 51 The third domain is the C2L 
domain and is similar to the C2 phospholipid binding domains found in 
phospholipases (Section 1.6.3).41, 51, 52 The fourth domain within the large 
subunit is a calcium binding domain that is composed of five EF hand motifs 
four of which bind calcium ions; it is known as the PEF(L) domain (Section 
1.6.4).41, 51 The two domains that are found in the small subunit (CAPNS1) are 
the N-terminal glycine rich (GR) domain (Section 1.6.5) and the PEF(S) calcium 
binding domain, which is also composed of five EF hand motifs (Section 
1.6.4).41, 51  
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Figure 1.5: (A) Domain structure of CAPN1 and CAPN2 along with the CAPNS1. (B) A secondary 
structure representation of inactive CAPN2 (PDB:1KFU).53 The large subunit; the anchor helix 
(orange), CysPc (cyan), C2L (red) and PEF(L) domain (blue). Small subunit; GR domain (purple) 
and PEF(S) domain (green). Image rendered in PyMOL as are all subsequent protein images.54 
The most significant functional difference between calpain-I and calpain-II is 
the concentration of calcium ions that is required for activation.50 ~50 µM of 
calcium is required for the activation of calpain-I where as ~0.35 mM of calcium 
is required for the activation of calpain-II.50 These required concentrations of 
calcium give rise to the two other names for these isoforms; μ-calpain and m-
calpain. The concentration of calcium required to activate these two isoforms 
was measured in vitro and both are higher than the levels of calcium ions that 
are found in vivo. Hence there must be other factors that come into play for the 
activation of these proteases within the body, such as the binding of activator 
proteins (Section 1.8).55 Both of these isoforms of calpain are inhibited by the 
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same regulatory endogenous inhibitor, calpastatin (Section 1.7), a highly 
specific inhibitor for conventional calpains.56  
1.6 Domain structure 
To date there are only full length X-ray structures published for calpain-II. 
These have enabled the classification of the domains within the structure 
(Section 1.5). There is only a hybrid crystal structure of calpain-I currently 
available, which contains the N-terminal helix and PEF(L) domains of calpain-II 
and the the CysPc and C2L domains of calpain-I.57 The calpain-I-like structure 
was very similar to that of calpain-II so the structural analysis of the individual 
domains (Sections 1.6.1 to 1.6.5) will be based on the structures of calpain-II. 
53,55,57   
1.6.1 The N-terminal anchor α-helix 
Situated at the N terminus of the protein, the anchor α-helix domain is a small 
domain of 19 residues in CAPN2 (Figure 1.6) and leads into the CysPc domain, 
the proteolytic core (Section 1.6.2).53 The sequence alignment of CAPN1 with 
CAPN2 indicates that this anchor α-helix is ten residues longer in CAPN1 than 
CAPN2, though there is no published structure demonstrating the purpose of 
this.58 The increase in the length of this domain, in calpain-I, has been shown to 
account for ~20% of the difference in the concentrations of calcium that is 
required for the activation of the two isoforms.59 The first 40 residues of 
calpain-II were substituted with those of calpain-I and the concentration of 
calcium that was required to activate the protease was reduced to 250 μM. 
Prior to calpain-II activation, the α-helix interacts with the PEF(S) domain 
(Section 1.6.4) (Figure 1.6), which enables clamping of the two subunits 
together.53 Numerous hydrophobic residues from the PEF(L) domain and the 
anchor α-helix interact with one another to stabilise the inactive conformation 
of the protease.60 Upon activation of calpain-II, the α-helix is released relieving 
some of the restraints that hold the two halves of the CysPc domain apart. The 
release of the α-helix is proposed to be followed by autolysis. Autolysis enables 
activation of calpain-II with a lower concentration of calcium ions.61 However 
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this autolysis also causes the heterodimer to become unstable and dissociation 
occurs, which in turn may lead to a loss of substrate specificity for calpain-II.62  
 
Figure 1.6: (A) A secondary structure representation of the 19 residue N-terminal α-helix of 
anchor in orange. (B) The interaction between the anchor helix and PEF(S) that, amongst other 
interactions, holds the catalytic active site open.53  
1.6.2 The CysPc proteolytic domain 
This proteolytic domain is where the catalytic triad, cysteine (Cys), histidine 
(His) and asparagine (Asn), is situated. This domain is composed of two 
subdomains that are known as PC1 and PC2.44 PC1 contains the catalytically 
active Cys residue and PC2 completes the catalytic triad with the His and the 
Asn.53, 60 These two subdomains are found in both calpain-I and calpain-II. The 
catalytic triad is composed of Cys 115, His 272 and Asn 296 in calpain-I,50 
whereas in CAPN2 the catalytic triad is at positions Cys 105, His 262 and Asn 
286.63 The secondary structure of this domain shares significant topology with 
papain, hence its inclusion in the papain superfamily, where the residues that 
are found within the immediate vicinity of the active site of calpain are very 
similar to those that are found in papain.53, 60 
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The secondary structure of the PC1 subdomain is composed of two anti-parallel 
β-sheets and a series of α-helices.60 In the structure of calpain-II the Cys is 
situated in a short α-helix.60 PC2 is also composed of a series of inter-connected 
α-helices and two anti-parallel β-sheets.60 The residues of the catalytic triad are 
situated on the interface between PC1 and PC2.   
 
Figure 1.7: (A) A secondary structure representation of the CysPc domain of calpain-II and its 
position within the protease, highlighted in cyan. (B) The catalytic triad in the inactive 
conformation of the CysPc domain of calpain-II, with the distance between the C105 and H286 at 
8.47 Å.53  
When calpain-II is inactive the catalytic triad is held apart through structural 
restraints, with Cys105 and the His262 are held 8.5 Å apart from one another in 
calpain-II (Figure 1.7).53 One of these structural restraints is the anchoring helix 
bound to the PEF(S) domain. The binding of calcium ions to PEF(S) causes 
structural movement of this domain, which in turn releases the anchor α-helix 
releaving the structural restraints.60 Another set of structural restraints is the 
negatively charged loop of the C2L domain that interacts with a series of 
positively charged residues in the PC2 subdomain. Upon binding calcium these 
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electrostatic interactions are released to allow for PC1 and PC2 to move 
towards one another and form the active form of the protease (see Section 
1.6.3) (Figure 1.8).64 The CysPc domain binds two calcium ions which 
contributes to the movement of the separated portions of the catalytic triad 
towards one another for catalysis to occur (see Section 1.8 for further 
discussion).65 
1.6.3 The C2L domain 
This 130 residue domain has a β-sheet based secondary structure and it acts as 
a bridge between the CysPc domain (Section 1.6.2) and the PEF(L) domain 
(Section 1.6.4). The C2L domain folds into a pair of four stranded parallel β-
sheets and is broadly similar to the structure of C2 binding domains.60 C2 
binding domains are known to bind to phospholipids but for this to occur there 
is a precursor step where the domain binds calcium.66 The C2L domain contains 
a negatively charged loop (Figure 1.8) that comprises residues 392 to 402 in 
calpain-II and residues 403 to 414 in calpain-I. When the whole of the C2L 
domain is expressed separately from the rest of the enzyme it does bind calcium 
with an affinity similar to PEF(L) (Section 1.6.4).67 The C2L domain has a higher 
affinity for calcium when phospholipids are also bound to the domain.67 The 
phospholipid binding nature of this domain gives evidence of how the protease 
is capable of migrating from the cytosol, to the site of action at the membrane 
where activation of the enzyme occurs.68 The calcium binding nature of the C2L 
domain has been contradicted with structural evidence where the acidic loop 
appears not to bind calcium in a crystal structure of calpain II bound with its 
endogenous inhibitor, calpastatin (Section 1.7) despite calcium ions being 
present elsewhere in the structure.69 
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Figure 1.8: (A) A secondary structure representation of calpain-II C2L domain, in red, (B) a close 
up of the negatively charged loop (residues 392 to 402) and its interactions with the positively 
charged residues in CysPc that keep the protease in an inactive conformation (PDB:1KFU).53  
The negatively charged loop, of the C2L domain, interacts with a series of 
positively charged lysines found in CysPc domain (Figure 1.8). These 
interactions hold the cleft between PC1 and PC2 open and therefore keep the 
protease in an inactive conformation.64 Another negatively charged residue 
which is situated on the linker between the CL2 domain and the PEF(L) domain, 
Glu504, interacts with Lys230 in PC2 subdomain.70 Mutations to the negatively 
charged loop and Glu504 cause lowering of the concentration of calcium that is 
required for activation in vitro, demonstrating that these electrostatic 
interactions are integral for keeping the protease in its inactive form.70 Upon 
activation, disruption of the electrostatic interactions occurs allowing the active 
site to ‘close’ and proteolysis to occur.  
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1.6.4 PEF(L) and PEF(S) domains 
These two domains are both calcium binding domains. PEF(L) is at the C-
terminus of the large subunit and PEF(S) is one half of the small subunit.44 Both 
of these domains are composed of five EF-hands.53, 60  
 
Figure 1.9: A secondary structure representation showing the position of calpain PEF(L) in blue, 
and PEF(S) in green, within the whole protein structure (PDB:1KFU).53 
EF-hands 
EF hands are composed of two perpendicular α-helices that are linked together 
through an interhelical loop, the loop contains residues that coordinate a single 
calcium ion (Figure 1.10).71 EF-hands (EFH) contain the X • Y • Z • -Y • –X • • –Z 
motif that is indicative of a calcium binding domain. Where X, Y, Z, -X, -Y and – Z 
are coordination ligands of calcium and the dots represent the intervening 
residues in the EF hand sequence.72 Typical coordinating functional groups are 
the carbonyls of the peptide bond, or negatively charged side chains such as the 
carboxylates of aspartate or glutamate, or hydroxyl groups such as in 
threonine.73 To complete the coordination of the calcium ion other molecules, 
such as water, may also be used.73 There are two forms of the EF-hand loop; the 
canonical and the non-canonical loop, both of which are found within PEF(L) 
and PEF(S) of calpain-I and calpain-II (Table 1.1).74 
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EF-hand Motif X * Y * Z * -Y * -X * * -Z 
EFH-2 domain VI 
(Canonical) 
D S D T T G K L G F E E 
EFH-1 domain VI 
(Non-Canonical) 
L A G D D M E V S A T E 
Table 1.1: Sequence alignment of a canonical (EFH-2 of PEF(S)) and a non-canonical (EFH-1 of 
PEF(S)) against the EFH binding motif, these sequences are from rat calpain-II.74 
The canonical EF-loop uses the calcium binding motif noted above, where five 
residues of the six bind to the calcium ion. The pentagonal bipyramidal 
structure is completed with the presence of a water molecule.75 EFH-2 of 
domain VI clearly demonstrates canonical binding; with X, Y, Z, -Y and –Z 
represented by residues within the peptide sequence; Asp154, Asp156, Thr158, 
Lys160 and Glu165 (Figure 1.10).74 In the case of Lys160 the carbonyl from the 
peptide backbone is used to coordinate the calcium ion. –X is not represented 
by a residue but is instead replaced with a water molecule for the completion of 
the pentagonal bipyramid coordination.74 
With non-canonical binding of a calcium ion the length of the peptide chain is 
generally shorter than 12 residues.73 Therefore fewer side chains and carbonyls 
are used for binding and extra water molecules are required to complete the 
coordination of calcium.73 An example of a non-canonical binding motif is EFH-1 
of PEF(S), with 11 residues within the coordinating sequence as opposed to the 
12 residues found in the canonical sequence (Table 1.1).74 The coordinating 
residues are Ala111, Asp114, Glu116 and Glu121, with the carbonyls of the 
peptide backbone of Ala111 and Glu116 coordinating the Ca2+ ion (Figure 1.10 
(B)).74 The coordination sphere is completed with two water molecules (Figure 
1.10 (B)).74  
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Figure 1.10: (A) A secondary structure representation of the full structure of an EF-hand with the 
helices perpendicular and interconnected through the calcium binding loop. (B) A stick 
representation EFH-2 of calpain PEF(S), demonstrating canonical binding and (C) EFH-1 of 
calpain PEF(S) demonstrating non-canonical calcium binding. All the binding residues are labelled 
[(B) and (C)], the water molecules are shown as a red spheres and the Ca2+ ions are shown as a 
grey sphere. (PDB: 1DVI)74 
PEF(L) domain 
This calcium binding domain varies between the two isoforms of calpain. As 
noted earlier the concentration of calcium required to activate calpain-I is 7-
fold lower than that required for the activation of calpain-II.50 The sequence 
similarity between the PEF(L) domains found in human calpains-I and II is 
48%.48 Transformation of PEF(L) residues of calpain-I into the residues of those 
found in calpain-II and vice versa demonstrated that PEF(L) is important for the 
difference in the concentration of calcium that are required for the activation of 
each isoform.59 There is no full crystal structure of calpain-I and therefore there 
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is no structure of PEF(L), so the discrepancy in the concentration required to 
activate both isoforms cannot yet be explained through structural analysis of 
PEF(L). The calcium binding residues in the PEF(L) domains of both isoforms 
are highly conserved, so the differing calcium concentrations required for 
activation of the isoforms is unlikely to be due to the ligands that coordinate the 
individual calcium ions (Table 1.2).76  
EF-hand Motif X * Y * Z * -Y * -X * * -Z 
EFH-1 (CAPN1) L A G D D M E I S V F E 
EFH-1 (CAPN2) L A G E D A E I S A K E 
EFH-2 (CAPN1) D R D G N G K L G L V E 
EFH-2 (CAPN2) D E D G S G K L G L K E 
EFH-3 (CAPN1) D L D K S G S M S A Y E 
EFH-3 (CAPN2) D V D R S G T M N S Y E 
EFH-4 (CAPN1) Y S E P D L A V D F D N 
EFH-4 (CAPN2) F A D D E L I I D F D N 
Table 1.2: A table comparing all of the Ca2+ ion binding residues for each of the calcium binding 
EF-hands for both CAPN1 (proposed since there is no crystal structure) and CAPN2 (rattus 
novigenius).74 The calcium binding residues are highlighted in bold.  
The PEF(L) domain of calpain-II comprises eight α-helices that form five 
individual EF-hands (Figure 1.9). Four of these loops bind calcium ions. Two 
bind calcium ions in the canonical EF-hand binding motif (EFH-2 and EFH-3) 
and two in the non-canonical formation (vide supra). Mutations to the individual 
EF hands of the large subunit of calpain-II found that the EFH-3 was vital for 
determining the concentration of calcium that is required for activation of the 
protease.77 The order of affinity for calcium to the EFH motifs is as follows; EFH-
3>EFH-2>EFH-1>>EFH-4.77 Instead of binding calcium, EFH-5 is involved in 
formation of the heterodimeric structure of calpain-I and calpain-II. This is 
acheived through a so called EF-handshake with its respective partner in PEF(S) 
(vide infra). 
There is only one published calcium-bound structure of full calpain-II and 
therefore PEF(L); this was achieved through the binding of the endogenous 
inhibitor calpastatin (see Section 1.7).69, 78 A structure of heterodimeric calpain-
II with calcium bound without calpastatin has yet to be obtained, as the protein 
has a tendency to aggregate in the presence of high concentrations of calcium.78 
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The EF handshake 
The fifth EF-hand of both PEF(L) and PEF(S) forms an integral part of the 
heterodimeric interface.79 The interacting residues that form this so called EF 
handshake are aromatic and hydrophobic residues (Figure 1.11).53, 60, 76  
 
EFH-5 PEF(L) CAPN1 EFH-5 PEF(L) CAPN2 EFH-5 PEF(L) CAPNS1 
Leu682 Leu669 Leu236 
Met685 Leu672 Met239 
Phe686 Phe673 Phe240 
Phe689 Phe676 Phe243 
Trp707 Trp694 Trp261 
Leu708 Leu695 Leu262 
Leu710 Phe697 Leu264 
Met712 Val699 Met266 
Phe713 Leu700 Tyr267 
Figure 1.11: (A) A secondary structure representation of PEF(L) in blue, and PEF(S) in green, with 
EFH-5 highlighted, (B) a close-up of EFH-5 of both PEF(L) and PEF(S) with the hydrophobic 
residues represented as sticks (PDB:1KFU). A table showing the interacting residues on EFH-5 in 
both the PEF(L) domain and the PEF(S) domain which form the heterodimer of rat calpain.50 
PEF(S) domain 
PEF(S) is part of the small subunit, which is also known as the regulatory 
subunit and is identical in both calpain-I and calpain-II.50 The regulatory 
subunit is so-called due to the fact that it forms a secondary layer of protection 
to prevent over-activation of the protease.50 PEF(S) and PEF(L) are structurally 
Introduction 
20 
 
very similar. PEF(S) comprises five EF-hands four of which bind calcium and the 
fifth binds to the corresponding EFH-5 in PEF(L) (Figure 1.11).53, 60 Of the four 
EF hands, that bind calcium ions, two coordinate calcium in a canonical fashion 
and the other two bind calcium in a non-canonical fashion (Table 1.3).74 PEF(S) 
is also capable of forming a homodimer, where two molecules of PEF(S) interact 
with one another through EFH-5 (Figure 1.12).80, 81  
EF-hand Motif X * Y * Z * -Y * -X * * -Z 
EFH-1 (CAPNS1) L A G D D M E V S A T E 
EFH-2 (CAPNS1) D S D T T G K L G F E E 
EFH-3 (CAPNS1) D T D R S G T I G S N E 
EFH-4 (CAPNS1) Y S D E T G N M D F D N 
Table 1.3: A table showing the residues in each of the EF hands of the calcium binding domain 
PEF(S).74  
 
Figure 1.12: A secondary structure representation of a crystal structure of PEF(S) demonstrating 
the formation of a homodimer. One monomer is shown in green and the other in pale green (PDB: 
1DVI). 
The structure of PEF(S) crystals grown in the presence of varying 
concentrations of calcium ions revealed EFH-4 required 20 mM calcium 
chloride before a chelated ion was visible; 20 times more than EFH-1 to EFH-
3.74, 77 The higher concentration of calcium chloride that was required for 
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coordination to EFH-4, relative to other EF-hands, suggests that it is less 
important for activation of calpain-I and calpain-II. 
It has been postulated that binding of Ca2+ to the heterodimeric complex causes 
dissociation of the two subunits, with subsequent homodimerisation of the 
small subunit.78 Small r.m.s.d. values calculated between calcium bound PEF(S) 
and calcium-free PEF(S) crystal structures implied that calcium binding does 
not directly induce subunit separation.74, 82  
1.6.5 The glycine rich domain 
This 95 residue domain contains 40 glycines.51 There is no structural data on 
this domain due to its flexible nature.53 However there are two sequences that 
are postulated to form structured regions. The first is the sequence 
GTAMRILGGVI, which is postulated to form an oblique α-helix that interacts 
with phospholipids. The second is a series of five prolines; prolines are 
structurally constrained and therefore this sequence is highly rigid.50, 83, 84 The 
flexibility of the domain in combination with the phospholipid binding α-helix 
suggests that this domain is used for the binding of the protease to the cell 
membrane.50 
1.7 Calpastatin 
Calpastatin is the endogenous inhibitor of both calpain-I and calpain-II and is 
composed of five domains totalling a molecular weight of 76,000.85 The N-
terminal domain is known as the L domain and is separate from the four 
individual inhibitory domains, each of which binds a single molecule of the 
heterodimeric calpain (Figure 1.13).56, 85, 86 The inhibitory domains are 
numbered I-IV from the L-domain.87 Each domain differs in affinity for calpain 
with the order being: I>IV>III>II, the Kd values of the domains range from 4.5 
pM to 4.0 nM.87  
Introduction 
22 
 
 
Figure 1.13: (A) A diagram representing the inhibitory domains of calpastatin; domain L and 
domains I to IV. The inhibitory regions, A, B and C are highlighted in yellow within each of those 
domains. (B) A secondary structure representation of inhibitory regions A, B and C bound to the 
heterodimeric structure of calpain-II; with CysPc in cyan, C2L in red, PEF(L) in blue and PEF(S) in 
green (PDB:3BOW).69 
The inhibitory domains are all approximately 140 amino acids in length and are 
constructed of three inhibitory regions that bind to different domains of calpain. 
The inhibitory regions are known as regions A, B and C (Figure 1.13).86 Regions 
A and C are α-helices that bind to hydrophobic grooves in PEF(L) and PEF(S), 
respectively.69 The hydrophobic grooves that bind regions A and C are formed 
between α-helix 1 and 2 of EFH-1 and α-helix 4 of EFH-2 in both PEF(L) and 
PEF(S).69 Inhibitory region B is inherently unstructured and initially interacts 
with the C2L domain, the poly peptide then runs through the narrow active site 
in the CysPc domain, from PC2 to PC1. Region B terminates in an α-helix that 
interacts with a hydrophobic groove of PC1 (Figure 1.13).69 The structure of 
calpastatin domain IV bound to calpain-II shows several coordinated calcium 
ions, implying that the endogenous inhibitor is used to sequester and inactivate 
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calpain following activation of the protease, preventing any further 
proteolysis.69  
Many peptide inhibitors have been produced based on the sequence of 
inhibitory region B of calpastatin and were found to be capable of inhibiting 
both calpain-I and calpain-II.88 In stark contrast peptides derived from regions 
A and C, without inhibitory region B, have been found to lower the 
concentration of calcium required for the activation of calpain-I and calpain-II.89  
1.8 Activation of calpain-I and calpain-II  
Calcium binds to calpain-I and calpain-II in vitro with concentrations of ~50 μM 
and ~0.35 mM respectively. This leads to structural alterations within the 
protease that enable the enzyme to reach its active form.50 The only calcium 
bound X-ray crystal structure of calpain is of calpain-II bound to one domain of 
calpastatin.69, 78 Hence a variety of alternative techniques have been used to 
indirectly study the conformational changes that occur during calcium mediated 
activation. These include mutation of residues within the enzyme and the 
solution of the structure of isolated calcium binding domains to determine the 
structural effect upon binding calcium.65, 70 
The penta-EF hand domains, PEF(L) and PEF(S), are thought to have more of a 
regulatory role than playing a major part in the activation of calpain upon 
binding calcium ions. It has been shown that there is very little movement in the 
overall structure of these domains when calcium is present.74, 81 However, both 
of these domains are important for the determination of the concentration of 
calcium that is required in the activation of both calpain-I and calpain-II.59, 77 
The greatest movement that was visualised in these domains was demonstrated 
at EFH-1 of PEF(S). This same movement may therefore occur with EFH-1 of 
PEF(L). Upon binding calcium to the PEF(L) domain, the polypeptide linker 
between the first α-helix of EFH-1 and the C2L domain is thought to extend and 
enable the disruption of the electrostatic interactions of the C2L domain and the 
PC2 domain.74, 90, 91 There is an important salt bridge interaction between the 
residues Glu504 and Lys234 and mutations at this point dramatically decrease 
the concentration of calcium that is required for activation.64, 70 Other 
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interactions between the domain interface of PEF(L) and C2L are also thought 
to be affected through calcium binding in the PEF(L) domain.51 Upon the 
binding of calcium to EFH2 of the PEF(S) domain repulsive interactions with the 
N-terminal anchor α-helix are presumed to occur releasing the constraints that 
hold the active site subdomains apart.62 The negatively charged loop of the C2L 
domain that interacts with the PC2 subdomain is thought to bind calcium, like 
other known C2 domains, disrupting the electrostatic interactions between 
these domains.66, 67 However the crystal structure of the calcium bound 
calpain/calpastatin system is in conflict with this due to the absence of Ca2+ 
observed within this domain.69  
The disruption of the electrostatic interactions between the proteolytic core 
and the auxiliary domains frees the restraints holding the PC1 and PC2 
subdomains apart, alignment of the catalytic triad occurs after PC1 and PC2 
bind calcium themselves.92 The two subdomains contain a non-EF hand calcium 
binding site each, this was observed through the crystallisation of the 
proteolytic core of calpain-I without any other domains in the presence of 
calcium ions (Figure 1.14).65 Negatively charged residues in the two loops and 
water molecules, one in PC1 and the other in PC2, are used to bind the 
calcium.65, 92 The calcium binding to the two loops in the subdomains allows for 
the two halves of the CysPc domain to rotate approximately 25° into the active 
conformation.  
In calpain-I the CysPc domain alone is also a calcium activated cysteine protease 
with a similar activation concentration as the parent molecule at ~40 μM .65 In 
contrast the CysPc domain for calpain-II alone was found to be either only 
weakly active93 or completely inactive.94 In the former case the specific activity 
of the proteolytic core of calpain-I alone only reached 10% of the parent 
molecule, demonstrating the proteolytic core requires the other domains for the 
maximum activity of the enzyme.65 
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Figure 1.14:  A secondary structure representation the inactive CysPc domain of calpain-I, derived 
from a hybrid structure of calpain-I and calpain-II (grey),57 overlaid with the calcium bound CysPc 
domain which is in the active conformation (cyan).65 A close up of the catalytic triad, with the 
cysteine mutated to a serine, the inactive protease (left) and the active protease (right).  
Therefore in-order to activate calpain with calcium a two-step activation route 
has been proposed. The initial step requires a release of the restraints that hold 
the proteolytic core in an inactive conformation through the binding of calcium 
to the PEF domains on both subunits. Once calcium is bound the electrostatic 
interactions between the C2L domain and the CysPc domain are disrupted, as 
well as the interactions between the anchor helix and PEF(S). The subsequent 
step is the binding of calcium to the proteolytic core to allow PC1 and PC2 to 
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rotate towards one another forming the catalytic triad and proteolysis may then 
occur (Figure 1.15). 
 
Figure 1.15: A schematic representation of how calcium binds to calpain through a postulated 
two-step process; calcium initially binds to the PEF domains releasing the anchor helix and the 
electrostatic interactions that hold PC1 and PC2 in an inactive conformation, calcium then binds to 
PC1 and PC2 causing an alignment of the proteolytic core. 
1.8.1 Factors that lead to activation in vivo 
The in vitro concentrations of calcium required for the activation of the two 
isoforms is much greater than the cellular concentrations which reach a 
maximum of 1 μM.50, 95 Though there are certain local high concentrations of 
calcium, such as just beneath the membrane in neutrophils, where the 
concentration can reach up to ~30 μM, this remains too low for the activation of 
either calpain isoform.31 Therefore, to lower the concentration required for the 
activation of calpain-I and calpain-II other factors must be involved. These 
include the binding of phospholipids,96, 97 autolysis, the binding of activator 
proteins,55, 98, 99 and phosphorylation.100   
Phospholipids have been observed to bind to the C2L and GR domains of 
calpain-I or calpain-II.67, 83, 84 This decreases the concentration of calcium 
required for activation implying that the binding to phospholipids may enable 
activation in vivo.96, 97 The ability of phospholipids to activate calpain-I and 
calpain-II suggests that these proteins are mainly active at the cell 
membrane.101, 102 The binding of phospholipids has also been found to lower the 
concentration of calcium required for autolysis via an intramolecular 
reaction.103 The autolysis in turn allows for a lowering in the required 
concentration for activation in vitro and therefore potentially in vivo (Figure 
1.16).96, 103 Autolysis of the large subunit of calpain-II occurs at the N-terminus 
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leaving a molecular weight of 78,000, from 80,000, this happens under low 
concentrations of calcium, leaving a less stable but readily active protease.104 
Further autolysis of calpain-II leads to an even less stable protease where the 
large subunit has a molecular weight of 76,000 which can also be activated at 
lower concentrations of calcium. Due to the instability of the structure of 
autolysed calpain-II, the fragments of the protease can be difficult to detect in 
vivo.104 Therefore it is difficult to establish whether autolysis is a precursor step 
to the full activation of calpain.104 Calpain-I has also been found to undergo 
autolysis which results in a reduction of the concentration of calcium required 
for the activation.105 Phospholipid binding is contradicted by Cong et al. 
however, who state that neither calpain-I or calpain-II undergo autolysis 
through the binding of phosphatidylinositol-1,3-bisphosphate.106 The 
concentration of calcium required for autolysis to occur, both with and without 
phosphatidylinositol-1,3-bisphosphate, was higher than the known in vitro 
activation concentrations for both isoforms.106 Therefore they state that there 
must be another mechanism utilised for activation.106 
 
Figure 1.16: A proposed activation mechanism of calpain-I/II via membrane association 
(phospholipid binding) and the subsequent autolysis.101, 103 Initially the inactive protease binds to 
the cell membrane, followed by the autolysis of the anchor helix. This lowers the calcium 
concentration required for activation and following this the active site moves together and the 
protease is release from the membrane in its activated form. 
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Another postulate is that association of activator proteins may lower the 
concentration of calcium that is required for the activation of both calpain-I and 
calpain-II (Figure 1.17). Acyl-CoA binding protein was found to decrease the 
concentration of Ca2+ ions that are required by over 50 fold.55 Another protein 
activator that was proposed by the same group is UK114, a tumour antigen 
from goat liver, that decreased the activation concentration required by over 10 
fold in the case of calpain-I.98 A second activator protein, of otherwise unknown 
function, for calpain-I was also found in human neutrophils.99 UK114 from 
Drosophila was used as an activator of calpain by Farkas A. et al. but they found 
that it did not act as an activator protein at all and was found to act merely as a 
molecular chaperone for other proteins such as citrate synthase.107 
 
Figure 1.17: Another theory; an activator protein is associated with calpain to lower the 
concentration of Ca2+ ions required for activation.55, 98, 108 The activator protein binds to the 
protease, lowering the concentration of calcium that is required for activation. Calcium then binds 
to the protease allowing the active site to close into the active form of the protease. 
1.9 Physiological function and known substrates 
Calpain-I and calpain-II are ubiquitously expressed throughout the human body 
and have been linked to many physiological roles. Determining the exact 
physiological role of these proteases has been difficult due to the way that they 
are analysed, mainly through use of inhibitors.109 Caution must be used with 
conclusions drawn through the use of inhibitors however, due to the lack of 
specificity of the inhibitors produced to date. The only calpain-selective 
inhibitor, calpastatin, is not cell permeable.109 There are many substrates 
known to be cleaved by calpain-I and calpain-II in vitro, these can be used to 
predict the function of the protease in vivo. 
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1.9.1 Known substrates of calpain-I and calpain-II 
Calpain-I and calpain-II have highly similar substrate specificity and over 100 
substrates have been discovered to date through in vitro studies.50, 109 These 
substrates include cytoskeletal proteins, several kinases and phosphatases, 
some membrane bound proteins and a few cytosolic proteins.50, 109, 110 Several 
of the substrates are cytoskeletal proteins that are mainly found in the region of 
the cellular membrane, examples of these include ezrin, talin, α-fodrin.111-113 
Calmodulin dependent proteins either membrane bound or in the cytosol are 
susceptible to calpain mediated hydrolysis, for example Ca2+-ATPase and the 
phosphatase calcineurin.110, 114, 115 Other cytosolic enzymes that get hydrolysed 
by calpain-I include caspase 12 during apoptosis.116 
Calpain demonstrates a preference for certain amino acids at specific positions 
within the active site.109 Through sequencing analysis of numerous substrates 
of calpain the most common of the amino acids that occur at position P1 and 
P1’, either side of the cleavage site, are tyrosine, lysine or an arginine at P1 and 
serine at P1’ (Table 1.4).117 However synthetic peptide library screening found 
that the optimum amino acids were either leucine or phenylalanine at P1 and at 
P1’ a methionine, alanine or an arginine (Table 1.4).118 This does not match any 
protein sequences of the known substrates of calpain to date.119 Proline 
residues are preferred at certain points within the sequence of the substrate 
(e.g. at P3, P2’ and P3’), this implies that there is a lack of secondary structure at 
the cleavage site.117 The lack of secondary structure may be important for the 
recognition of the substrate by the protease.117 This was corroborated with 
allignment of the structures of papain and calpain-I active sites with the 
inhibitor leupeptin bound (Section 1.11.2).120 This revealed that the inhibitor 
resides deeper within the active site of calpain-I than papain, with the calcium 
binding loops surrounding the active site.120 The narrow active site of calpain 
suggests that only a disordered secondary structure of the substrate is capable 
of accessing the active site.120  
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Sequence P3 P2 P1 P1’ P2’ P3’ 
A Trp>Pro Leu>Thr 
>Val 
Lys>Tyr 
>Arg 
Ser Pro Pro>Trp 
B Phe>Leu 
>Pro 
Leu>Val Leu=Phe Met>Ala 
>Arg 
Glu Arg>Lys 
Table 1.4: The optimum sequences of amino acids at the cleavage site for calpain-I the cleavage 
site is shown in red, sequence A was derived from the sequences of 49 known substrates,117 
sequence B was derived from a peptide library screen.118 
1.9.2  Physiological function 
Through the specific amino acids that are required for substrate activity, 
numerous substrates have been identified in vitro and can be used to imply 
roles for the protease in vivo. However, caution must be used as the 
environment within cells greatly differs to the conditions used in vitro, for 
example the concentration of calcium that is used for the activation. Both 
calpain-I and calpain-II have a variety of postulated roles within the human 
body including involvement in signal transduction,121 the cell cycle,109, 122 
platelet function,123 prevention of erythrocyte deformability,124 apoptosis125 
and cell spreading and migration.126  
The cell cycle  
Both isoforms of calpain have been shown to affect progression through the cell 
cycle.122 Microinjections of calpain-II at different phases of the cell cycle and 
especially during mitosis revealed that the cell progresses rapidly through the 
phases of mitosis.127 When calpain-II was added to cells whilst in the metaphase 
the cells proceeded to the anaphase in a reduced time, and similarly it could 
accelerate the progression from the prophase to the interphase.127 Inhibition of 
a calpain-like protease in fibroblasts has been shown to stop the growth of 
these cells at the G1 stage of growth and therefore there was no progression to 
the S phase.128  
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Platelet function 
Platelet agonists cause an increase in the concentration of intracellular calcium, 
leading to cytoskeletal remodelling and the secretion of α-granules for 
membrane fusion.129, 130 The increase in calcium levels in platelets leads to the 
activation of calpains for the hydrolysis of cytoskeletal proteins such as 
fodrin.131 The inhibition of calpain in platelets, with a cell permeable calpastatin 
derived peptide, demonstrated that the protease has an essential role with 
secretion, aggregation and the spreading of platelets.132 Knockout of the gene 
encoding for calpain-I reveal that this isoform is important for platelet secretion 
and aggregation.133 
There is a disagreement as to the expression levels of both these proteases in 
platelets. Studies have found that calpain-II makes up approximately 2% of all 
the protein within platelets, distributed evenly within the cytosol and at the 
membrane of platelets.134 This is disputed, however, with claims that calpain-I 
is the dominant protease and not calpain-II.135, 136  
Apoptosis 
Programmed cell death involves both calpain-I and calpain-II. In the earlier 
stages of apoptosis calpain-I is activated through the release of calcium from the 
endoplasmic reticulum.137, 138 The activated protease hydrolyses Bid, a 
proapoptotic protein.139 This truncated Bid (tBid) is now active and 
translocates to the mitochondria allowing for oligomerisation with the fellow 
pro-apoptotic proteins, Bak and Bax.138 These oligomers form pores in the 
mitochondrial membrane releasing cytochrome c thereby continuing the 
mitochondrial mediated apoptosis cascade.138  
Caspases are a well-known group of cysteine proteases that are intrinsically 
linked to the apoptosis pathway. Calpains are linked to the cleavage and 
activation of these enzymes during apoptosis, caspase 12 is just one example.116 
Calpain-I and calpain-II have also been found within mitochondria and have 
been associated with the latter stages of apoptosis, through the truncation and 
transportation of apoptosis inducing factor from the mitochondria.140-142 Joshi 
Introduction 
32 
 
et al. have, however, contradicted this proposed physiological role of calpain-I 
as they did not observe this phenomenon.143  
Cell spreading and migration 
Calpain-I appears to play an integral role in the ability of cell membranes to 
spread and hence enable the migration of neutrophils (Section 1.2).23 The two 
isoforms of calpain are important for the motility of other cell types also.144, 145 
Many of the putative substrates of calpain are located at the cell membrane and 
form focal adhesion complexes and are cleaved in vivo.146 These proteins 
include ezrin,34 talin33 and β2-integrins.147, 148 Integrin complexes comprise 
many proteins that are membrane bound proteins that span the plasma 
membrane and protrude out into the extracellular space. These integrins allow 
for the adhesion of the cell to the endothelial wall, beginning the process of 
migration to the target site of action.   
Calpains are implicated in the cell spreading capability of T-cells and fibroblasts. 
Calpain-II is a vital component in the ability of the cell to form these integrin 
interaction complexes and therefore in the capability of the cell to spread.145, 149 
Caution must be used in this interpretation as inhibitors were used to observe 
this process and there is the poor specificity of most inhibitors towards 
individual calpain isoforms.149 A decrease in the activity of calpain-II through 
the over expression of calpastatin suppressed the cell spreading capability of 
fibroblasts, as the cells were not capable of forming protrusions of the cell 
membrane.150, 151  
1.10 Calpain related diseases 
Calpain-I and calpain-II are both linked to many diseases, through either the 
disruption of the calpain-calpastatin system or the over-activation of calpain. As 
well as rheumatoid arthritis (Section 1.1) both isoforms are linked to 
Alzheimer’s disease,152, 153 ischemic cell death,154 cancer,155 cataracts,156 
multiple sclerosis157 and malaria.158 
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1.10.1 Alzheimer’s disease 
Alzheimer’s disease is the death of neurons within the brain due to aggregation 
of β-amyloid particles and tau protein to form β-amyloid plaques and neuronal 
filaments respectively. 159, 160 Cellular extracts from neurons of Alzheimer’s 
patients when compared to healthy brain neurons, post-mortem, indicated an 
unusually high activity of calpain-I.152 This increase in calpain activity may lead 
to damage of the cellular membranes since calpain-I is known to cleave 
cytoskeletal proteins, and induction of neuronal apoptosis through the cleavage 
of proapoptotic protein p53.101 However, in contrast to this, a decrease in 
calpain-I activity is linked to the formation of β amyloid plaques, due to the lack 
of proteolysis of the precursor protein α-secretase.161 Also the over-expression 
of calpain-II has been detected in the brains of patients suffering from 
Alzheimer’s disease, through the use of a calpain-II specific antigen.162, 163  
1.10.2 Ischemic cell death 
During ischemic associated cell death which generally occurs as a consequence 
of strokes, cardiac arrest, or through trauma, there is a rapid increase in calcium 
concentration within the cells.164 The increase in calcium levels leads to the 
over activation of calpain and in turn, to necrotic cell death. The rapid increase 
in calcium levels is generally thought to be caused, within the brain, by the 
excessive influx of the major excitatory neurotransmitter glutamate.165, 166 
When glutamate reaches these excessive levels it is considered a neurotoxin. It 
causes the depolarisation of the membrane, causing sodium and calcium ions to 
flood into the cytosol and consequently activating a variety of proteins, such as 
calpain.165 The activation of calpains within the cytosol then leads to neuronal 
apoptosis and the degradation of cytoskeletal proteins.159, 165 With cardiac 
ischemia the over-activation of calpain-I has been linked to the release of the 
apoptosis inducing factor from the mitochondria within these cells, leading to 
cell death.167 The degradation of cytoskeletal proteins may also enable cell 
death.165 
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1.10.3 Calpain and cancer 
A link between cancer and calpain has been established through the detection 
of an over expression of both calpain-I and calpain-II in a variety of cancers.168-
170 Also a decrease in the expression of the endogenous inhibitor calpastatin 
occurs in cancer cells found within endometrial cancer.155 The over activation of 
calpain is considered to play a major role in the metastasis of cancer.155, 168  The 
down regulation of calpain-II, as well as the use of inhibitors, has demonstrated 
that the invasiveness of prostate cancer cells can be significantly reduced.169 
Due to the numerous diseases that both of these isoforms of calpain have been 
linked to, these are attractive targets for the development of new inhibitors. The 
knockout of calpain-I within cells, and therefore the loss of calpain activity, 
demonstrated a deformity within erythrocytes124 and platelets,133 whereas the 
knockout of calpain-II is embryonically lethal.171 Therefore the development of 
inhibitors that are selective for calpain-I is desirable. 
1.11 Inhibition of calpain 
The optimum selective inhibitor for calpain-I and calpain-II is the endogenous 
inhibitor calpastatin (Section 1.7). This inhibitor is both potent and selective 
towards calpain-I and calpain-II. The main problem in the use of this inhibitor in 
vivo is that due to its size it is not cell permeable. Additionally it binds to both of 
the isoforms and the total inhibition of calpain-II is detrimental to life.171 
Therefore efforts have been made to develop inhibitors that are potent, cell 
permeable and selective between these two calpain isoforms.172, 173 
1.11.1 Calpastatin based inhibitors 
Inhibitors have been developed based on the sequence of calpastatin inhibitory 
region B, which binds to the active site of calpain-I and calpain-II.173 CP1B is a 
27 residue peptide based on inhibitory region B of calpastatin and inhibited 
both isoforms of calpain with a Ki of ~0.2 nM, though the protein was incapable 
of penetrating the cell membrane (Table 1.5).88 The cell penetrating peptide 
penetratin was attached to CP1B, to make PCP1B, this did not affect the 
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apparent potency of the inhibitor towards calpain (Ki = ~0.5 nM) (Table 1.5).174 
Truncation of penetratin to an 8 residue peptide (from a 17 residue peptide) 
did not affect the cell penetrating ability of CP1B but increased the potency with 
a Ki of 0.18 nM (Table 1.5).175 Since these inhibitors were based on calpastatin, 
they were not selective between the isoforms. 
Inhibitor Sequence Ki (nM) 
CP1B88 Ac-DPMSSTYIEELGKREVTIPPKYRELLA-NH2 0.20 
PCP1B174 Ac-CDPMSSTYIEELGKREVTIPPKYRELLA-NH2 
Ac-CRQIKIWFQNRRMKWKK-NH2 
0.50 
8-mer-
PCP1B175 
Ac-CDPMSSTYIEELGKREVTIPPKYRELLA-NH2 
Ac-CRRMKWKK-NH2 
0.18 
Table 1.5: The sequences of inhibitors derived from calpastatin inhibitory region B with their 
reported Ki values. 
1.11.2 Inhibitors containing warheads 
Inhibitors that contain so-called warheads attack the cysteine within the active 
site meaning that the inhibitor is likely to bind to many other cysteine proteases 
since they have similar acitive sites. Inhibiting several different cysteine 
proteases would be to the detriment of normal body function. Functional 
groups commonly found in these warheads are epoxides, aldehydes and 
hemiacetals.172 The most well known inhibitors are E-64 (1),176 leupeptin (3) , 
calpeptin (4) and ALLN (5).  
E-64 (1) contains an epoxide based warhead and is known to irreversibly 
alkylate the catalytic cysteine residue (Figure 1.19).120 The peptide is non-
selective towards calpains (Figure 1.18).177 E64 inhibits calpain-I and calpain-II 
with IC50 values of 1.53 μM and 1.09 μM respectively.178 A derivative of this 
inhibitor has been developed, WRH(R,R) (2), which has greater selectivity 
towards calpains over other cysteine proteases, such as cathepsins (Figure 
1.18). Compound 2 inhibits calpain-I and calpain-II with IC50 values of 0.46 μM 
and 0.10 μM respectively.179  
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Figure 1.18: Peptide based warhead inhibitors with epoxide functional groups that alkylate the 
cysteine. (1) E64; IC50 = 1.53 μM (calpain-I) and 1.09 μM (calpain-II), (2) WRH(R,R); IC50 = 0.46 μM 
(calpain-I) and 0.10 μM (calpain-II).178, 179 The general mechanism of epoxide based inhibition of 
the cysteine protease.  
 
Figure 1.19: A secondary structure representation of the CysPc domain of calpain-I, the catalytic 
triad is represented as sticks with the cys115 having been alkylated with 1 (PDB:1TLO).120 
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Inhibitors that contain an aldehyde warhead attack the catalytic cysteine 
residue but are fully reversible inhibitors.  Leupeptin (3) (Figure 1.21), an 
example of this family, had been found in various Streptomyces species and is 
highly potent towards calpain-I and calpain-II with IC50 values of 0.27 μM and 
0.38 μM respectively (Figure 1.21).172, 178 Leupeptin is unspecific, attacking 
other cysteine proteases as well as some serine proteases (Figure 1.20).180 
Derivatives of 3 such as calpeptin (4) have been produced, that possess the 
ability to pass through the cell membrane, as well as being highly potent 
towards calpain-I and calpain-II (Figure 1.21).178, 181, 182 Calpeptin inhibits 
calpain-I and calpain-II with IC50 values of 0.010 μM  and 0.014 μM 
respectively.178 ALLN (5) and ALLM (6), or calpain inhibitor I and calpain 
inhibitor II as they are otherwise known, are two other peptide inhibitors that 
contain aldehyde warheads (Figure 1.21). These are synthetic inhibitors and 
both are cell permeable; they inhibit calpain-I with IC50 values of 0.023 μM and 
0.13 μM for and calpain-II with IC50 values of 0.022 μM and 0.23 μM 
respectively. However both were found to be more potent inhibitors of 
cathepsins than of calpains.178  
 
Figure 1.20: A secondary structure representation of the CysPc domain of calpain-I, the catalytic 
triad is represented as sticks with the aldehyde based inhibitor 3 alkylating the proteolytic cysteine 
(PDB:1TLO).120 
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Figure 1.21: The structures of peptide based inhibitors that contain aldehyde warheads; (3) 
leupeptin; IC50 = 0.27 μM (calpain-I) and 0.38 μM (calpain-II),178 (4) calpeptin; IC50 = 0.010 μM 
(calpain-I) and 0.014 μM (calpain-II),178 (5) ALLN; IC50 = 0.023 μM (calpain-I) and 0.022 μM 
(calpain-II),172 and  (6)  ALLM; IC50 = 0.13 μM (calpain-I) and 0.23 μM (calpain-II),.172 The 
mechanism of action. 
1.11.3 Inhibitors without warheads 
Ideally, calpain-I selective inhibitors should not contain warheads which 
alkylate the active site cysteine residue, due to the similar substrate specificities 
of both isoforms. Numerous non-warhead based inhibitors have been 
discovered from natural sources as well as through rational design. A synthetic 
peptide based compound 7 has been reported to be the most potent inhibitor to 
date, with an IC50 value for calpain-I at 87 pM (Figure 1.22).183 Compound 7 
does not interact with other cysteine proteases such as papain or cathepsins, 
although no data has been recorded for its interaction with calpain-II.183 This 
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compound contains a biphenyl linker between two peptide chains, it is thought 
that it prevents calpain activation through the chelation of calcium ions.183  
 
Figure 1.22: The structures of non-warhead based inhibitors; (7) a biphenyl derivative that is one 
of the most potent inhibitor of calpain-I to date (IC50 = 87 pM)183, (8) penicillide (IC50 = 7.1 μM) 
(calpain-II), (9) quinolinecorboxamide derivative (IC50 = 0.50 μM) and (10) another 
quinolinecarboxamide derivative (IC50 = 0.28 μM). 
Other non-peptide based inhibitors have also been found to inhibit calpain such 
as penicillide (8), a polyketide that was found in Penicillium sp. It has activity 
against calpain-II with an IC50 of 7.1 μM (Figure 1.22).172 Quinoline derivatives 
have also shown inhibitory properties towards calpain-I, with derivatives of 3-
quinolinecarboxamide 9 and 10 with IC50 values of 0.5 μM and 0.28 μM 
respectively.184 Docking studies suggested that the molecule binds within the 
active site of calpain-I.185 These compounds inhibit calpain-I, but no data on 
inhibition of calpain-II has been published. However there are two small 
molecules that have shown a modest selectivity towards calpain-I over calpain-
II (Section 1.11.4). 
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1.11.4 Small molecule inhibitors 
 
Figure 1.23: A secondary structure representation of calpastatin inhibitory region C bound to 
porcine PEF(S) (PDB:1NX1). A secondary structure representation of PD150606 bound to the same 
region of porcine PEF(S) (PDB:1NX3).186 
Two small molecule inhibitors were developed in 1996 that displayed 
selectivity towards calpain-I over calpain-II.187 Known as PD150606 (11) and 
PD151746 (12) these small molecule mercaptoacrylic acid inhibitors are potent 
and do not permanently bind to the enzyme (Figure 1.24). PD150606 is a 
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phenyl based mercaptoacrylic acid with an iodine in the para position (Figure 
1.24). The other inhibitor, PD151746 is an indole based mercaptoacrylic acid, 
with the mercaptoacrylic acid and fluorine situated at positions 3 and 5, 
respectively (Figure 1.24).  
These inhibitors are allosteric inhibitors targetting the PEF(L) and the PEF(S) 
domains of the heterodimeric structure. A crystal structure of PD150606 bound 
to PEF(S) demonstrated that it binds to the same region of PEF(S) as calpastatin 
region C (Figure 1.23).81, 186 PD151746 displayed 20 fold selectivity towards 
calpain-I over calpain-II. The phenyl derivative was less selective for calpain-I, 
though it was found to be a slightly more potent inhibitor.187 The discrepancy in 
the potency of these derivatives may imply that these inhibitors also interact 
with the PEF(L) domain as well as with the small subunit, since PEF(S) is 
identical in both isoforms. 
  
Figure 1.24: The structures of PD150606 and PD151746.187 
1.12 Aims 
The exact physiological roles of these proteases are poorly understood and 
hence also their roles in disease processes. One reason for the lack of 
knowledge is the paucity of specific inhibitors for each isoform. Therefore it is 
important to develop inhibitors that are selective towards calpain-I over 
calpain-II and vice versa.  
The aim of this work was to develop a series of monohalogenated 
mercaptoacrylic acids based on the structures of PD150606 and PD151746. 
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These inhibitors were to contain the same skeletal structures with the 
mercaptoacrylic acid present at the same position of both the indole and phenyl 
ring. These compounds were then to be tested as inhibitors of calpain-I and 
calpain-II. X-ray crystallography could then be used to determine how they bind 
to the PEF(S) domain. The most potent and specific compounds could then be 
employed for the study of the physiological and pathophysiological effects of 
calpain-I inhibition. 
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2.1 α-Mercaptoacrylic acid derivatives 
The aim of the work discussed in this chapter was to produce a series of α-
mercaptoacrylic acid derivatives based upon the two structures of PD150606 
and PD151746. The target compounds were both phenyl and indole based 
derivatives, with a single halogen substituent (fluorine, chlorine, bromine or 
iodine) at all possible positions of the six membered ring in each case (Figure 
2.1). Once prepared, they were to be tested as inhibitors of both calpain-I and 
calpain-II. 
 
Figure 2.1: The structure of the target compounds. 
2.1.1 Synthetic routes to α-mercaptoacrylic acid derivatives 
The synthetic routes used for preparing these compounds are summarised in 
Scheme 2.1. Phenyl and indole derivatives were prepared from substituted 
benzaldehydes or indole-3-carboxaldehydes, respectively, via a Knoevenagel 
condensation with 2-thioxothiazolidin-4-one followed by hydrolysis to the 
appropriate α-mercaptoacrylic acid compounds (reactions (v) and (vi) in 
Scheme 2.1).188 In some cases a Vilsmeier-Haack reaction [(iv) in Scheme 2.1] 
was used to obtain the required aldehyde from the parent arene.189  
Moreover, several of the halogenated indoles required synthesis prior to 
introduction of the aldehyde functionality. For example 4-iodoindole was 
prepared using a two-step synthesis with the use of 
thallium(III)trifluoroacetate [(iii) of Scheme 2.1 and Section 2.2].190 Preparation 
of 6-iodoindole was achieved using a five step synthesis. The initial starting 
material 6-nitroindoline was transformed using a Sandmeyer reaction as the 
key step to introduce the halogen atom [(ii) in Scheme 2.1], see Section 2.3.191 
Finally, two 7-substituted indole derivatives required synthesis, 7-fluoroindole 
and 7-bromoindole. These were prepared via a Bartoli indole synthesis from 1-
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fluoro-2-nitrobenzene and 1-bromo-2-nitrobenzene, respectively [(i) of Scheme 
2.1] (see Section 2.4 for more details).192 
 
Scheme 2.1: The synthetic routes for preparation of the target α-mercaptoacrylic acids. 
 
 
(i) Bartoli Indole Synthesis 
(ii) Five step synthesis of the 
6-iodoindole 
(iii) Two step synthesis of 4-
iodoindole 
(iv) Vilsmeier-Haack Reaction 
(v) Knoevenagel condensation 
reaction 
(vi) Hydrolysis reaction 
 
(a) Commercially available 
substituted indoles  
(b) Commercially available 
substituted benzaldehydes  
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2.2 Synthesis of 4-iodoindole  
 
Scheme 2.2: The formation of 4-iodoindole (15) from methyl indole-3-carboxylate (13).190, 193  
Here the treatment of 13 with thallium(III)trifluoroacetate resulted in 
substitution at position 4 of the indole ring. Treatment of the intermediate with 
potassium iodide (KI) replaced the thallium with iodide.193 The resulting 
compound 14 was then hydrolysed using sodium hydroxide to obtain 4-
iodoindole (15) in an overall yield of 33% (Scheme 2.2). 
   
Scheme 2.3: The coordination of thallium(III)trifluoroacetate to position 4 of methyl indole-3-
carboxylate and the subsequent replacement of thallium with iodide.194  
In the first step thallium(III)trifluoroacetate coordinates to the oxygen in the 
carbonyl group of the methyl ester at position 3 and it is this that directs it to 
position 4 (Scheme 2.3). 190, 195 Deprotonation at the ipso position generates a 
thallium substituted aromatic ring (Scheme 2.3).195 This intermediate then 
reacts with KI in water to form methyl 4-iodoindole-3-carboxylate (Scheme 
2.3).190 The addition of KI causes the relatively weak coordination bond of the 
thallium ion to the indole to break and be replaced with iodine (Scheme 2.3). 
Hydrolysis of the methyl ester with 40% sodium hydroxide solution for 1.5 
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hours created a carboxylate that then spontaneoutsly lost CO2 to give the 
desired product. 
2.3 Synthesis of 6-iodoindole 
To prepare 6-iodoindole a five step synthetic route was used. 6-Nitroindoline 
was acetylated to protect the NH group (Scheme 2.4) (Section 2.3.1).191 The 
resulting compound was reduced using a palladium catalysed hydrogenation 
reaction to form N-acetyl-6-aminoindoline (Scheme 2.4) (Section 2.3.2).191 This 
compound then underwent a Sandmeyer reaction, to generate a diazonium salt. 
Reaction with potassium iodide then resulted in N-acetyl-6-iodoindoline 
(Scheme 2.4) (Section 2.3.3).191, 196 The acetyl group was then removed by base 
catalysed hydrolysis with 40% sodium hydroxide in water (Scheme 2.4) 
(Section 2.3.4).191 The final step was air oxidation of the indoline ring in the 
presence of a Co(II)salen catalyst (Scheme 2.4) (Section 2.3.5).191, 197 
 
Scheme 2.4: The synthetic route for the preparation of 6-iodoindole. (i) Ac2O, 130 °C, (ii) H2, 10%-
Pd/C, 25 °C, (iii) NaNO2, KI, AcOH, 0 °C, (iv) NaOH, MeOH, 75 °C, (v) Co(II)salen, air, MeOH, 25 °C191 
2.3.1 Acetylation of 6-nitroindoline 
 
Scheme 2.5: The acetylation reaction of 6-nitroindoline to form N-acetyl-6-nitroindoline. 
To protect the amino group of 16, it was heated with acetic anhydride under 
reflux for 15 minutes (Scheme 2.5). The reaction was then allowed to cool to 
room temperature and water was added to precipitate the yellow compound 17 
in 95% yield after collection by filtration and drying under reduced pressure.  
Synthesis of α-Mercaptoacrylic acids for Inhibition of Calpain-I 
 
48 
 
2.3.2 Hydrogenation of N-acetyl-6-nitroindoline 
 
Scheme 2.6: Reduction of N-acetyl-6-nitroindoline to form N-acetyl-6-aminoindoline. 
After reduction of 17 with hydrogen gas (under 1 atmosphere’s pressure) over 
10% palladium on activated charcoal 18 was isolated as a white solid in 80% 
yield (Scheme 2.6).  
2.3.3 The Sandmeyer reaction 
 
Scheme 2.7: The Sandmeyer reaction.196 
Compound 18 was reacted with nitrosonium ions formed through the reaction 
of 80% aqueous acetic acid with sodium nitrite (Scheme 2.8). The nitrosonium 
ions then react with the amino substituent of the starting material to form a 
diazonium salt and a molecule of water. The diazonium functionality is a good 
leaving group so upon reaction with the KI via a radical nucleophilic reaction, 
nitrogen gas leaves and is replaced with iodide (Scheme 2.8).198 After 
purification by flash chromatography on silica gel 19 was isolated in 60% yield.  
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Scheme 2.8: (A) The mechanism of formation of the nitrosonium ion. (B) The mechanism for the 
formation of 19.198, 199  
2.3.4 Hydrolysis of the protecting group 
 
Scheme 2.9: Hydrolysis of the N-acetyl protecting group. 
The acyl protecting group of 19 was removed through treatment with 40% 
NaOH solution in methanol for 2.5 hours (Scheme 2.9). The desired product 20 
was isolated in 64% yield after purification by flash chromatography on silica 
gel.  
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2.3.5 Oxidation of indoline  
 
Scheme 2.10: Conversion of indoline to indole.197 
N,N′-Bis(salicylidene)ethylenediaminocobalt(II) was used as a catalyst to carry 
out the oxidation. This catalyst uses oxygen to oxidise the indoline to form 
indole.197 Air was used as the source of oxygen for the reaction and was bubbled 
through the stirred reaction mixture for 24 hr. The desired product was isolated 
as pale brown crystals in a yield of 77%.  
2.4 Bartoli indole synthesis 
 
Scheme 2.11: The Bartoli indole synthesis.200 
The Bartoli indole synthesis is used to form 7-substituted indoles through the 
reaction of three equivalents of vinyl magnesium bromide with 2-substituted 
nitrobenzenes (Scheme 2.11).192 This reaction was used for the formation of 7-
fluoroindole (23) and 7-bromoindole (25) in yields of 14% and 44% 
respectively. 
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Scheme 2.12: The reaction mechanism for the Bartoli indole synthesis.200  
2.5 Vilsmeier-Haack reaction 
 
Scheme 2.13: A reaction scheme for the Vilsmeier-Haack reaction.189 
To form several of the required indole-3-carboxaldehydes a Vilsmeier-Haack 
reaction was used.201 In this reaction N,N-dimethylformamide (DMF) was 
reacted with phosphorus oxychloride (POCl3) to form a N-(chloromethylene)-N-
methylmethanimminium cation (Scheme 2.14). The intermediate was then 
attacked by the nucleophilic aromatic ring; treatment with water hydrolysed 
the resulting imminum ion to form an aldehyde (Scheme 2.14).201 
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Scheme 2.14: The mechanism of the Vilsmeier- Haack reaction.201 
This reaction was carried out on the following substituted indoles; 4-
fluoroindole, 4-chloroindole, 4-bromoindole, 4-iodoindole, 5-iodoindole, 6-
fluoroindole, 6-chloroindole, 6-iodoindole, 7-fluoroindole, 7-chloroindole, 7-
bromoindole and 7-iodoindole. Yields were generally excellent ranging from 
54% to 98% (Figure 2.2).  
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Figure 2.2: The compounds produced using the Vilsmeier-Haack reaction. 
2.6 Synthesis of α-mercaptoacrylic acid  
The desired α-mercaptoacrylic acid functionality was formed via a Knoevenagel 
condensation and was carried out between a substituted benzaldehyde or 
indole-3-carboxaldehyde and 2-thioxothazolidin-4-one followed by base 
catalysed hydrolysis of the resulting condensation product (Section 2.6.1 and 
Section 2.6.2). 
2.6.1 Knovenagel condensation reaction 
 
Scheme 2.15: The Knoevenagel condensation reaction of 2-thioxothiazolidin-4-one with a halo 
substituted benzaldehyde.188 
A halo-substituted benzaldehyde or indole-3-carboxaldehyde was reacted with 
2-thioxothiazolidin-4-one using sodium acetate in acetic acid as the catalyst 
(Scheme 2.15). 
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Figure 2.3: The yields of the phenyl and indole based derivatives after the Knoevenagel 
condensation. 
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The yields achieved for the majority of the compounds were above 60%, with 
the exception of compounds 39, 51, 52 and 60 (Figure 2.3). The lower yields 
achieved for compounds 39, 51 and 52 may be down to the proximity of the 
halogen towards the 2-thioxothiazolidin-4-one ring.  
2.6.2 Base-catalysed hydrolysis 
 
Scheme 2.16: The base catalysed hydrolysis of the 2-thioxothiazolidin-4-one ring to form the α-
mercaptoacrylic acid substituent.188 
The compounds produced by the Knoevenagel condensation reaction (Section 
2.6.1) were subjected to a base-catalysed hydrolysis to form the α-
mercaptoacrylic acid (Scheme 2.16). After refluxing in 15% aqueous sodium 
hydroxide solution the reaction was cooled to 5 °C and quenched with 2M 
hydrochloric acid. The precipitates that formed were filtered and air-dried 
under reduced pressure. Through mass spectrometry, 1H NMR and 13C NMR 
spectroscopy 24 compounds were identified as the desired α-mercaptoacrylic 
acids. The thiol of the indole based mercaptoacrylic acids was visible in the 1H 
NMR spectra as a broad peak at ~5 ppm, when carried out in DMSO-d6. The 
proton of the NH in the 2-thioxothiazolidin-4-one ring was no longer visible at 
~14 ppm in the 1H NMR spectra. 
The hydrolysis of compounds 41 and 52 yielded compounds 67 and 78, which 
were not the desired α-mercaptoacrylic acids. The thiol group had replaced the 
halogen through an ipso substitution to give a benzothiophene, 67, in the case of 
the phenyl derivative and a thiopyranoindole-2-carboxylic acid in the case of 
the indole, 78 (Figure 2.4) (Section 2.6.3). All of the compounds, apart from 81, 
were isolated in yields in excess of 50 % (Figure 2.4).  
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Figure 2.4: The final phenyl and indole α-mercaptoacrylic acid derivatives. 
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2.6.3 Intra-molecular cyclisation  
The target compounds (Z)-3-(2-iodophenyl)-2-mercaptoacrylic acid and (Z)-3-
(4-iodoindol-3-yl)-2-mercaptoacrylic acid could not be prepared using this 
chemistry since during the hydrolysis reaction the compound underwent a 
cyclisation reaction (Scheme 2.17).  
 
Scheme 2.17: The base catalysed hydrolysis of 41 and 52 resulting in undesired products. 
This intra-molecular ipso-substitution reaction presumably occurs via the 
nucleophilic thiolate that forms during the hydrolysis. The thiolate attacks at 
the iodo-substituted carbon and the iodide is then lost to form the 
benzothiophene product (Scheme 2.18). 
 
Scheme 2.18: Proposed mechanism for the thiophene formation. 
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The intra-molecular reaction only occurs when the iodine is attached to the 
ortho position relative to the mercaptoacrylic acid substituent. I- is a much 
better leaving group than fluoride, chloride and bromide, therefore it appears 
that cyclisation is faster than the formation of the α-mercaptoacrylic acid 
substituent. 
2.7 Disulfide formation 
The final α-mercaptoacrylic acid compounds contain a thiol group. Therefore it 
was important to determine whether a disulfide bond forms between two thiols 
(Scheme 2.19).  
 
Scheme 2.19: Formation of the disulfide bond between two molecules of α-mercaptoacrylic acid. 
2.7.1 Disulfide formation with indole based α-mercaptoacrylic acids 
To determine whether the disulfide formation occurred with the indole based 
α-mercaptoacrylic acids, compound 88 was used as a model compound 
(Scheme 2.20). Disulfide formation occurs spontaneously in air or by the 
addition of oxidising agents and may be reversed by the addition of reducing 
agents such as dithiothreitol (DTT). Observation of any disulfide formation was 
carried out using three techniques; 1H NMR spectroscopy, UV-Vis 
spectrophotometry and HPLC analysis. 1H NMR spectroscopy was used to 
observe the change in the chemical shift as dimerization occurs. This was 
carried out in DMSO-d6 and as this is an oxidising solvent the addition of DTT 
would have little effect on the dimeric compound. UV-Vis spectrophotometric 
analysis was used to follow disulfide formation and reduction through the 
absorbance of the reduced form at 324 nm. Reversed phase HPLC analysis was 
also used to observe the formation of the disulfide and the reduction back to the 
monomeric compound through the change in retention time. 
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Scheme 2.20: Oxidation of 88 to form a disulfide. 
UV-Vis spectroscopy  
 
Figure 2.5: UV-Vis spectra of 88 in a 1:1 mixture of acetonitrile and 100 mM potassium phosphate 
buffer at pH 7.4, recorded every 20 minutes for 300 minutes, where the process of gradual 
oxidation was observed. This was followed by the addition of DTT (10 mM) to reduce the 
compound back to its monomeric form. 
The reaction was carried out in a 1 ml cuvette using a 1:1 solution of 
acetonitrile and 100 mM potassium phosphate buffer at pH 7.4. The solvent 
mixture was used to ensure the compound remained in solution over the course 
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of the experiment. 2 μl of 88 (50 mM in DMSO) was added to the solution to 
make a total concentration of 100 μM. Spectra were recorded from 250 – 450 
nm every 20 minutes for 300 minutes. The λmax at 324 nm diminished in 
intensity over the course of the experiment, resulting from structural 
alterations to the compound in solution (Figure 2.5).  
10 μl of 1 M dithiothreitol (DTT) was then added to the solution giving a total 
concentration of 10 mM. UV-Vis spectra were then recorded every 60 seconds 
until the compound appeared to have been reduced back to the monomeric 
form (Figure 2.5). The addition of DTT revealed an increase in the absorbance 
at 324nm and that the reaction was reversible (Figure 2.5). The absorbance 
observed, at 324 nm, 4 minutes after the addition of DTT to the solution did not 
reach the original absorbance at the start of the experiment. This may be due to 
the gradual degradation of the compound in aqueous solutions, evidence for 
this degradation was also seen in the HPLC analysis (vide infra). 
HPLC analysis 
 
Figure 2.6: HPLC traces demonstrating that the monomeric 88 (retention of 26.8 minutes bottom 
trace) changes to give another compound of retention time of 29.6 minutes (middle trace). 10 mM 
DTT was added to the solution and the compound rapidly returns to is original form (top trace). 
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Compound 88 (6.7 mM) was dissolved in 0.5 ml of a 1:1 mixture of acetonitrile 
and 100 mM phosphate buffer at pH 7.4. 20 μl of this sample was analysed by 
revesed phase HPLC. Elution was carried out a reversed phase analytical 
column (Acclaim® 120, C18, 3 μm, 120 Å, 150 × 4.6 mm) with the wavelength of 
the detector set to 290 nm. The solvent gradient ranged from 100% water 
(0.1% trifluoroacetic acid (TFA)) to 100% acetonitrile (0.1% TFA) over the 
course of 60 minutes, with the flow rate set to 1 ml/min. 
The retention time of 88 at 0 hours was 26.8 minutes (Figure 2.6). After 5 hours 
in solution (at 20 °C) a second 20 μl sample was analysed. The peak at 26.8 min 
had disappeared and a second peak was clearly visible, at 29.6 minutes (Figure 
2.6). 5 μl of a 1M DTT solution (in 100 mM phosphate buffer) was added to the 
solution of 88 to give a total concentration of 10 mM DTT, after 0.5 hours at 20 
°C a 20μl sample was analysed to reveal that the majority of the compound had 
been reduced to the monomeric form. Again over the duration of the 
experiment it appears that some of the compound had been lost due to 
degredation in aqueous solution. The HPLC traces indicate that the loss of the 
compound is likely to be due to decomposition, as the number of peaks 
observed in the chromatogram increased over time (Figure 2.6).  
1H NMR spectroscopic analysis 
1H NMR spectroscopic analysis of 88 revealed that in DMSO the compound 
alters structurally, over the course of 22 hours (Figure 2.7). The resonances 
arising from the protons in the vicinity of the mercaptoacrylic acid substituent 
showed the most dramatic changes in chemical shift (Figure 2.7).  The signals 
for the C3 proton, the alkene proton and the NH proton moved by 0.51, 0.21 and 
0.20 ppm in chemical shift, respectively, during this time (Figure 2.7). This is 
consistent with disulfide formation since the greatest changes in chemical shift 
are found in the protons localised around the mercaptoacrylic acid. After 22 
hours in DMSO-d6 other peaks are visible, that are not related to the disulfide 
compound, this is yet another indication that these compounds are not stable in 
solution. 
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Proton δH (Monomer) δH (Dimer)  
1 12.07 ppm 12.27 ppm 
2 8.00 ppm 8.21 ppm 
3 7.95 ppm 8.46 ppm 
4 7.80 ppm 7.78 ppm 
5 7.10 ppm 7.13 ppm 
6 7.46 ppm 7.47 ppm 
Figure 2.7: 1H NMR spectra of 88 in DMSO-d6 at 0 hours (blue), 5 hours (green) and 22 hours 
(red) and table listing the chemical shifts and assignment of the resonances due to each proton. 
2.7.2 Phenyl based α-mercaptoacrylic acids 
Two techniques were used for the detection of the dimerisation of phenyl based 
inhibitors, UV-Vis spectroscopy and HPLC analysis. The analyses were carried 
out using 74 (Scheme 2.21).  
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Scheme 2.21: Oxidation of 74 to form a disulfide.  
UV-Vis spectroscopy 
 
Figure 2.8: UV-Vis spectra of 74 in a 1:1 mixture of acetonitrile and 100 mM potassium phosphate 
buffer at pH 7.4, recorded every 20 minutes for 300 minutes, where the process of gradual 
oxidation was observed. This was followed by the addition of DTT (10 mM) to reduce the 
compound back to its monomeric form.  
Compound 74 (100 μM) was dissolved in 1 ml of a 1:1 mixture of acetonitrile 
and 100 mM potassium phosphate buffer at pH 7.4, UV-Vis spectra were then 
recorded from 450 – 250 nm every 20 minutes for 300 minutes. The spectra 
revealed that the λmax of 309 nm decreases steadily over time, but at a slower 
rate than 88 (vide supra). DTT was added (final concentration 10 mM) after 300 
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minutes and spectra were recorded every 60 seconds until absorbance at 309 
nm stopped increasing. The compound was reduced to the monomeric form 
within 3 minutes (Figure 2.8).  The slower oxidation of 74 implies that the 
compound is more stable in the monomeric form than compound 88 is in 
solution.  
HPLC analysis  
This technique was used to establish whether the disulfide that forms is fully 
reduced by the addition of 10 mM DTT. 74 was dissolved in 1 ml of a 1:1 
mixture of acetonitrile and potassium phosphate buffer at pH 7.4, to make a 
total concentration of 5.6 mM. 20 μl of this sample was analysed by reversed 
phase HPLC in an identical manner to that used for the indole derivative 88 
(vide supra). 
The retention time of 74 at 0 hours was 30.0 minutes (Figure 2.9). The solution 
containing the inhibitor was left for 5 hours at 20 °C and a 20 μl sample was 
analysed revealing the formation of a new peak at 33.3 min. The solution was 
left for a further 19 hours before the sample was analysed again revealing that 
the peak at 30.0 min had disappeared (Figure 2.9). DTT was added to a total 
concentration of 10 mM, after 0.5 hours the HPLC analysis was repeated to 
determine whether the compound had returned the original monomeric form. 
The compound had fully reduced after 0.5 hours (Figure 2.9).  
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Figure 2.9: Chromatograms demonstrating that the monomeric 74 (30.0 minutes bottom trace) 
forms a disulfide with a retention time of 33.3 minutes (middle trace). 10 mM DTT was added to 
the solution and the compound rapidly underwent a reduction to the monomeric form (top trace).  
2.7.3 Discussion 
Both compound 88 and 74 readily react to form disulfides leading to dimers.  
The combination of the UV-Vis spectra and the HPLC chromatograms revealed 
that 88 has a greater tendency to dimerise than its phenyl counterpart. Through 
the addition of 10 mM DTT the dimers are swiftly reduced back to the 
monomeric form. This reducing agent is representative of the reducing 
conditions that are found within the cell, as the cytosol contains reducing agents 
such as glutathione.202 Therefore when these inhibitors were tested with 
calpain-I and calpain-II in the fluorogenic assays and within the neutrophil itself 
(Section 2.8), the compound that was active was the very likely monomeric 
mercaptoacrylic acid and not the disulfide form of the compound.  
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2.8 Testing for calpain-I inhibition 
Each α-mercaptoacrylic acid was tested for its inhibitory properties toward 
both calpain-I and calpain-II. FRET based assays were used to determine the 
IC50 values for each inhibitor. The two assays used different substrates, the first 
substrate was calpain-I specific (Section 2.8.1) and the second could be 
hydrolysed by both isoforms (Section 2.8.2). Calpain-I inhibition was preferred 
over inhibition of calpain-II as inhibition of calpain-II is embryonically lethal.171  
All inhibition assays were performed by Dr. C. Parr, Dr E. Robinson and Prof. M. 
B. Hallett (School of Medicine, Cardiff University, Cardiff). 
2.8.1 Calpain-I specific FRET based assay 
This FRET based assay employed a peptide linker derived from the known 
substrate α-fodrin between the donor chromophore and the acceptor 
chromophore.203, 204 α-Fodrin, also known as non-erythroid α-spectrin, is a 
major structural protein found in the hippocampus. It is used in the cytoskeletal 
binding of cell plasma membrane to actin filaments within the cell.205, 206 
Calpain-I is known to cleave this protein and the cleavage site is therefore used 
as substrate for a FRET based inhibition assay.203, 204, 206 
The donor chromophore was fluorescein amidite (FAM) attached to the N-
terminal lysine side chain (Figure 2.10). The acceptor chromophore was 4-
(dimethylaminophenyl)diazenylbenzoic acid (DABCYL) covalently linked to the 
side chain of a C-terminal lysine (Figure 2.10). The linker between the two 
chromophores was the hexapeptide Glu-Val-Tyr-Gly-Met-Met, therefore giving 
an octapeptide in total - Lys(FAM)-Glu-Val-Tyr-Gly-Met-Met-Lys(DABCYL).206 
The peptide bond that lies between Tyr and Gly is hydrolysed by calpain-I 
allowing fluorescence to be detected. 
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Figure 2.10: The calpain-I specific fluorogenic substrate derived from α-fodrin. Fluorescein is 
bound to the side chain of the N-terminal lysine and DABCYL is attached to the C-terminal lysine 
side chain. The cleavage site is highlighted in red. 
The fluorogenic assay was set-up in a 96-well plate reader with different 
concentrations of the final compounds in each well (0, 0.005, 0.05, 0.5, 5, 50, 
500 μM). Each well also contained buffer (10 mM HEPES, 10 mM DTT, 0.5 mM 
EDTA, 0.1% BSA at pH 7.2), 25 nM human calpain-I and 1 μM of the fluorogenic 
substrate. The excitation wavelength was 490 nm and the emission wavelength 
of 520 nm was detected by the plate reader. The fluorescence of the assay 
solutions in each well was monitored prior to the activation of calpain-I to 
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obtain a baseline. Due to the internal fluorescence quenching of the substrate 
no signal was detected. 5 mM CaCl2 was then added to initiate the calpain 
activity. Upon activation calpain-I cleaves the peptide bond between the 
tyrosine (Tyr) and the glycine (Gly) of the substrate. The cleaved substrate 
allowed the fluorescence of FAM to be detected (Figure 2.10). The rate of 
increase of fluorescence intensity was directly proportional to the activity of the 
enzyme. Thus increasing the concentration of inhibitor suppressed the rate of 
increase of fluorescence intensity. The concentration of inhibitor that was 
required to suppress the rate of increase of fluorescence intensity by half was 
recorded as the IC50 value of each inhibitor. 
Compound IC50 (μM) Compound IC50 (μM) 
64 21.9 ± 8.4 77 0.006 ± 0.003 
65 11.9 ± 8.9 79 0.25 ± 0.21 
66 21.0 ± 5.2 80 0.006 ± 0.003 
68 19.0 ± 6.2 81 0.10 ± 0.09 
69 4.2 ± 1.8 82 0.01 ± 0.007 
70 4.0 ± 1.2 83 0.21 ± 0.10 
71 4.3 ± 2.1 84 0.007 ± 0.002 
72 6.9 ± 1.4 85 0.17 ± 0.09 
73 2.5 ± 1.4 86 0.12 ± 0.009 
74 1.5 ± 0.9 87 0.01 ± 0.01 
75 0.01 ± 0.009 88 0.002 ± 0.001 
76 0.02 ± 0.01 89 0.09 ± 0.09 
Table 2.1: The IC50 values (μM) of the α-mercaptoacrylic acids for the inhibition of calpain-I. 
Assays were performed with the calpain-I specific FRET substrate (1 mM), calpain-I (25 nM) and 
an assay buffer at pH 7.2 consisting of HEPES (10 mM), DTT (10 mM), EDTA (0.5 Mm) and BSA 
(0.1%). Reactions were initiated by addition of CaCl2 (5 mM). Each figure quoted is the average of 
four readings. 
The data obtained revealed that the phenyl derivatives were all potent 
inhibitors with IC50 values in the micromolar region with the most potent 
derivatives to be 4-substituted phenyl mercapotacrylates. The 2-substituted 
compounds proved the least potent implying that the favoured position for 
substitution in this series is as far away as possible from the mercaptoacrylate 
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group. Bromine substituted compounds proved to be the most potent 
inhibitors, with 74 ((Z)-3-(4-bromophenyl)-2-mercaptoacrylic acid) having an 
IC50 of 1.5 μM. Therefore in order of potency of the final compounds the position 
of the substituent favoured is 2<3<4 and the nature of the halogen substituent 
varies as; F<Cl<Br≈I. 
The data for the indole derivatives indicates that the potency of the derivative 
significantly increases as the aromatic ring system changes from a phenyl ring 
to a 3-substituted indole system, as these compounds all gave sub-micromolar 
IC50 values. In contrast to the phenyl derivatives, the most potent derivatives 
had the halogen in position 4 and 7 on the indole ring, position 4 being closer to 
the mercaptoacrylic acid substituent than positions 5 and 6. The compounds 
that contain halogens in position 4 all gave IC50 values of 20 nM or lower. When 
the halogen was substituted into position 7 the inhibitors gave IC50 values of 
120 nM or lower. The compounds containing halogens at positions 5 and 6 on 
the indole ring are less potent towards calpain-I than those with substituents at 
positions 4 and 7, though the IC50 values obtained were still in the nanomolar 
region. The reason for the reduced potency of the compounds may be the size of 
the pocket that the inhibitor resides in, which may be too small for the bulky 
iodine. Fluorine and chlorine substituents at positions 5 and 6 may be 
disfavoured due to unfavourable electronic interactions with the halogens 
within the hydrophobic pocket. The most potent inhibitors contained a bromine 
substituent regardless of the position of the halogen, with the IC50 values of the 
bromine substituted indole based inhibitors all in the low nanomolar region, 
ranging from 2 nM to 7 nM.  
Therefore the most potent inhibitors of calpain-I in these two series contained 
bromine substituents. The indole based mercaptoacrylic acids were more 
potent inhibitors of calpain I than the phenyl based inhibitors.  
2.8.2 Calpain-I and calpain-II assay  
The substrate that was used for this assay was not specific for calpain-I and 
could be used to determine the inhibition of calpain-II. Therefore the results 
obtained for this assay with both isoforms were directly comparable. This assay 
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was also a FRET based assay (Section 2.8.1) and was carried out in a 96-well 
plate reader. The substrate used in this assay contained 7-amido-4-coumarin 
(AMC), which fluoresces prior to cleavage but not as intensely as it does once 
hydrolysed. The peptide substrate was Leu-Leu-Val-Tyr, with a succinic acid 
attached at the N terminus and AMC attached at the C terminus (Figure 2.11).207 
Upon activation of calpain through addition of CaCl2 the protease hydrolyses the 
peptide bond between tyrosine and AMC. The hydrolysis of the bond relieves 
the quenching effect of the peptide and fluorescence was detected at the 
emission wavelength 460 nm.207  
 
Figure 2.11: The structure of Suc-Leu-Leu-Val-Tyr-AMC. The cleavage site is highlighted in red. 
Testing with calpain-I  
The buffer and the method used for this assay were the same as that used for 
the calpain-I specific assay, with CaCl2 used as the source of calcium for the 
initiation of the assay. The excitation wavelength of the fluorophore was 360 
nm and the emission wavelength 460 nm. The concentrations of the inhibitors 
used in the assays were 0, 0.005, 0.05, 0.5, 5, 50, 500 µM. The IC50 values were 
defined as the concentration of inhibitor required to suppress the rate of the 
increase of fluorescence by 50% (Table 2.2).  
The IC50 values that were obtained for the non-specific assay were much higher 
than those measured for the calpain-I specific assay (Table 2.2). The poor 
specificity of the substrate may be the cause for the discrepancy in the IC50 data 
that was obtained from the two assays (Table 2.1 and Table 2.2). The same 
trends were noted however for both the position and nature of the halogen 
substrate in the most potent phenyl based substrate. Most of the 4-substituted 
analogues gave low micromolar IC50 values in this assay.  
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Compound IC50 (μM) Compound IC50 (μM) 
64 23.2 77 0.10 
65 20.7 79 0.05 
66 9.1 80 0.02 
68 31.5 81 0.09 
69 13.1 82 0.30 
70 8.4 83 0.10 
71 23.9 84 0.09 
72 5.6 85 0.30 
73 15.0 86 0.11 
74 1.5 87 0.09 
75 0.30 88 0.07 
76 0.14 89 0.22 
Table 2.2: The IC50 values of the α-mercaptoacrylic acid derivatives determined from the AMC 
based FRET assay. 
The indole based mercaptoacrylic acid derivatives, when tested with this assay, 
gave IC50 values that were in the nanomolar region. Therefore the indole 
derivatives have a higher potency than the phenyl derivatives, corroborating 
the data obtained from the calpain-I specific assay (Section 2.8.1). Bromoindole 
inhibitors displayed a higher potency towards the enzyme than any other halo-
substituted inhibitors, with the IC50 values ranging from 20 nM to 100 nM. The 
data obtained from this assay does not appear to show a definitive trend 
towards where the halogen should be positioned on the indole ring. However 
there is an indication that position 5 and position 7 of the indole ring are 
important for potency. This contradicts the data obtained from the calpain-I 
specific assay (Section 2.8.1), where position 4 not position 5 was important for 
a higher potency.  
Testing with calpain-II 
The AMC-based assay was also used to test the inhibitors against calpain-II.  The 
same assay conditions that were utilised for testing the AMC fluorogenic 
substrate with calpain-I were employed (Section 2.8.2). The results indicated 
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that these compounds are selective towards calpain-I over calpain-II, but 
remain capable of inhibiting calpain-II (Figure 2.12). 
 
Figure 2.12: A graph representing the difference in potency of selected mercaptoacrylic acid 
compound towards calpain-I and calpain-II. This data was measured with the fluorogenic AMC 
substrate.  
The results demonstrate that the inhibitors are moderately selective for 
calpain-I over calpain-II, no matter whether their structure is a phenyl based or 
indole based derivative (Figure 2.12). The indole based inhibitors were found to 
have a slightly higher selectivity towards calpain-I than the phenyl based 
derivatives however. 
2.8.3 In cell testing of inhibitors 
Live neutrophils purified from human blood were used to determine whether 
these inhibitors could pass through cell membranes. The cells had to be used 
immediately due to the short lifetime of neutrophils (5-7 days). The cells were 
suspended in Krebs medium (120 mM NaCl, 4.9 mM KH2PO4, 1.2 mM MgSO4, 1.2 
mM CaCl2, 1.3 mM KCl, 25 mM HEPES and 0.1% BSA at pH 7.4) along with 10 
μM of each of the inhibitors (added as a 50 mM solution in DMSO). 100 µl of the 
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cell solution containing the inhibitor was loaded onto a coverslip containing 
100 µl of the Krebs medium prewarmed to 37 °C. Once the cells make contact 
with the glass from the coverslip they spontaneously start to spread. The initial 
cell area was monitored with a Leica microscope and images were collected 
over a 3 minute period whilst the cells spread. Approximately 50 cells were 
monitored so an average surface area could be determined. 0.1% DMSO was 
used as a control to determine whether this solvent has an effect upon the 
neutrophils since this was the solvent that was used to create the stock 
solutions of the mercaptoacrylic acid compounds.  
 
 
Figure 2.13: A graph demonstrating that the addition of 10 μM of 6 substituted indole inhibitors 
slows down the rate of neutrophil spreading. The control was performed with 0.1% DMSO and 
showed a150% increase in cell surface area during the assay, the inhibitors reduced the cell 
spreading area by 50 – 70%. 
The cells in the control spread ~2.5× the original area of the cell. The control 
assay demonstrated the DMSO has little effect on the cell spreading capability of 
the neutrophil (Figure 2.13). The addition of the 6-substituted indole 
mercaptoacrylic acids inhibited the capability of the cells’ spreading process. 
Compound 84 appeared to be the most effective at slowing the cell spreading 
process with a reduction of ~70% in comparison to the control. Both 83 and 82 
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were less effective but curtailed the neutrophil spreading with a reduction of 
~60% and ~50%, respectively (Figure 2.13).  This shows clearly that calpain-I 
is instrumental in accelerating the cell spreading process as its inhibition within 
a live cell causes the cell spreading process to slow down. These inhibitors do 
not completely stop the capability of the cells to spread - this could be 
disastrous for the immune system. They do however slow the cell spreading 
process down, which may be beneficial as a treatment for inflammatory 
diseases.  
2.9 Photochemical effect 
When the inhibitors were tested in neutrophils, an intriguing phenomenon was 
observed. If the cells containing the inhibitor were irradiated with 410 nm light 
the cells would lose their ability to spread. 410 nm light is normally used to 
release caged inositol triphosphate (IP3) within the cell, as the release of this 
messenger stimulates release of calcium ions from intracellular stores.208-210 
Caged IP3 is microinjected into individual neutrophils, and upon irradiation the 
cells begin to spread through the release of calcium and the activation of 
calpain-I.211 
The neutrophils were observed with a Leica microscope and were suspended in 
Krebs medium (Section 2.8.3) and 10 μM of 81 ((Z)-3-(5-iodoindol-3-yl)-2-
mercaptoacrylic acid). The cells were irradiated, with a 410 nm laser, in a select 
area in the field of view of the microscope, then for the activation of the cell 
spreading process the small peptide formyl-methionyl-leucyl-phenylalanine 
(FMLP) was added. FMLP is a known chemoattractant that influences the 
activation of neutrophils and the addition of this peptide causes the cells to 
spread and flatten and to migrate towards the source of the chemoattractant.212, 
213 After 5 minutes incubation with FMLP, the cells contained within the 
irradiated area remained spherical, whereas all the cells that were outside of 
the area had spread and formed a flatter shape (Figure 2.14).  
In section 2.8.3 it was demonstrated that the addition of the α-mercaptoacrylic 
acid derivatives slowed down the rate of neutrophil cell spreading. The fact that 
upon irradiation the ability for the cells to spread is completely lost implies that 
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calpain is permanently inhibited, as it has been shown that this protease has an 
integral role in the cell spreading process. The apparent irrevesible inhibition of 
calpain-I hints that irradiation might affect the structure of 81 and cause it to 
permanently bind to the enzyme.  
 
Figure 2.14: (A) A microscope image prior to the addition of the peptide FMLP, the area with the 
cells that were irradiated with 405 nm light is highlighted in blue, (B) An image collected 5 
minutes after FMLP addition, the cells within the irradiation area are held in a spherical shape. 
2.9.1 Photo-inhibition of calpain-I 
To determine whether the photo-inhibition reaction occurs with calpain-I the 
AMC assay (Section 2.8.2) was used. 20 nM of calpain-I was used under four 
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different assay conditions in the presence or absence of 1 μM of 81 and with or 
without irradiation (Figure 2.15). Samples were irradiated for 5 minutes with a 
100 W light source with a 360 nm band pass filter. 100 μl aliquots were then 
placed in a 96 well plate and 5 mM CaCl2 was added to activate the enzyme. The 
cleavage of the substrate was monitored continuously for an hour with the 
excitation wavelength set to 360 nm and the emission wavelength set to 460 
nm. 
Conditions Calpain-I Inhibitor Irradiation 
1 20 nm N/A (DMSO control) N/A 
2 20 nm N/A (DMSO control 360 nm (5 min) 
3 20 nm 81 N/A 
4 20 nm 81 360 nm (5 min) 
 
Figure 2.15: The conditions used for the irradiation experiment on calpain-I using the AMC assay 
and the relative rates of the increase in fluorescence in the AMC assay, with the different 
irradiation conditions in calpain-I. 
The results of the AMC fluorescence assay revealed that the irradiation of the 
protein alone has an effect on the protease itself with a 50% drop in the activity 
of the protease (Figure 2.15). The addition of 1 μM of 81 showed that without 
light there was a minimal drop in the overall rate of the increase in 
fluorescence, ~6%. Irradiated inhibitor however suppressed the activity of the 
enzyme by approximately 85%.  The irradiated inhibitor sample shows a 
Synthesis of α-Mercaptoacrylic acids for Inhibition of Calpain-I 
 
77 
 
decrease in the enzyme activity by 31%, when compared to the irradiated 
control sample. Taking all these results into account, irradiation of the inhibitor 
dramatically decreases the overall activity of calpain-I. Comparison of this with 
the activity of the enzyme in the presence of inhibitor without light indicates 
that the light has a dramatic effect on the potency of the inhibitor, increasing it 
greatly. 
The data from the AMC assay and the cell spreading assay might demonstrate 
that the light has a dramatic effect on the potency of the inhibitor, however it 
appears that damage may also occur to the enzyme itself as the AMC assay 
showed a decrease in the activity of the enzyme by 50% upon irradiation.  
2.10 Conclusions 
The synthetic routes that were employed for the production of these α-
mercaptoacrylic acids were generally high yielding and generated a library of 
potent inhibitors of calpain-I. The two step synthesis to form the 
mercaptoacrylic acids from substituted benzaldehydes or indole-3-
carboxaldehydes gave overall yields varying from 50% to 94% with a few minor 
exceptions. For the synthesis of the indole-3-carboxaldehydes a Vilsmeier-
Haack procedure was employed to transform suitably substituted indoles, with 
yields of the desired products ranging from 54-98%.189 The Bartoli indole 
synthesis was required for the production of 7-substituted indoles; 14% and 
43% yields were recorded for 7-fluoroindole and 7-bromoindole 
respectively.192 For the five step synthesis that yielded 6-iodoindole, each step 
recorded a yield that was at least 50% or above, this resulted in an overall yield 
of 22%. The thallium trifluoroacetate based chemistry required for the 
synthesis of 4-iodoindole gave an overall yield of 43% for the three steps, 
although unfortunately the 4-iodoindole final product could not be prepared 
with this methodology due to an undesired ipso-substitution reaction in the 
final hydrolysis step. 
The analogues proved to be potent and moderately selective towards calpain-I, 
with the size and position of the halogen important for the potency of inhibition. 
The bromide analogues proved to be most potent analogues of this class 
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prepared to date. The assays demonstrated that the larger indole ring system, 
gave inhibitors that were more potent than the phenyl based inhibitors. 
The testing of inhibitors within live neutrophils revealed that these 
mercaptoacrylic acid analogues were effective at slowing down the rate of cell 
spreading, providing further evidence that calpain-I is instrumental in 
accelerating the cell spreading process. Additional experiments corroborated 
this when irradiation of neutrophils with 410 nm light completely ceased the 
cells spreading process. Testing calpain-I with the AMC assay and with incident 
light revealed that the potency of the inhibitor dramatically increases when 
light is shone upon the enzyme-inhibitor complex.  
This work demonstrates that the mercaptoacrylic analogues prepared here may 
lead to a viable small molecule based treatment of the autoimmune disease 
rheumatoid arthritis.  
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Characterisation 
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3.1 α-Mercaptoacrylic acids and PEF(S) 
X-ray crystal structures demonstrated that the phenyl based α-mercaptoacrylic 
acid inhibitor, PD150606, binds to a hydrophobic pocket of PEF(S) (Figure 
3.1).81, 186 This is also the pocket that binds inhibitory region C of calpastatin.81 
The aromatic ring on PD150606 interacts with leucine and phenylalanine 
residues within this pocket and the α-mercaptoacrylic acid moiety interacts 
with hydrophilic residues on the surface of the protein. 
 
 
Figure 3.1: A cartoon representation of PD150606, bound to PEF(S) of calpain, the aromatic ring 
of the inhibitor binds in a hydrophobic pocket (PDB:1NX3).186  
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To determine whether the α-mercaptoacrylic acid derivatives described in 
Chapter 2 bind to calpain-I in a similar fashion, a gene encoding for the porcine 
PEF(S) (MW 19,992) was expressed in E. coli and the resulting protein purified 
and characterised.  
3.2 Sub-cloning PEF(S) into an expression vector 
 
Figure 3.2: Plasmid maps of pBSK-PEF(S) with PEF(S) gene highlighted in blue and the expression 
vector pET21d, the unique restriction sites are noted on the maps. Both vectors were digested with 
NcoI and BamHI, the PEF(S) gene was ligated into the pET21d vector.  
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A cDNA for porcine PEF(S), codon optimised for E. coli, was purchased from 
Epoch in a pBSK vector (pBSK-PEF(S)) (Epoch Biolabs, Texas, USA). The gene 
was located between an NcoI and a BamHI restriction site (Figure 3.2). PEF(S) 
was sub-cloned into pET21d vector (Figure 3.2) for expression.  
3.2.1 Restriction endonuclease digestion 
 
Figure 3.3: (A) The sequences of recognition by the restriction endonucleases NcoI (i) and BamHI 
(ii). The black triangles represent the site of cleavage. (B) An image of the agarose gel of the 
products resulting from digestion of the pBSK vector containing the PEF(S) gene, 530 base pairs, 
(highlighted in a white box) and the pET21-d expression vector (highlighted in a white box), M = 
marker.  
The PEF(S) gene was excised from the pBSK vector using restriction 
endonucleases NcoI-HF (high fidelity) and BamHI. Both pET21d and pBSK-
PEF(S) were incubated with the restriction endonucleases sequentially. The 
DNA was incubated at 37 °C for 3 hours with NcoI-HF followed by BamHI for 4 
hours (Section 6.3.6). The same sequence of digestions was carried out on the 
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pET21d vector. Agarose gel electrophoresis separated the fragments (Figure 
3.3).  The bands of DNA corresponding to the correct molecular weight for the 
PEF(S) gene and digested pET21d expression vector were retrieved from the gel 
and used for the ligation of the pET21d-PEF(S) construct. 
3.2.2 DNA Ligation 
For the ligation, pET21d and PEF(S) were incubated with T4 ligase in ratios of 
1:3 and 1:6. The resulting ligated DNA was then incubated and was used to 
transform E. coli XL1-Blue super competent cells. Following a 10 ml overnight 
culture the DNA was purified using QIAprep spin miniprep kit according to the 
manufacturers instructions. The DNA was sequenced to reveal that the PEF(S) 
had been successfully ligated into pET21d (Figure 3.4). 
ATTTTGTTTACTTTAAGAAGGAGATATACCATGGAGGAAGTCCGCCAATTTCNCCGTCTG 
I  L  F  T  L  R  R  R  Y  T  M  E  E  V  R  Q  F  X  R  L 
TTTGCACAACTGGCAGGTGATGATATGGAAGTTAGTGCGACAGAACTGATGAACATCCTG 
F  A  Q  L  A  G  D  D  M  E  V  S  A  T  E  L  M  N  I  L 
AATAAAGTTGTTACACGTCATCCGGATCTGAAAACTGATGGGTTTGGGATCGACACGTGT 
N  K  V  V  T  R  H  P  D  L  K  T  D  G  F  G  I  D  T  C 
CGTAGCATGGTGGCCGTGATGGATAGCGACACGACTGGTAAACTGGGCTTCGAAGAATTC 
R  S  M  V  A  V  M  D  S  D  T  T  G  K  L  G  F  E  E  F 
AAATACCTGTGGAATAACATCAAGAAATGGCAGGCGATCTACAAACAATTTGATGTGGAT 
K  Y  L  W  N  N  I  K  K  W  Q  A  I  Y  K  Q  F  D  V  D 
CGCAGCGGTACCATTGGTAGTAGCGAACTGCCGGGTGCTTTTGAAGCGGCTGGCTTTCAC 
R  S  G  T  I  G  S  S  E  L  P  G  A  F  E  A  A  G  F  H 
CTGAACGAGCATCTGTATTCTATGATTATCCGTCGCTATAGTGATGAGGGCGGCAATATG 
L  N  E  H  L  Y  S  M  I  I  R  R  Y  S  D  E  G  G  N  M 
GACTTCGATAACTTCATTTCTTGCCTGGTACGTCTGGACGCCATGTTCCGCGCCTTCAAG 
D  F  D  N  F  I  S  C  L  V  R  L  D  A  M  F  R  A  F  K 
TCTCTGGACAAAGACGGCACCGGCCAGATTCAGGTCAATATTCAGGAGTGGCTGCAACTG 
S  L  D  K  D  G  T  G  Q  I  Q  V  N  I  Q  E  W  L  Q  L 
ACCATGTATAGCTAATGAGGATCCGAATTCGAGCTCCGTCGACAAGCTTGCGGCCGCACT 
T  M  Y  S  -  -  G  S  E  F  E  L  R  R  Q  A  C  G  R  T 
CGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGA 
R  A  P  P  P  P  P  L  R  S  G  C  -  Q  S  P  K  G  S  - 
Figure 3.4: DNA sequence of the PEF(S) gene inserted (red) into the pET21-d expression vector 
(black), with the NcoI and BamHI restriction sites highlighted in blue. The amino acid sequence 
that the gene encodes for is shown below the DNA sequence, as a one letter code. 
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3.3 Expression of the PEF(S) gene 
Expression tests were carried out on the pET21d-PEF(S) construct using the E. 
coli expression strains BL21-CodonPlus(DE3)-RP 214 and BL21-
CodonPlus(DE3)-RIL.214 The cells were grown in 500 ml of ampicillin (1 μg/ml) 
selective LB medium at 37 °C (shaking at 150 rpm), until an optical density (OD) 
of 0.6 a.u. at 600 nm was reached. IPTG (63 mg) was then added to give a total 
concentration of 0.5 mM and the expression was carried out at 37 °C for 4 
hours. A 1 ml sample of the culture was collected every hour. The samples that 
were collected were analysed by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) (Section 6.3.7) to determine whether the 
expression of the gene had been a success (Figure 3.5). The SDS-PAGE indicated 
that the optimum time for expression of the gene was 3 hours at 37 °C using 
BL21-CodonPlus(DE3)-RP E. coli cells.  
 
Figure 3.5: The SDS polyacrylamide gel that was used to assess the performance of the small scale 
expression experiments. M = molecular weight marker, Un = uninduced cells, 1 h = 1 hour after 
induction, 2 h = 2 hours after induction, 3 h = 3 hours after induction, 4 h = 4 hours after induction, 
RIL = BL21-CodonPlus(DE3)-RIL, RP = BL21-CodonPlus(DE3)-RP and MW = molecular weight (× 
1000). 
3.3.1 Large scale expression and purification of PEF(S) 
Transformed BL21-CodonPlus(DE3)-RP E. coli cells were grown in  6 x 500 ml 
of ampicillin (1 μg/ml) selective LB media at 37 °C (shaking at 150 rpm). Once 
the cells reached an OD of 0.6 a.u. at 600 nm, the cells were induced with IPTG. 
After further incubation for 3 hours the cells were harvested by high-speed 
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centrifugation at 4 °C (6080 RCF, 15 min). The pellet was re-suspended in cell 
lysis buffer (Tris-Base (20 mM), βME (5 mM) and EDTA (2 mM) at pH 8.0). After 
sonication and clarification by centrifugation (30310 RCF, 30 min), the pellet 
and the crude cell extract were analysed by SDS-PAGE revealing that the over-
expressed protein was soluble and was clearly visible as a band at a MW 
~20,000. 
3.4 Purification of PEF(S) 
A two-step purification process was required to gain protein of sufficient purity 
for protein crystallography. Anion exchange chromatography using 
diethylaminoethyl-sepharose (DEAE) was used to purify the protein from the 
crude cell extract. The column was attached to a fast protein liquid 
chromatography instrument (FPLC). The FPLC instrument allowed for an 
increasing NaCl concentration to be applied to the column whilst the UV 
absorption of the eluent was monitored at 280 nm. The protein was applied to 
the column at a salt concentration of 0 M NaCl (Purification buffer A, section 
6.3.4). A linear salt gradient was then applied to the column from 0 M to 1 M 
NaCl (20 mM Tris-Base, 2 mM EDTA and 5 mM βME at pH 8.0) over 6 CV, the 
eluent was collected in 6 ml fractions (Figure 3.6). 
A 20 μl sample was taken from each of the fractions that contained eluted 
proteins (with an UV absorbance above 500 mAU) and analysed using SDS-
PAGE, to determine which fractions contained the desired protein (Figure 3.6). 
The resulting gel revealed that the protein eluted from the DEAE anion 
exchange column at a salt concentration of ~0.3 M NaCl. Even though the anion 
exchange column had purified PEF(S) from many of the other proteins that 
were found within the cell extract, the protein is required to be at a higher level 
of purity than that obtained from this purification to be suitable for protein X-
ray crystallography. Therefore the fractions that contained the protein were 
pooled and concentrated for further purification. The solution (~42 ml) was 
concentrated to 15 ml, using an Amicon ultrafiltration membrane with a 
molecular weight cut off of 10,000. 
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Fraction Volume/ml NaCl Concentration/% NaCl Concentration/M 
7 37-43 6.6-7.7 0.07-0.08 
13-18 73-109 13.2-18.7 0.13-0.19 
25-31 145-187 26.2-34.2 0.26-0.34 
37-38 217-229 39.8-42.1 0.40-0.42   
  
Figure 3.6: The chromatogram resulting from the purification of the crude cell extract from the 
expression of porcine PEF(S) gene, with the use of a DEAE anion exchange column, the red lines 
represent the fractions collected. The table shows the fractions collected and their relative column 
and salt concentration. The SDS-PAGE of the eluted fractions from the DEAE anion exchange 
column, where M = marker, SN = supernatant solution, FT = flow through and the numbers 
correspond to the fractions collected with a level of UV absorbance above 500 mAU, detected 
through the FPLC. The white box represents the desired PEF(S) protein (MW 20,000). 
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Size exclusion chromatography 
This method of purification, also known as gel filtration, separates proteins 
according to their molecular weight.215 Larger molecules elute with a shorter 
retention time than smaller molecules.216 The size exclusion column that was 
used for purification of PEF(S) was a SuperDex™ 75 (GE Healthcare Life 
Sciences, Buckinghamshire, UK), this column resolves of proteins with a 
molecular weights ranging from 3,000 to 70,000.215 The size exclusion column 
(CV 320 ml) was connected to the FPLC instrument and equilibrated in a buffer 
containing Tris-Base (20 mM), EDTA (2 mM), βME (5 mM) and NaCl (0.15 M) at 
a pH of 8.0 (Purification buffer C, Section 6.3.4). The 15 ml solution of PEF(S) 
protein was applied to the size exclusion column and eluted using 1.5 CV of 
protein purification buffer C. The eluent from the column was monitored at 280 
nm, 10 ml fractions were collected (Figure 3.7). 
 
Figure 3.7: The chromatogram resolution from the purification of PEF(S) with the Superdex 75 
size exclusion column, fractions with UV absorbance >100 mAU (280 nm) are labelled. The red 
lines represent the fractions collected. 
The three fractions with the highest absorbance at 280 nm were analysed with 
SDS-PAGE (Figure 3.8), to reveal which of them contained PEF(S). The required 
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protein PEF(S) corresponded to the large peak that absorbed at 1800 mAU 
(fractions 15 and 16) and it was judged to be ~95 % pure. 
 
Figure 3.8: The SDS-PAGE of the fractions that were eluted from the size exclusion column, with M 
= marker, SN = crude sample before the DEAE column and DEAE = fractions from the DEAE 
column. The white box highlights the PEF(S) protein (MW 20,000).  
The pooled fractions 15 and 16 were dialysed against a buffer containing KiPO4 
(5 mM), EDTA (2 mM) and βME (5 mM) at pH 7.0 (Dialysis buffer, Section 6.3.4). 
The 20 ml solution containing PEF(S) was concentrated to 2 ml by Amicon 
ultrafiltration as above. The concentration of the resulting protein solution was 
measured with UV-Vis spectroscopy, at different wavelengths (210, 215 and 
220 nm) (Section 6.3.7).217 The result of the concentration measurement 
revealed that the protein was capable of reaching high concentrations in 
solution without precipitating. A final concentration of 2.2 mM (43 mg/ml) was 
measured. The overall yield obtained from 3 l culture was approximately 86 mg 
of protein. 
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3.5 Characterisation of PEF(S) 
In addition to SDS-PAGE, the purified protein was characterised using mass 
spectrometry, circular dichroism spectroscopy and analytical size exclusion 
chromatography. 
3.5.1 Mass spectrometry 
The mass of the protein was determined using matrix-assisted laser 
desorption/ionisation - time of flight mass spectrometry (MALDI-TOF). A 1:1 
mixture of the protein solution at 2 μM (in phosphate buffer) and matrix 
solution (sinapinic acid in acetonitrile/water solution), was placed on a MALDI 
plate and analysed in a MALDI-TOF Micro MX spectrophotometer. The mass 
spectrum obtained contained a major peak at m/z 19988.81 which is 4 mass 
units off the predicted mass of the protein (m/z 19992.69) (Figure 3.9). A 
second peak at m/z 999.75 is consistent with a protein ion of +2 charge. The 
molecular ion is consistent with the predicted mass of the PEF(S) domain.  
 
Figure 3.9: The mass spectrum of the purified protein obtained through MALDI-TOF mass 
spectrometry, where the peak found at 9999.75 is the molecular ion with a +2 charge and 
19988.82 is the PEF(S) molecular ion of +1 charge. 
PEF(S); Expression, Purification and Characterisation 
 
90 
 
3.5.2 Analytical size exclusion chromatography 
To determine whether the protein is a monomer, dimer or takes any other form 
in solution, the sample was passed through an analytical size exclusion column. 
500 μl of the dilute sample of purified protein from the SuperDex 75 (CV 320 
ml) purification step (Section 3.3.1), was injected onto an analytical SuperDex 
75 (CV 26 ml), which was connected to an FPLC instrument. The column was 
equilibrated in purification buffer C (Section 6.3.4).  
 
Figure 3.10: Analytical size exclusion chromatogram of porcine PEF(S), shown in blue, overlaid on 
the calibration chromatogram shown in red where the first protein to elute is BSA (MW 66,000), 
the second trypsin inhibitor (MW 20,090) and the final protein is RNAase A (MW 13,700).  
The chromatogram obtained (Figure 3.10) was compared to a calibration 
chromatogram using the same analytical column. The proteins that were used 
to calibrate the size exclusion column were: bovine serum albumin (BSA 
molecular weight of 66,000), trypsin inhibitor (from soya beans, 20,090) and 
ribonuclease A (from bovine pancreas, 13,700). When compared to the 
calibration chromatogram the protein eluted at 10.7 ml which was in between 
the elution times of BSA and the trypsin inhibitor, implying that the mass of the 
protein was approximately 40,000. This means that the protein formed a dimer 
in solution, as the molecular weight of monomeric protein is 20,000 (Section 
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3.5.2). This corroborates previous reports of the PEF(S) domain forming a 
dimer in solution.80 
3.5.3 Circular Dichroism spectroscopy 
Proteins can fold into three main types of secondary structure; they can be α-
helical, β-sheets or a random loop. The secondary structure of the protein can 
be analysed using circular polarised light. When the angle of the light emitted 
from the circular polarised light source hits a chiral molecule within a sample it 
changes in orientation. The change in orientation of the polarised light allows 
for the change in signal at a given wavelength, it is this signal alteration that 
allows for the determination of the overall secondary structure of a protein. 
Negative peaks at 208nm and 220 nm and a positive peak at 192 in a CD 
spectrum are indicative of α-helices.218 If the protein structure contains a lot of 
β-sheets a negative peak is observed at 216 nm with two positive peaks at 200 
nm.218 When the protein structure is mainly composed of random coils the CD 
spectrum that is obtained has a negative peak at 195 nm (Figure 3.11).219  
 
Figure 3.11: Examples of the CD spectra obtained from ideal protein structure consisting of an α-
helical structure (yellow), β-sheet (blue) and random coil (red).219  
The protein solution was diluted to 20 μM in a CD cuvette containing 350 μl of 
degassed KiPO4 (10 mM) at pH 7.0. A CD spectrum was then recorded between 
350 nm to 190 nm, with 1 nm steps at 20 °C (Section 6.3.7). The data obtained 
contained two minima at 220 nm and 208 nm indicating that the majority of the 
secondary structure was α-helical (Figure 3.12). 
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Figure 3.12: The CD spectrum of PEF(S) showing that it forms a mainly α-helical secondary 
structure. 
The raw data was then de-convoluted to determine the percentage of the 
different forms of secondary structure found within PEF(S).220-222 This revealed 
that the secondary structure of the protein was 62% α-helical (Table 3.1). The 
dominance of α-helices within the secondary structure correlates with the 
published X-ray crystal structure of PEF(S).74  
Secondary structure PEF(S) 
α-Helix 62% 
β-sheets 6% 
β-turns 11% 
Unordered 21% 
Total 100% 
Table 3.1: The relative percentages of the secondary structure found within PEF(S).220, 221 
3.6 Conclusion 
The expression and purification of PEF(S) yielded a useful quantity of pure 
protein. The characterisation of the over-expressed protein indicated that it 
resembled the desired PEF(S) domain. With the aid of mass spectrometry it was 
shown that the mass of the expressed protein was identical, within 
experimental error, to the calculated mass of PEF(S). Circular dichroism 
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spectroscopy indicated that the secondary structure of the protein was 
composed mostly of α-helices, consistent with the published X-ray crystal 
structure.74 Finally analytical size exclusion chromatography demonstrated that 
the protein forms a homodimer in solution. The formation of the dimer is 
consistent with the EFH-5 within each monomer binding to its respective 
partner forming an EF-handshake, as previously observed in the crystal 
structure of PEF(S) and the structure of full calpain-II.74, 76 
The fully characterised protein was then used to determine whether the α-
mercaptoacrylic acid derivatives prepared as described in chapter 2 bound to 
this part of calpain-I. 
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4.1 Interaction of α-mercaptoacrylic acids with PEF(S) 
The synthesis of α-mercaptoacrylic acid compounds was discussed in Chapter 2 
where it was shown that they are inhibitors of calpain. Previous X-ray 
crystallography work on the parent mercaptoacrylic acid compound PD150606 
indicated that it binds to the PEF(S) domain.81, 186 To determine whether the 
inhibitors prepared in this project interact with this calcium binding domain, a 
fluorescence displacement assay187 was carried out using the PEF(S) protein 
expressed and purified as described in Chapter 3.  The α-mercaptoacrylic acid 
derivatives do not fluoresce, but can be used to displace a fluorescent 
compound with a lower binding affinity for the target protein domain. The 
probe used was 6-(p-toluidino)-2-naphthalenesulfonic acid (TNS). The complex 
of TNS with PEF(S) was titrated with compound 74 (Figure 4.1).187 
                      
Figure 4.1: The structure of the fluorescent probe TNS and the inhibitor 74.  
TNS has an absorption maximum at 340 nm and an emission maximum at 445 
nm. A 20 μM solution of the PEF(S) in 20 mM Tris-HCl, 0.1 mM EDTA was 
incubated with 20 μM TNS for five minutes and initial fluorescence emission 
spectra were obtained from 350 nm to 600 nm in both the presence and 
absence of 1.1 mM CaCl2. The inhibitor was then added and new fluorescence 
spectra were measured. Reduction in the intensity of the fluorescent signal 
from TNS at 447 nm indicated its displacement from a binding site of the 
protein into the solution where its fluorescence was quenched by water. The 
spectra obtained revealed that when calcium was present the fluorescence of 
TNS-PEF(S) complex increased in intensity by 100%. Upon addition of 74 to the 
solution to a final concentration of 83 μM the fluorescence intensity decreased 
in both the calcium containing and the calcium free samples by 55% and 14%, 
respectively (Figure 4.2). Even though the decrease of the fluorescent signal 
was 4 times greater in the presence of calcium the signal still fell to the same 
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final intensity, implying that calcium does not affect inhibitor binding or TNS 
displacement, but instead affects the fluorescence intensity of TNS itself. Most 
importantly, the inhibitor seemed able to bind to PEF(S) in the presence and 
absence of calcium. 
 
Figure 4.2: The fluorescence spectra of the fluorescent probe, TNS, bound to PEF(S) and the 
displacement of TNS through the addition of 74. Initial spectra were obtained from 3 ml solutions 
containing 20 μM PEF(S), 20 μM TNS, 0.1 mM EDTA and 20 mM Tris-HCl at pH 7.4, both with or 
without 1.1 mM CaCl2. Compound 74 (83 μM) was added reducing intensity of the fluorescence at 
447 nm. Excitation = 340 nm and emission = 445 nm.  
4.2 Single crystal X-ray diffraction 
Having established the PEF(S) domain as a binding site for α-mercaptoacrylic 
acid derivatives single crystal X-ray diffraction was used to elucidate the mode 
of binding.  
4.2.1 Screening 
To obtain the optimal conditions for the formation of crystals, commercial wide 
screens were carried out. These screens contain a variety of precipitating 
solutions based upon the conditions that are known to crystallise many 
proteins. Three different screens were used: JCSG-plus™, PACT-premier™ and a 
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ProPlex screen (Molecular Dimensions, Suffolk, UK). Each screen contains 96 
different precipitating conditions.223, 224 The JCSG-plus™ screen is an optimised 
sparse matrix screen, specifically designed to incorporate a wide range of 
precipitants223, 225 and is generally used in tandem with the PEG based PACT-
premier™ screen.225 The PACT-premier™ screen contains precipitants that vary 
in pH, cationic and anionic concentrations, whilst maintaining constant PEG 
concentrations and molecular weights.226 The ProPlex screen is optimised for 
the crystallisation of protein complexes and is a targeted sparse matrix screen 
based on solutions used to successfully crystallise protein complexes.224  
4.2.2 Plate set-up 
The most common crystallisation method applied to proteins is vapour 
diffusion, either by sitting drop or hanging drop methods (Figure 4.3). With the 
sitting drop approach the protein solution is contained in a small depression 
beside a deeper well containing the precipitating solution. The protein solution 
is generally a mixture of 1:1 purified protein at 10 mg/ml and the precipitating 
solution. In the hanging drop scenario the protein solution hangs from a surface 
above the precipitant. In both cases the volume of the precipitant, in the deep 
well, is normally in excess of 150 × the volume of the protein drop. The 
precipitant in solution is much more concentrated than the drop containing the 
protein. Hence to achieve equilibrium, water vapour diffuses into the deep well 
containing the concentrated precipitant solution. The diffusion of the water 
from the protein-containing droplet gradually increases the concentration of 
the protein within the drop, allowing the protein to aggregate and form crystals.  
 
Figure 4.3: Diagram of the sitting drop and the hanging drop techniques used in protein 
crystallography. 
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The sitting drop technique was used to screen and crystallise PEF(S). 96 Well 
plates were used with each of the JCSG-plus™, PACT-premier™ and ProPlex 
screening solutions. The plates were set-up using an Art-Robbins Phoenix 
dispensing robot (Alpha Biotech, Glasgow, UK). 70 μl of the crystallisation 
solution was dispensed into the deep well followed by 0.2 μl of the same 
solution dispensed in the small well. 0.2 μl of the PEF(S) solution (5 mg/ml) was 
then dispensed into the small well of the crystallisation plate. The plates were 
sealed and were stored at 20 °C until crystals formed.  
A number of crystals formed over a short period of time (~1 day). The crystals 
were collected using a cryoloop and flash frozen in liquid nitrogen, as the 
crystal would not survive X-ray irradiation at room temperature. The samples 
were taken to the synchrotron (Diamond Light Source, Oxfordshire, UK) and 
crystals were sequentially mounted onto a goniometer under a stream of 
gaseous nitrogen at 100 K in order to maintain the temperature and stability of 
the crystal. The crystal was then irradiated with X-rays of wavelength ~0.976 Å. 
The diffraction patterns were recorded using an ADSC Q315 charge-coupled 
device detector. Xia2 software reduced and analysed the data set with the CCP4 
package (Collaborative Computational Project number 4).227 A model of a 
similar protein was then used to fit to the density map (PDB:1NX2) as a starting 
point for structure solution.186 
4.3 PEF(S) structure – initial crystallisation conditions 
A diffraction pattern was obtained at a resolution of 2.09 Å in C2 space group 
from a crystal grown using a precipitation solution that contained 1 M sodium 
citrate and 0.1 M HEPES at pH 7.0, which was found in the ProPlex screen. 
Initially the data set was run through the molecular replacement programme 
Phaser-MR from the CCP4 program suite228 using the PDB file 1NX2, which is a 
previously published structure of holo-PEF(S).186 The data was then carried 
through numerous cycles of refinement with COOT and REFMAC5 until the 
model and the density map agreed with one another and no further refinements 
could be made. 229, 230 
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Phaser-MR is used for the molecular replacement of a known protein structure 
(model) into the asymmetric unit of the unknown crystal in order to phase the 
data.228 Rigid body refinement is used to optimise the positioning of the model 
into the density map, while avoiding deviations of the model when positioned in 
the data.228 A log likelihood score is given, based on Bayesian statistics, which is 
representative of whether the model is a good fit to the data. The program then 
outputs a PDB file that best fits the data, and the resulting phases are used to 
calculate an observed density map and a difference density map. These maps 
are used for model adjustment using COOT for a better fit of the model. The 
improved model is then subjected to refinement with REFMAC to make even 
finer adjustments without manual intervention, while minimising the difference 
between the observed and calculated structure factors.230 The process is 
repeated iteratively until no further improvement can be made. The quality of 
fit is monitored by the residual factor, or R-factor, which needs to be minimised 
to below 0.25 (25%) on average. This metric is considered to be sub-optimal, so 
a subset of the observations (reflections or data points) are set aside from the 
refinement calculations, but their R-factor, the so-called free R-factor or Rfree, 
ought to be reduced if the improvement upon refinement is genuine. 
COOT (Computational Object-Oriented Toolkit) is used to manually adjust the 
model against both the observed density and difference maps obtained from 
PHASER-MR or REFMAC. A number of parameters are used for the validation of 
the data, these include the Ramachandran plot, geometrical parameters, density 
fit analysis and B-factor analysis.229  
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Data Reduction Statistics Holo-PEF(S) 
Unit cell dimensions/Å a = 183.16, b = 41.05, c = 48.23 
Unit cell angles/° a = 90.00, b = 101.54, c = 90.00 
Space Group C 1 2 1 
Resolution range/Å 47.26 – 2.09 Å 
Total Reflections 62904 
Unique Reflections 18402 
Completeness/% (last shell) 87.1 (71.7) 
I/σ (last shell) 9.4 (2.4) 
R(merge)/% (last shell) 12.7 (90.4) 
B(iso) from Wilson/Å2 38.61 
Refinement Statistics  
Protein atoms excluding H 2790 
Calcium atoms 2 
Solvent molecules 72 
R factor/% 25.08 
Rfree/% 32.97 
R.m.s. bond length/Å 0.0122 
R.m.s. bond angle/° 1.4738 
Table 4.1: The data statistics from structure of holo-PEF(S), with the final refined data statistics. 
The statistics from the data demonstrate that the unit cell is different from the 
previously reported data, having a C2 space group as opposed to P3121.186 The 
R factor and the Rfree for the refined data-set are 24.5% and 31.3%, respectively 
(Table 4.1). The values obtained for the R factor gives an indication as to how 
well the refined model fits the data obtained and Rfree is based on reflections 
that were never used in refinement and therefore cannot bias the model.231, 232 
The difference between the R factor and the Rfree gives an overall indication as 
to how well the model fits to the data.231 The refined structure demonstrated 
that the protein is a dimer, which is the form the protein takes in solution as 
shown by analytical size exclusion chromatography (Chapter 3). The density 
map shows little density at the N-termini of both monomers but does show a 
calcium ion bound to each monomer within the structure. 
4.3.1 PEF(S) soak with α-mercaptoacrylic acid derivatives 
With crystallisation conditions in hand a 48-well sitting drop plate was set-up 
with the precipitating conditions obtained from the ProPlex screen (vide supra). 
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The precipitant used was 1.4 M sodium citrate, 0.1 M HEPES at pH 7.0. 300 μl of 
this solution was placed into the deep well and 1 μl of the precipitant was 
placed in the sitting drop with the equivalent quantity of PEF(S) (5 mg/ml). The 
plates were sealed with an adhesive film and left at 20 °C until crystals formed 
(~1 week).  
24 hours prior to crystal harvesting, they were soaked with different inhibitors 
at a variety of concentrations (Table 4.2). All inhibitors contained a bromine 
atom, as these α-mercaptoacrylic acid derivatives had shown the highest 
activity as calpain-I inhibitors (Chapter 2).  
Inhibitor Concentration
/mM 
Ratio/inhibitor 
to protein 
Resolution
/Å 
77 1.0 4:1 6.3  
80 0.5 
0.75 
0.75 
2:1 
3:1 
3:1 
2.6  
2.5 
2.6  
84 0.5 
0.5 
0.75 
1.0 
2:1 
2:1 
3:1 
4:1 
2.5 
2.7 
2.9 
3.3 
88 0.5 
0.75 
2:1 
3:1 
2.4 
2.9 
66 0.75 
1.0 
3:1 
4:1 
2.4 
3.0 
70 0.75 
1.0 
3:1 
4:1 
2.9 
No data 
74 0.75 
1.0 
3:1 
4:1 
No data 
No data 
Table 4.2: A table collating all of the data that was recorded from the soaks that were carried out 
of PEF(S) for 24 hours at 20 °C. Soaking solutions contained 10 mM DTT within the solution.  
The data sets were uniformly of lower resolution than the data set obtained for 
the holo structure, an effect that is often observed in soaking experiments. 
Though all the data remained in the C2 space group, the lower resolution 
implied that the soaks had caused some damage to the lattice of the holo-PEF(S) 
protein. The damage to the crystal lattice suggested uptake of the ligands into 
the structure of the protein.  
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Molecular replacement was carried out on the data sets from the soaked 
crystals using the holo structure previously refined. Unfortunately, processing 
and refinement revealed little or no extra density that could indicate another 
molecule within the structure.  
4.4 PEF(S) structure – new crystallisation conditions 
Due to these results, alternative conditions for forming crystals of PEF(S) were 
used. The new precipitating solution contained 50 mM sodium cacodylate, 
12.5% (w/v) PEG 6000 and 20 mM calcium chloride at pH 7.0 (Section 6.4.3).233 
The crystallisation plates were set up using the hanging drop vapour diffusion 
technique, where 1 ml of the precipitant was placed in the well and 3 μl of 
precipitant was mixed with 1 μl of deionised water and 3 μl of protein solution 
(10 mg/ml in 5 mM sodium cacodylate, 2 mM EDTA, 5 mM βME, 1 mM CaCl2 at 
pH 7.0) in the drop. Crystals formed after 3 days at 20 °C (Figure 4.4). 
 
Figure 4.4: Image taken of a crystals formed (highlighted in the white boxes) in 50 mM sodium 
cacodylate, 12.5% PEG 6000 and 20 mM CaCl2 at pH 7.0, PEF(S) concentration was 10 mg/ml. 
Data was again collected at the Diamond Light Source and scaled and reduced 
using xia2 to yield a data set with a resolution of 1.79 Å in the P21 space group. 
The reduced data was fitted with a model based on holo porcine PEF(S) (PDB 
1ALV); this was used due to the correspondence of the space groups.81 Many 
iterations of refinement with COOT and REFMAC5 were carried out to obtain 
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the final structure. The statistics obtained from the refinement process revealed 
a final R factor of 18.6% and Rfree of 22.4% (Table 4.3). 
Data Reduction Statistics Holo-PEF(S) 
Unit cell dimensions/Å a = 49.53, b = 70.56, c = 58.67 
Unit cell angles/° a = 90.00, b = 108.79, c = 90.00 
Space Group P 1 21 1 
Resolution/Å 39.05 – 1.79 Å 
Total Reflections 133085 
Unique Reflections 35505 
Completeness/% (last shell) 98.4 (99.9) 
I/σ (last shell) 16.6 (2.1) 
R-merge/% (last shell) 5.0 (7.1) 
B(iso) from Wilson/Å2 24.49 
Refinement Statistics  
Protein atoms excluding H 2790 
Calcium atoms 8 
Solvent molecules 296 
R factor/% 18.62 
Rfree/% 22.45 
R.m.s. bond length/Å 0.019 
R.m.s. bond angle/° 1.904 
Table 4.3: The data statistics from structure of holo-PEF(S), with the final refined data statistics. 
The refined structure of PEF(S) is highly similar to other reported 
crystallographic structures.81, 186 Superposition of the holo-PEF(S) structure 
with the PDB entry 1ALV revealed that it is identical to the published structure 
of the protein (Figure 4.5).81 Comparison of the residues in chain A of the 
refined structure and the previously published structure was carried out with 
Superpose from CCP4.234 Superpose aligned the PDB entry 1ALV to the holo-
PEF(S) structure and calculated the root mean square deviation (r.m.s.d) of 
each amino acid between the structures. The r.m.s.d. values obtained were 
plotted on a graph and revealed that the residues that show the greatest 
positional root mean square deviation (r.m.s.d.) were localised found the loop 
regions of the structure (Figure 4.5). 
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Figure 4.5: (A) Secondary structure alignment of holo-PEF(S) (cyan and pale cyan) derived from 
the density map and a published structure of PEF(S) (green and dark green) (PDB 1ALV) using 
PyMOL.54 The calcium ions represented as grey and dark grey spheres for holo-PEF(S) and the 
published structure.81 (B) A graph representing the r.m.s.d. of the residues as calculated by 
Superpose in CCP4, the comparison was carried out between chain A of holo-PEF(S) and the PDB 
1ALV.81, 234 
PEF(S) forms a homodimer in solution as shown by size exclusion 
chromatography (Chapter 3). In the crystalline form the protein remains as a 
homodimer with EFH-5 of each monomer in a classical EF-handshake (Figure 
4.5). The mainly hydrophobic residues of the EFH-5 bind to one another to form 
the dimer interface and comprise Val254, Ile252, Leu262 and Trp259 (Figure 
4.6).  
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Figure 4.6: Secondary structure representations of the hydrophobic interactions between the 
residues of EFH-5 at the interface between two monomers of PEF(S). 
The other four EF-hands within the structure all bind calcium ions, in the same 
manner as previously published structures of porcine PEF(S) (Figure 4.7). With 
EF-hands 2 and 3 the bound calcium ion interacts with numerous amino acids, 
and a single water molecule completes the coordination shell around Ca2+. EF-
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hand 1 required two water molecules to complete the binding of calcium. The 
fourth EF-hand also does not demonstrate the canonical EF-hand binding motif 
(Section 1.6.4), as the helix-loop-helix motif is not used to bind the Ca2+, the four 
residues used are Asp135, Asp223, Asp225 and Asn226 (Figure 4.7).72 
 
Figure 4.7: (A) A stick representation of EFH-2 which binding calcium in a canonical fashion and 
(B) EFH-4 where the binding site is non-canonical. The density map is contoured to 1.5σ. Calcium 
ion is represented as a sphere. 
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4.5 Inhibitor interaction with PEF(S) 
To obtain a complex of the inhibitor, the compounds were soaked into crystals 
preformed under the new conditions. Each inhibitor was dissolved in DMSO to 
create a 50 mM stock solution, these stock solutions were then diluted into the 
precipitation buffer used to form the crystals, 50 mM sodium cacodylate, 12.5% 
(w/v) PEG 6000 and 20 mM CaCl2 at pH 7.0 with the addition of 10 mM DTT. 
The overall concentration of the inhibitor in the solution was 8 mM. 1 μl of the 
inhibitor solution was added to the 7 μl drop that contained the crystals, giving 
an overall final concentration of 1 mM of the inhibitor within the drop. The 
hanging drops were resealed and the inhibitor was left to soak into the crystals 
for 24 hours. (Z)-3-(4-bromophenyl)-2-mercaptoacrylic acid (74) and (Z)-3-(6-
bromoindol-3-yl)-2-mercaptoacrylic acid (84) were chosen as representative 
example inhibitors (Figure 4.8). 
 
Figure 4.8: The structures of (Z)-3-(4-bromophenyl)-2-mercaptoacrylic acid (74) and (Z)-3-(6-
bromoindol-3-yl)-2-mercaptoacrylic acid (84). 
Molecular replacement was carried out on the reduced mtz file, with Phaser 
from the CCP4 package using the refined holo structure model (Section 4.4).228 
The data was then carried through sequential rounds of refinement with COOT 
and REFMAC5 as before.229, 230 
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4.5.1 Structure of phenyl derivative 74 bound to PEF(S) 
Compound 74 was the most potent inhibitor of the phenyl based α-
mercaptoacrylic acid based compounds with an IC50 value of 1.5 μM (Chapter 
2). The data set extended to a resolution of 2.10 Å. The statistics obtained from 
refinement reveal that the model and the density map fit well, with the R factor 
and Rfree with values of 18.7% and 26.0% (Table 4.4).  
Crystallographic Data PEF(S) with 74 
Unit cell dimensions/Å a = 49.74, b = 70.29, c = 57.92 
Unit cell angles/° a = 90.00, b = 108.42, c = 90.00 
Space Group P 1 21 1 
Resolution/Å 39.18 – 2.10 Å 
Total Reflections 79602 
Unique Reflections 20053 
Completeness/% (last shell) 90.4 (91.1) 
1/σ (last shell) 8.4 (2.2) 
R-merge/% (last shell) 9.6 (57.6) 
B(iso) from Wilson/Å2 28.86 
Refinement Statisitics  
Protein atoms excluding H 2790 
Calcium atoms 8 
Ligand atoms 26 
Solvent atoms 194 
R factor/% 18.72 
Rfree/% 25.96 
R.m.s. bond length/Å 0.015 
R.m.s. bond angle/° 1.716 
Table 4.4: The data statistics from the structure of PEF(S) soaked with 74, with the final refined 
data statistics.  
The refinement of the model revealed a volume of unoccupied positive 
difference density, where 74 was situated. After further refinement, the density 
accounted for 50% of that expected for the inhibitor molecule. This area of 
density was present in both copies of PEF(S) within the asymmetric unit (Figure 
4.9). 
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Figure 4.9: A cartoon representation of the dimer of PEF(S) with two molecules of 74 bound, 
represented as white sticks. 
The residues at the interface between 74 and the hydrophobic pocket were 
calculated with PDBePISA and all the individual interactions below 4.0 Å were 
calculated using Contact.234, 235 The analysis of the interface revealed that 
extensive interactions occur between the protein and the aromatic portion of 
the inhibitor. These hydrophobic interactions occurred with both aromatic 
residues and alkyl residues (Table 4.5). The hydrophilic residues that interact 
with the α-mercaptoacrylic acid are Arg128 and Gln173 (Table 4.5). Lys170 
appeared to interact primarily through the alkyl chain rather than with the 
hydrophilic ammonium end group. Measurement of the contacts between the 
ligand and its binding pocket indicates that there are no significant hydrogen 
bonds that enable the ligand to bind tightly to the pocket (Table 4.5) (Figure 
4.10). Both Arg128 and Lys170 contain highly flexible side chains of course, so 
in reality these are capable of moving in solution to form hydrogen bonds with 
the α-mercaptoacrylic acid.   
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Interface residues  vdW  
(≤ 4.0 Å) 
Distance/Å and Atoms involved 
 (residue:74) 
Leu122   
Val125 5 3.42 (Cγ1 - 10)            3.75 (Cγ1 - 5) 
3.53 (Cγ1 - 4)               3.87 (Cγ1 - Br) 
3.92 (Cγ1 - 3)              
Val126   
Arg128 2 3.70 (Nη1 - 10)           3.79 (Nη1 - 11) 
His 129 2 3.99 (Nε2 - 3)              3.93 (Nε2 - 2) 
Leu132   
Phe137   
Trp166 3 3.57 (Cζ2 - 6)               3.84 (Cη2 - 5) 
3.83 (Cζ2 - 5) 
Ile169   
Lys170 1 3.40 (Cγ - 7)               
Gln173   5 3.40 (Cγ - 3)                3.95 (Cδ – 3) 
3.71 (Cγ - 2)                3.70 (Oε1 - 2) 
3.74 (Cδ - 2)                  
Phe224 1 3.84 (Cε2-Br) 
Table 4.5: A table listing the residues found at the interface with 74 and the interactions that 
occur between the molecule and the amino acids. Interface residues were calculated with 
PDBePISA.235 Van der Waals (vdW) distances calculated with the program Contact in the CCP4 
package.234 
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Figure 4.10: (A) A stick representation of 74 bound to the PEF(S) highlighting the hydrophobic 
binding pocket and (B) the α-mercaptoacrylic acid interacting with the residues on the surface of 
PEF(S). Density map is contoured at 1.0σ. 
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Comparison of PEF(S)-74 structure with holo-PEF(S) 
When comparing the structure of the complex with that of the holo protein 
there is very little overall movement of the residues that interact 74. Only a 
slight displacement of the hydrophobic residues within the cavity is required 
for the inhibitor to bind. The hydrophilic residues that bind to the α-
mercaptoacrylic acid demonstrate the greatest deviation, with Arg128 and 
Gln173 moving most to accommodate the ligand (Figure 4.11). The sidechain of 
Arg128 moves to interact with the α-mercaptoacrylic acid. 
 
Figure 4.11: Aligned secondary structure representations of holo-PEF(S) (green) and the complex 
of 74 with PEF(S) (cyan). Arg128 and Gln173 demonstrate the greatest deviation. 
To determine how significantly the residues move upon binding 74 into the 
hydrophobic pocket, an r.m.s.d. plot of the residues was carried out with 
Superpose in CCP4, with all the atoms in each residue taken into account.234  
The r.m.s.d. values were calculated between monomer (chain A) of the dimeric 
structure of both the holo structure and the inhibitor complex. The plot 
revealed that at the binding site residue Gln173 and Lys170 have r.m.s.d. values 
of 2.8 Å (Figure 4.12). Other residues show higher r.m.s.d values at ~4 Å, these 
are either located at flexible loops within the protein or are comprised of long 
alkyl side chains, such as Arg101. 
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 Figure 4.12: A graph representing the r.m.s.d. of the residues as calculated by Superpose in CCP4, 
the comparison was carried out between chain A of holo-PEF(S) and the complex of PEF(S) and 
74.234 
Comparison of PEF(S)-74 with PEF(S)-PD150606 
 
Figure 4.13: Aligned secondary structure representations of the structure of 74 (white) bound to 
PEF(S) (cyan) and the published PD150606 (yellow) bound to PEF(S) (green) (PDB 1NX3).186 
The structure of 74 bound to the protein is very similar to the published 
structure of PD150606 bound to PEF(S) (Figure 4.13).186 The inhibitor resides 
in the same hydrophobic pocket occupied by PD150606 and hence interacts 
with the same residues. The side chain of Arg128 also moves to interact with 
the carboxylate group of the α-mercaptoacrylic acid in the published structure 
(Figure 4.13). 
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4.5.2 Structure of indole derivative 84 bound to PEF(S) 
Bromine-substituted indole based α-mercaptoacrylic acid derivatives were 
found to be highly potent inhibitors of calpain-I. (Z)-3-(6-Bromoindol-3-yl)-2-
mercaptoacrylic acid (84) in particular gave an IC50 value of 6 nM. Therefore to 
determine the molecular basis for the improved activity of 84, this compound 
was soaked into preformed PEF(S) crystals for 24 hours at 1 mM and data was 
collected. The diffraction pattern extended to a resolution of 1.96 Å with the 
same P21 space group (Table 4.6). Upon refinement with COOT and REFMAC5, 
the R factors and R free yielded values of 18.0% and 22.6%, respectively (Table 
4.6). 
Crystallographic Data PEF(S) with 84 
Unit cell dimensions/Å a = 49.75, b = 70.36, c = 58.59 
Unit cell angles/° a = 90.00, b = 108.72, c = 90.00 
Space Group P 1 21 1 
Resolution/Å 39.15 – 1.96 Å 
Total Reflections 102564 
Unique Reflections 27012 
Completeness/% (last shell) 98.0 (98.9) 
I/σ (last shell) 17.0 (2.3) 
R-merge/% (last shell) 3.9 (50.4) 
B(iso) from Wilson/Å2 30.88 
Refinement Statisitics  
Protein atoms excluding H 2790 
Calcium atoms 8 
Ligand atoms 32 
Solvent atoms 206 
Rmerge/% 18.02 
Rfree/% 22.64 
R.m.s. bond length/Å 0.019 
R.m.s. bond angle/° 1.985 
Table 4.6: The data statistics from the structure of PEF(S) soaked with 84, with the final refined 
data statistics. 
During refinement a volume of density appeared within the same hydrophobic 
pocket where both 74 and PD150606 bind. This unoccupied density was found 
in both monomers of the protein (Figure 4.14). A model of 84 was placed into 
the unoccupied density and further refinement was carried out. Once again, 
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only partial occupancy by the inhibitor was found with the density only 
accounting for 50% of the model inserted at 1σ. This occupancy is sufficient to 
summarise the interactions that occur between the protein and this inhibitor. 
 
Figure 4.14: A secondary structure representation of two molecules of 84 bound to the dimer of 
PEF(S). 
Compound 84 interacts with the same aromatic and alkyl residues within the 
hydrophobic pocket as 74. The distances between the aliphatic residues and the 
indole ring of the inhibitor reveal that there are a greater number of van der 
Waals (vdW) interactions than observed in the 74-PEF(S) complex (Section 
4.5.1) (Table 4.7). Arg128, one of the residues found to interact with 74, is not 
found at the interface with 84. The distance between the NH2 and the 
carboxylate increases from 3.70 Å to 6.85 Å. Lys177 is a residue involved in the 
interface although this residue does not appear to have any integral hydrogen 
bonds or vdW contacts with 84, due to the distance of the ligand from the 
residue (6.0 Å) (Figure 4.15). Lys170 and Gln173 demonstrate many vdW 
interactions with the ligand, both with the hydrophilic parts and with the alkyl 
chains of these residues (Table 4.7). The hydrophilic residues that interact with 
the α-mercaptoacrylic acid moiety in 74 were not close enough for hydrogen 
bonds to form with the carboxylate or sulfhydryl groups. In the case of Lys170 
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this may be deceptive as the side chain of this residue is flexible and can move 
towards the α-mercaptoacrylate and eventually form a strong hydrogen bond 
with the ligand. 
 
Interface residues  vdW  
(≤ 4.0 Å) 
Distance/Å and Atoms involved 
 (residue:84) 
Leu122 2 3.96 (Cα - Br)             3.46 (O - Br) 
Val125 8 3.72 (Cγ1 - 3)             3.42 (Cγ1 - 4) 
3.18 (Cγ1 - 5)             3.73 (Cβ - 6) 
3.28 (Cγ1 - 6)             3.95 (Cβ - Br) 
3.59 (Cγ1 - 7)             3.79 (Cγ1 - 8) 
Val126 1 3.56 (Cγ1 - Br) 
His 129 2 3.79 (Nε2 - 4)             3.99 (Cδ2 - 4) 
Leu132   
Phe137   
Trp166 3 3.83 (Cε2 - NH)           3.74 (Cη2 - NH) 
3.55 (Cζ2 - NH) 
Ile169 2 3.56 (Cγ2 - 7)              3.95 (Cγ2 - 8) 
Lys170 7 3.87 (Nζ - 13)              3.90 (Cγ - SH) 
3.70 (Cδ - SH)              3.98 (Cε - SH) 
3.56 (Nζ - SH)              3.92 (Cα - 1) 
3.80 (Cβ - 1) 
Gln173 6 3.70 (Nε2 - 12)            3.94 (Cδ - 12) 
3.74 (Oε1 - 12)            3.54 (Nε2 - 9) 
3.79 (Cδ - 9)                 3.73 (Cγ - 4) 
Lys177   
Phe224 1 3.85 (Cε2-Br) 
Table 4.7: A table listing the residues found at the interface with 84 and the interactions that 
occur between the molecule and the amino acids. Interface residues were calculated with 
PDBePISA.235 Van der Waals (vdW) distances calculated with the program Contact in the CCP4 
package.234 
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Figure 4.15: (A) A stick representation of 84 bound to the PEF(S) highlighting the hydrophobic 
pocket and (B) the α-mercaptoacrylic acid interacts with the residues on the surface of PEF(S). 
Density map is contoured to 1.0σ. 
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Comparison of PEF(S)-84 structure with holo-PEF(S)  
Very little reorganisation is required for 84 to occupy the binding pocket. The 
most significant movement occurs with Gln173, where the side chain moves out 
of the hydrophobic pocket to accommodate the ligand (Figure 4.16). The amine 
of Lys170 angles towards the thiol of 84 enabling hydrophilic interactions to 
occur (Figure 4.16). 
 
Figure 4.16: Aligned secondary structure of holo-PEF(S) (green) and the complex of 84 (white) 
bound to PEF(S) (cyan) demonstrating the movement of the side chains upon ligand binding. 
The r.m.s.d values of all the residues of one monomer, within the homodimer, 
were calculated with Superpose where a monomer of 84 bound to PEF(S) 
(chain A) was compared to holo-PEF(S) (chain A) (Figure 4.17).234 The values 
obtained corroborate visual analysis of the binding site; there is very little 
movement of the residues within the binding site of the ligand. The residues 
that gave r.m.s.d. values of ~4 Å are mainly located at loop regions or contain 
highly mobile side chains (Figure 4.17).  
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Figure 4.17: A graph representing the r.m.s.d. of the residues as calculated by Superpose in CCP4, 
the comparison was carried out between chain A of holo-PEF(S) and the complex of PEF(S) and 
84.234 
Comparison of PEF(S)-84 with PEF(S)-PD150606 
 
Figure 4.18: Aligned secondary structure of 84 (white) bound to PEF(S) (cyan) and the published 
structure of PD150606 (yellow) bound to PEF(S) (green) (PDB 1NX3).186  
Structural analysis of the 84 complex in comparison to the PD150606 complex 
reveals that the indole based inhibitor appears to bind more deeply into the 
hydrophobic pocket than the phenyl based inhibitor (Figure 4.18).186 The α-
mercaptoacrylic acid interacts with different residues within the structure. 
PD150606 interacts with the NH of the indole of Trp166, whereas in the case of 
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84 the interaction is formed between the carboxylate group of the inhibitor and 
Lys170 and Gln173.   
4.5.3 Comparison of the new ligand bound structures 
 
 
Figure 4.19: Aligned secondary structure of 74 (grey) bound to PEF(S) (yellow) and the structure 
of 84 (white) bound to PEF(S) (cyan). A graph representing the r.m.s.d. values of the residues in 
chain A of the 74/PEF(S) complex and the 84/PEF(S) complex, values obtained with Superpose in 
the CCP4 package.234 
The aligned structures of the 74-PEF(S) complex and 84-PEF(S) complex show 
little movement of the side chains of the residues involved in the binding of 
each ligand. The residues within the hydrophobic pocket maintain very similar 
conformations upon binding either ligand. The main differences in side chain 
conformation are those interacting with the α-mercaptoacrylic acid, with 
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Arg128 interacting with the carboxylate upon the binding of 74 (Figure 4.19). 
When 84 binds to the pocket the α-mercaptoacrylic acid substituent interacts 
with Gln173 and Lys170 (Figure 4.19). The different hydrophilic interactions 
are due to the orientation of the α-mercaptoacrylic acid relative to the aromatic 
component of the inhibitor. Where the indole is completely planar in the case of 
84, the hydrophilic part of 74 is perpendicular to the phenyl ring and therefore 
interacts with different hydrophilic residues. The r.m.s.d. plot comparing the 
two complexes revealed only very small alterations in the residue conformation 
between both structures (Figure 4.19).234  
The fact that 84 appears to bind further into the hydrophobic pocket than 74 
might indicate a better fit for the pocket. The tighter binding to the hydrophobic 
pocket in combination with the residues that interact with the α-
mercaptoacrylic acid may be the reason why the indole based derivative is a 
more potent inhibitor than the phenyl based α-mercaptoacrylic acid. 
4.6 Conclusion 
The two compounds that were soaked into PEF(S), 74 ((Z)-3-(4-bromophenyl)-
2-mercaptoacrylic acid) and 84 ((Z)-3-(6-bromoindol-3-yl)-2-mercaptoacrylic 
acid), bind into the same hydrophobic pocket in the protein. Though the 
interactions of these ligands within the binding site are slightly different, the 
differences are more significant in the hydrophilic interactions with the α-
mercaptoacrylic acid. When (Z)-3-(6-bromoindol-3-yl)-2-mercaptoacrylic acid 
binds to the pocket, the residues that interact with the α-mercaptoacrylic acid 
are Lys170 and Gln173. With (Z)-3-(4-bromophenyl)-2-mercaptoacrylic acid 
this interaction is with Arg128. The different hydrophilic interactions are due to 
the orientation of the α-mercaptoacrylic acid relative to the aromatic moiety 
which varies between the compounds. The α-mercaptoacrylic acid group is 
perpendicular to the phenyl group in the structure of (Z)-3-(4-bromophenyl)-2-
mercaptoacrylic acid whereas the hydrophilic group is coplanar with the indole 
of (Z)-3-(6-bromoindol-3-yl)-2-mercaptoacrylic acid. The hydrophobic pocket 
that binds the two analogues is composed of a variety of non-polar residues; 
Leu122, Val125, Val126, His129, Leu132, Phe137, Trp166, Ile169 and Phe224. 
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(Z)-3-(6-bromoindol-3-yl)-2-mercaptoacrylic acid appears to bind more deeply 
within the hydrophobic pocket than (Z)-3-(4-bromophenyl)-2-mercaptoacrylic 
acid.  
Therefore the difference in the potency of the indole based derivatives (as 
compared to the phenyl based compounds) may be explained through the 
increased hydrophilic and electrostatic interactions between the α-
mercaptoacrylic acid substituents and hydrophilic residues. The fact that the 
aromatic component of the indole is bulkier may explain the increased number 
of contacts. The larger size may also explain why it is positioned more deeply 
into the hydrophobic pocket. 
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Summary 
Routes were identified to allow the synthesis of 24 novel mono-halogenated 
aromatic α-mercaptoacrylic acids in good yields. These compounds readily form 
dimers via disulfide bonds, but the addition of 10 mM DTT restores the 
mercaptoacrylate group within 5 minutes allowing the monomeric form to be 
tested for activity against isolated calpain and live cell motility.  
Phenyl α-mercaptoacrylates all displayed low micromolar IC50 values towards 
calpain-I with the nature and position of halogen substituents around the 
aromatic ring proving important for potency. Indole-based α-mercaptoacrylates 
were much more potent inhibitors, with IC50 values in the nanomolar range. 
Compounds with a bromine substituent displayed the greatest efficacy (2-7 
nM). Testing these compounds against calpain-II revealed them to be 
moderately selective towards calpain-I. 
Single crystal soaks of the PEF(S) domain bound to (Z)-3-(6-bromoindol-3-yl)-
2-mercaptoacrylic acid and (Z)-3-(4-bromophenyl)-2-mercaptoacrylic acid 
diffracted to resolutions of 2.0 Å and 2.1 Å, respectively. The inhibitors bound in 
a pocket known to host hydrophobic side chains of the endogenous calpain 
inhibitor calpastatin. The X-ray structure of the 6-bromoindole-PEF(S) complex 
revealed that the indole-based inhibitor formed more interactions with alkyl 
and aromatic residues within the pocket and hydrophilic residues on the 
surface of the protein than the phenyl-based compound. The indole based 
inhibitor also appeared to sit more deeply within the pocket than the phenyl 
ring of the 4-bromophenyl derivative. The combination of these effects provides 
a likely explanation for the difference in the potency of the indole and phenyl 
based inhibitors.  
When live neutrophils were treated with these inhibitors their ability to spread 
in response to chemical stimuli, a process mediated by calpain-I, was reduced, 
with (Z)-3-(6-bromoindol-3-yl)-2-mercaptoacrylic acid subduing this process 
by ~70% over a 3 minute period. Irradiation of live cells containing an 
inhibitor, with 410 nm light, completely inhibited the cell spreading process, 
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implying that these compounds have an additional photo-reactive mode of 
calpain-I inhibition.  
Outlook 
These compounds are allosteric in their mode of inhibition and are capable of 
passing through cell membranes. Their activity has also shown that calpain-I is 
integral for the rapid response of neutrophils to damage cues within the body. 
Therefore these compounds can be used in vivo to define the role of neutrophils 
in rheumatoid arthritis as well as other diseases where these cells are involved 
in the pathology. 
Calpain-I has also been linked to many other pathological conditions such as 
cancer metastasis, ischemic cell death and Alzheimer’s disease. The α-
mercaptoacrylic acid compounds can therefore be used both in cells and in vivo 
to elucidate the exact consequences of calpain-I over-activation within these 
disease states. The inhibition of calpain-I may prove to be an important 
component in halting the progression of these diseases and therefore may 
prove to be a highly valuable therapeutic target. 
These inhibitors were shown to bind to the common calcium binding domain, 
PEF(S), but also demonstrated a greater affinity towards calpain-I over calpain-
II. These results imply further interactions must be made with the 
discriminatory calcium binding domain, PEF(L). Since inhibitor binding to 
PEF(S) complicates whole-enzyme assays, domains of PEF(L) must be examined 
individually to determine further inhibitor binding sites. Crystallisation of 
PEF(L) from both calpain-I and calpain-II (and/or the whole large subunit), 
with mercaptoacrylic acids will elucidate the molecular basis of the observed 
differences in affinity. Crystal structures of inhibitors bound to PEF(L) will 
inform the design of a second generation of inhibitors, that are more stable and 
interact with increased selectivity with calpain-I or II. Even though the 
inhibition of calpain-II is embryonically lethal the development of molecular 
probes for the selective inhibition of this protease will lead to a greater 
understanding of why this occurs.171 The role that calpain-II has demonstrated 
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in mitosis could be exploited to prevent the progression of cancer through its 
inhibition.127  
In addition to their use as inhibitors, the α-mercaptoacrylic acid derivatives 
used in this work have the potential to be used for the development of a new 
screening assay. Fluorescent derivatives of these compounds may be used as 
probes that bind to the calcium binding domains of calpain-I and libraries of 
known compounds can then be used to displace the probe. This would enable 
rapid screening and discovery of novel classes of calpain inhibitors. 
Both of the major isoforms of calpain are involved in many fundamental cellular 
processes but their individual roles are still poorly understood. Armed with 
specific inhibitors for each isoform, researchers in many areas of cell biology 
will be able to make major advances in the understanding and control of cell 
behaviour linked to calpains I and II within living systems. 
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6.1 Organic Synthesis 
General Synthetic Methods 
All chemicals were purchased from Sigma-Aldrich unless otherwise stated.  
Anhydrous THF, diethyl ether, toluene and MeCN were obtained from a MBraun 
SPS800 solvent purification system. All other chemicals were of analytical 
quality or better and used as received unless otherwise stated.  Reactions were 
stirred at room temperature in air unless otherwise stated.  All glassware was 
clean and dry before use. 
1H and 13C NMR spectra were measured on a Bruker Avance 500 NMR 
spectrometer, a Bruker Avance DPX400 NMR spectrometer, a Bruker Fourier 
300 or a Bruker Avance DPX250 NMR spectrometer and are reported as 
chemical shifts in parts per million downfield from tetramethylsilane, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), 
coupling constant (to the nearest 0.5 Hz) and assignment, respectively.  
Assignments are made to the limitations of COSY, DEPT 90/135, gradient HSQC 
and gradient HMBC spectra.  19F NMR spectra were recorded on a Jeol Eclipse 
+300 NMR spectrometer and are reported in chemical shift downfield from 
CFCl3 followed by multiplicity and coupling constant (to the nearest 0.5 Hz) if 
appropriate. IR spectra were recorded on a Perkin-Elmer 1600 series FTIR 
spectrometer and samples were prepared as KBr disks.  Mass spectra were 
recorded by the UK National Mass spectrometry service in Swansea. High 
performance liquid chromatography was performed on a Dionex Ultimate 3000 
HPLC system fitted with a Dionex Acclaim analytic C18 reverse phase HPLC 
column (3 μm, 120 Å, 4.6 x 150 mm).  Melting points were recorded on a 
Gallenlamp and are quoted uncorrected. 
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6.1.1 Synthesis 
4-Iodoindole193 (15) 
 
To a stirred suspension of thallium(III)trifluoroacetate (9.13 g, 16.19 mmol) in 
trifluoroacetic acid (40 ml), methyl indole-3-carboxylate (2.0 g, 11.42 mmol) in 
trifluoroacetic acid (2 ml) was added dropwise under argon. The suspension 
was left to stir for 2 hr at room temperature. The suspension was concentrated 
under reduced pressure then water (128 ml) and potassium iodide (5.7 g, 34.34 
ml) were added. This mixture was left to stir for 2 hr. The suspension was 
extracted with dichloromethane:methanol (95:5, 68 ml) and filtered to remove 
the solid. The organic layer was extracted and washed with aq. Na2SO3 (5% 
(w/v) 2 × 50 ml) and brine (50 ml). The separated organic layer was dried over 
anhydrous MgSO4, filtered and concentrated under reduced pressure. The 
resulting brown oil was passed through a pad of flash silica using hexane:ethyl 
acetate (1:1) resulting in a crude product which was hydrolysed without further 
purification. 
To a solution of the crude material (2.0 g, 6.62 mmol) in methanol (45 ml), 40% 
aqueous sodium hydroxide solution was added (45 ml) and the solution was 
heated under reflux for 1.5 hr. The solution was cooled to room temperature 
and concentrated under reduced pressure to remove the methanol. The 
suspension was extracted with dichloromethane:methanol (95:5, 3 x 50 ml ml)  
and the organic layer was washed with brine (50 ml). The organic layer was 
dried over anhydrous MgSO4, filtered and concentrated under reduced 
pressure. The resulting brown oil was purified by flash chromatography on 
silica gel (hexane:ethyl acetate 3:1) to give the title compound as pale yellow 
crystals (0.90 g, 33%). mp. 96 - 99 °C (lit. 98.5 - 99.5 °C)236. δH (400 MHz. CDCl3): 
8.36 (1 H, s, NH), 7.56 (1 H, d, J = 7.5, ArCH), 7.39 (1 H, d, J = 8.5, ArCH), 7.29 (1 
H, d, J = 2.5, ArCH), 6.96 (1 H, t, J = 7.5, ArCH), 6.52 (1 H, td, J1 = 2.5, J2 = 1.0, 
ArCH). δC (100 MHz, CDCl3): 134.73 (ArC), 132.53 (ArC), 129.45 (ArCH), 124.49 
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(ArCH), 123.36 (ArCH), 111.11 (ArCH), 106.39 (ArCH), 87.49 (ArCI). Mass 
spectrum: HRMS (EI+) found 242.9544, C8H6IN calculated 242.9545. υ cm-1: 
3101.9, 1733.7, 1623.3, 1605.5, 1558.2, 1500.4, 1483.0, 1474.3, 1424.7, 1411.2, 
1330.2, 1268.5, 1175.9, 1138.3, 1094.9, 1067.4, 1042.8, 902.0, 881.8, 799.8, 
777.2, 757.9, 745.8, 702.8, 619.0, 562.6, 515.4, 484.5, 437.3.  
N-Acetyl-6-nitroindoline191 (17) 
 
A stirred suspension of 6-nitroindoline (1.0 g, 6.09 mmol) in acetic anhydride (5 
ml) was heated to 130 °C for 15 min. The reaction mixture was cooled to room 
temperature and water was added (20 ml). The resulting suspension was 
heated under reflux for 45 min. The reaction mixture was left to cool to room 
temperature; the precipitate that formed was collected by filtration under 
reduced pressure and washed with water (20 ml). The solid was then air dried 
under reduced pressure to give the title compound as a yellow solid (1.19 g, 
5.77 mmol, 95%). mp. 167 - 169 °C (lit. 152 - 156 °C)191. δH (400 MHz, DMSO-
d6): 8.73 (1H, d, J = 2.0, ArCH), 7.87 (1 H, dd, J1 = 8.5, J2 = 2.0, ArCH), 7.45 (1 H, d, 
J = 8.5, ArCH), 4.18 (2 H, t, J = 8.5, CH2), 3.24 (2 H, t, J = 8.5, CH2), 2.19 (3H, s, 
CH3). δC (125 MHz, DMSO-d6): 170.00 (COCH3), 147.33 (ArC), 144.23 (ArC), 
140.87 (ArCNO2), 125.77 (ArCH), 119.11 (ArCH), 110.15 (ArCH), 49.26 (CH2), 
27.96 (CH2), 24.31 (CH3). Mass spectrum: HRMS (EI+) found 206.0694, 
C10H10N2O3 calculated 206.0691. υ cm-1 : 3135.2, 1666.7, 1592.4, 1526.4, 
1515.8, 1481.1, 1430.4, 1401.5, 1334.5, 1103.1, 1069.8, 1029.8, 892.9, 813.3, 
745.4, 636.4, 565.5, 516.8. 
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N-Acetyl-6-aminoindoline191 (18) 
 
A suspension of N-acetyl-6-nitroindoline (1.00 g, 4.86 mmol), 10% Pd/C (0.1 g, 
0.09 mmol Pd) in methanol (160 ml) was stirred vigorously under an 
atmosphere of hydrogen for 24 hrs. The Pd/C was removed by filtration under 
reduced pressure through a plug of Celite©. The filtrate was concentrated in 
vacuo to leave the title compound as a white solid (0.68 g, 3.89 mmol, 80%). mp. 
172 - 177 °C (lit. 187 - 191 °C)191. δH (400 MHz, DMSO-d6): 7.43 (1 H, d, J = 2.0, 
ArCH), 6.83 (1 H, d, J = 8.0, ArCH), 6.20 (1 H, dd, J1 = 8.0, J2 = 2.0, ArCH), 4.97 (2H, 
s, NH2), 3.99 (2 H, t, J = 8.0, CH2), 2.92 (2 H, t, J = 8.0, CH2), 2.11 (3 H, s, CH3). δC 
(62.5 MHz, DMSO-d6): 168.05 (COCH3), 147.86 (ArC), 143.52 (ArC), 124.51 
(ArCH), 118.28 (ArCH), 108.79 (ArCH), 102.59 (ArCNH2), 48.73 (CH2), 26.50 
(CH2), 24.12 (CH3). Mass spectrum: HRMS (APCI+) found 177.1031, C10H13N2O 
calculated 177.1028. υ cm-1: 3413.4, 3320.8, 3113.5, 2916.8, 1644.5, 1605.9, 
1497.0, 1456.5, 1417.4, 1362.5, 1330.2, 1308.5, 1243.9, 1204.8, 1167.2, 1030.3, 
954.6, 876.5, 806.1, 631.6, 550.1. 
N-Acetyl-6-iodoindoline191 (19) 
 
To a stirred solution of N-acetyl-6-aminoindoline (0.70 g, 4.04 mmol) in 80% 
acetic acid (31 ml) under argon at 0 °C, sodium nitrite (0.32 g, 4.64 mmol) in 
water (1.4 ml) was added and the mixture was stirred for 15 min. Potassium 
iodide (3.3 g, 19.88 mmol) in water (7.0 ml) was added to the reaction mixture 
which was then stirred for 24 hrs at 0 °C.  The solution was concentrated in 
vacuo and the black residue was dissolved in ethyl acetate (45 ml) and washed 
with water (3 × 45 ml). The organic layer was separated and dried over 
anhydrous MgSO4 then filtered and concentrated under reduced pressure. The 
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brown residue was purified using flash chromatography on silica gel 
(toluene:acetone 20:1) to give  the title compound as yellow crystals. (0.70 g, 
2.42 mmol, 60%). mp. 131 - 135 °C (lit. 102 - 118 °C)191. δH (400 MHz, CDCl3): 
8.55 (1 H, d, J = 2.0, ArCH), 7.30 (1 H, dd, J1 = 8.0, J2 = 2.0, ArCH), 6.87 (1 H, d, J = 
8.0, ArCH), 4.07 (2 H, t, J = 8.5, CH2), 3.12 (2 H, t, J = 8.5, CH2), 2.19 (3 H, s, CH3). 
δC (125 MHz, CDCl3): 168.87 (COCH3), 144.14 (ArC), 132.55 (ArCH), 130.96 
(ArC), 126.09 (ArCH), 125.56 (ArCH), 92.19 (ArCI), 48.98 (CH2), 28.01 (CH2), 
24.21 (CH3). Mass spectrum: HRMS (EI+) found 286.9800, C10H13INO calculated 
287.9807. υ cm-1: 3113.5, 2960.2, 2360.0, 1659.5, 1594.8, 1482.0, 1437.7, 
1413.1, 1340.3, 1309.4, 1264.6, 1125.7, 1101.6, 1031.3, 927.1, 882.8, 787.3, 
768.0, 624.3, 598.3, 558.3, 508.6, 425.7. 
6-Iodoindoline191  (20) 
 
A 40% aqueous sodium hydroxide solution (12 ml) was added to a solution of 
N-acetyl-6-iodoindoline (0.2 g, 0.68 mmol) in methanol (12 ml). The reaction 
mixture was heated to 75 °C for 2.5 hrs. The cooled reaction mixture was 
concentrated under reduced pressure. The residue was extracted with ethyl 
acetate (3 × 30 ml) and the organic layer was dried over anhydrous MgSO4, 
filtered and then concentrated under reduced pressure. The resulting yellow oil 
was purified using flash chromatography on silica gel (hexane:ethyl acetate 
10:1) to give the title compound as white crystals, (0.11 g, 0.44 mmol, 64%). 
mp. 93 - 96 °C (lit. 83 - 90 °C)191. δH (250 MHz, CDCl3): 6.91 (1 H, dd, J1 = 7.5, J2 = 
1.5, ArCH), 6.85 (1 H, d, J = 1.5, ArCH), 6.74 (1 H, d, J = 7.5, ArCH), 3.45 (2 H, t, 
J=8.5, CH2), 2.89 (2H, t, J = 8.5, CH2). δC (100 MHz, CDCl3): 153.41 (ArC), 129.19 
(ArC), 127.35 (ArCH), 126.24 (ArCH), 117.97 (ArCH), 91.95 (ArCI), 47.49 (CH2), 
29.36 (CH2). Mass spectrum: HRMS (EI+) found 244.9707, C8H8IN calculated 
244.9702. υ cm-1: 3378.2, 2931.3, 2864.3, 1590.0, 1488.3, 1474.3, 1438.2, 
1321.0, 1309.4, 1250.6, 1239.0, 1160.9, 1048.1, 1021.6, 929.0, 881.8, 845.2, 
798.4, 724.6, 699.1, 573.7, 551.5, 513.9, 422.3, 409.3. 
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6-Iodoindole191 (21) 
 
Air was bubbled through a stirred solution of 6-iodoindoline (0.23 g, 0.94 
mmol) and N,N-bis(salicylidene)ethylenediaminocobalt(II) (0.034 g, 0.10 
mmol) in methanol (30 ml) for 24 hr. The reaction mixture was concentrated 
under reduced pressure. The residue was then purified by flash 
chromatography on silica gel (hexane:ethyl acetate  8:1) to give the title 
compound as pale brown crystals, (0.18 g, 0.73 mmol, 77%). mp. 108 - 113 °C 
(lit. 111.0 – 111.5 °C)237. δH (400 MHz, CDCl3): 7.96 (1 H, s, NH), 7.62 (1 H, d, J = 
1.0, ArCH), 7.31 (2 H, s, ArCH), 7.02 (1 H, t, J = 3.0, ArCH), 6.43 (1 H, q, J = 1.0, 
ArCH). δC (125 MHz, CDCl3): 137.14 (ArC), 128.67 (ArCH), 127.25 (ArC), 124.66 
(ArCH), 122.40 (ArCH), 120.06 (ArCH), 102.90 (ArCH), 85.80 (ArCI). Mass 
spectrum: HRMS (EI+) found 242.9538, C8H6IN calculated 242.9545. υ cm-1: 
3412.4 1624.3, 1598.7, 1494.6, 1451.7, 1440.1, 1394.3, 1333.1, 1311.4, 1232.8, 
1201.4, 1089.6, 1042.8, 996.1, 890.0, 878.9, 859.1, 810.0, 758.4, 729.9, 609.4. 
6.1.2 General method for the preparation of 7 substituted indoles192 
7-Bromoindole (23) 
 
A stirred solution of 1-bromo-2-nitrobenzene (1.0 g, 4.95 mmol) in THF (50 ml) 
under argon was cooled to -40 °C (dry-ice - acetone bath). To this solution was 
quickly added vinylmagnesium bromide (1 M in THF, 14.76 ml, 14.76 mmol). 
The reaction was left to stir for 20 minutes at -40 °C. The reaction mixture was 
quenched with saturated aq. NH4Cl (50 ml) then extracted with diethyl ether (2 
× 50 ml). The pooled organic extracts were dried with MgSO4, filtered and 
concentrated under reduced pressure. The black oil that resulted was purified 
using flash chromatography on silica gel (hexane:ethyl acetate 6:1) giving the 
title compound as an orange solid (0.43 g, 44%). mp. 39 - 41 °C (lit. 43 - 44 
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°C)192. δH (400 MHz. CDCl3): 8.37 (1 H, s, NH), 7.62 (1 H, d, J = 8.0, ArCH), 7.29 (1 
H, t, J = 3.0, ArCH), 7.04 (1 H, t, J = 8.0, ArCH), 6.67 (1 H, dt, J1 = 3.0, J2 = 1.0, 
ArCH). δC (100 MHz, CDCl3): 134.59 (ArC), 129.00 (ArC), 124.74 (ArCH), 124.34 
(ArCH), 121.02 (ArCH), 119.98 (ArCH), 104.67 (ArCBr), 103.86 (ArCH). Mass 
spectrum: HRMS (EI+) found 194.9686, C8H679BrN calculated 194.9684. υ cm-1: 
3400.9, 1901.0, 1613.6, 1560.1, 1483.0, 1428.0, 1408.3, 1329.7, 1282.0, 1214.0, 
1190.4, 1135.9, 1094.4, 1065.5, 1032.2, 1032.2, 920.4, 878.4, 817.2. 
7-Fluoroindole (25) 
 
Yield; 14%. mp. 43 - 52 °C (lit. 61 - 63 °C)192. δH (400 MHz. CDCl3): 8.17 (1 H, s, 
NH), 7.31 (1 H, td, J1 = 8.0, J2 = 1.0, ArCH), 7.07 (1 H, t, J = 3.0, ArCH), 6.92 (1 H, 
td, J1 = 8.0, J2 = 2.5, ArCH), 6.81 (1 H, m, ArCH), 6.49 (1 H, dd, J1 = 2.5, J2 = 1.0, 
ArCH). δC (100 MHz, CDCl3): 149.71 (ArCF, d, J = 24.0), 131.52 (ArC, d, J = 5.0), 
124.91 (ArCH, s), 124.27 (ArC, d, J = 13.0), 120.06 (ArCH, d, J = 6.0), 116.46 
(ArCH, d, J = 13.0), 106.79 (ArCH, d, J = 16.0), 103.35 (ArCH, d, J = 2.0). Mass 
spectrum: HRMS (EI+) 135.0481, found C8H6FN calculated 135.0484. υ cm-1: 
3390.7, 3111.1, 3071.1, 2956.3, 2923.6, 2689.8, 2627.1, 2516.2, 2361.9, 1895.7, 
1823.9, 1726.9, 1640.6, 1610.3, 1579.4, 1521.6, 1489.7, 1443.0, 1415.0, 1342.7, 
1286.8, 1235.2, 1214.9, 1160.9, 1106.0, 1066.0, 1046.2, 1023.5, 949.3, 891.9, 
878.9, 867.0, 849.0, 841.3. 
6.1.3 General method for the preparation of indole-3-carboxaldehydes189 
4-Fluoroindole-3-carboxaldehyde (26) 
 
A stirred mixture of 4-fluoroindole (0.50 g, 3.71 mmol) and N,N-
dimethylformamide (1.37 g, 18.78 mmol) was placed in an ice bath until the 
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solution reached 5 °C. Phosphorous oxychloride (0.69 g, 4.50 mmol) was then 
added dropwise. The mixture was left to stand for 15 minutes at room 
temperature. The stirred mixture was then heated to 40 °C for 1 hr and was 
then cooled. Ice (5 g) was added along with sodium hydroxide solution (2 M, 6 
ml) and then the mixture was heated under reflux for 16 hr. After cooling to 
room temperature; the precipitate that formed was collected by filtration under 
reduced pressure and washed with water (2 × 10 ml). The solid was air dried 
under reduced pressure to give the required product as a pink solid (0.59 g, 
3.61 mmol, 98%). mp. 175 - 181 °C. δH (400 MHz, DMSO-d6): 12.51 (1 H, s, NH), 
10.00 (1 H, dd, J1 = 8.0, J2 = 3.5, CHO), 8.31 (1 H, d, J = 3.5, ArCH), 7.35 (1 H, t, J = 
8.0, ArCH), 7.24 (1 H, td, J1 = 8.0, J2 = 5.0, ArCH), 7.01 (1 H, td, J1 = 8.0, J2 = 3.0, 
ArCH). δC (125 MHz, DMSO-d6): 184.07 (CHO), 156.48 (ArCF, d, J = 248.5), 
140.21 (ArCH, d, J = 12.0), 136.42 (ArC, s), 124.39 (ArCH, d, J = 8.0), 117.43 (ArC, 
d, J = 6.0), 113.39 (ArCH, d, J = 21.9), 109.55 (ArCH, d, J = 4.0), 107.71 (ArCH, d, J 
= 19.0).  Mass spectrum: HRMS (EI+) found 162.0434, C9H5FNO calculated 
162.0433. υ cm-1: 3231.2, 2819.4, 2748.1, 1653.7, 1635.3, 1581.3, 1513.4, 
1455.0, 1437.7, 1428.0, 1403.4, 1364.9, 1347.0, 1301.2, 1251.6, 1222.7, 1161.9, 
1140.2, 1111.3, 1146.7, 1030.3, 849.0, 789.7, 783.0, 764.6, 734.3, 638.3, 618.1, 
588.2, 531.3, 519.2. 
4-Chloroindole-3-carboxaldehyde (27) 
 
Yield; 80%. mp. 158 - 162 °C (lit. 166 - 167 °C)238. δH (400 MHz, DMSO-d6): 
12.59 (1 H, s, NH), 10.50 (1 H, s, CHO), 8.31 (1 H, s, ArCH), 7.53 (1 H, d, J = 8.0, 
ArCH), 7.30 (1 H, d, J = 8.0, ArCH), 7.23 (1 H, t, J = 8.0, ArCH). δC (125 MHz, 
DMSO-d6): 185.20 (CHO), 138.75 (ArC), 134.47 (ArCH), 125.03 (ArCCl), 124.01 
(ArCH), 123.37 (ArC), 123.05 (ArCH), 118.27 (ArC), 112.45 (ArCH). Mass 
Spectrum HRMS [EI+] found 179.0138, C9H735ClNO calculated 179.0138. υ cm-1: 
3163.7, 3127.5, 3006.5, 2939.5, 2870.5, 1894.7, 1818.5, 1747.2, 1639.4, 1570.3, 
Materials and Methods  
 
136 
 
1521.1, 1485.4, 1459.4, 1430.0, 1388.5, 1341.3, 1331.6, 1293.0, 1258.8, 1189.4, 
1147.4, 1082.4, 1072.2, 1048.6, 937.7, 872.6, 845.2, 773.8, 729.9, 665.3, 602.6. 
4-Bromoindole-3-carboxaldehyde (28) 
 
Yield; 94 %. mp. 175 - 177 °C (lit. 185 - 187 °C)238. δH (400 MHz, DMSO-d6): 
12.59 (1 H, s, NH), 10.69 (1 H, s, CHO), 8.30 (1 H, s, ArCH), 7.58 (1 H, d, J = 8.0, 
ArCH), 7.48 (1H, d, J=8.0, ArCH), 7.17 (1 H, t, J = 8.0, ArCH). δC (125 MHz, DMSO-
d6): 185.03 (CHO), 138.71 (ArC), 134.31 (ArCH), 126.45 (ArCH), 125.16 (ArC), 
124.27 (ArCH), 118.29 (ArC), 112.92 (ArCH), 112.75 (ArCBr). Mass Spectrum 
HRMS [EI+] found 222.9635, C9H779BrNO calculated 222.9633. υ cm-1: 3166.1, 
3065.3, 2865.3, 1902.0, 1761.7, 1635.8, 1518.2, 1483.0, 1457.0, 1428.5, 1385.6, 
1330.6, 1293.5, 1260.7, 1191.3, 1147.9, 1130.1, 1075.1, 1045.2, 913.6, 888.1, 
841.3, 773.3, 732.3, 658.6, 608.9. 
4-Iodoindole-3-carboxaldehyde (29) 
 
Yield; 92%. mp. 186 - 188 °C (lit. 182 – 183 °C)239. δH (400 MHz, DMSO-d6): 
12.50 (1 H, s, NH), 10.95 (1 H, s, CHO), 8.30 (1 H, s, ArCH), 7.73 (1 H, d, J = 8.0, 
ArCH), 7.59 (1 H, d, J = 8.0, ArCH), 7.01 (1 H, t, J = 8.0, ArCH). δC (125 MHz, 
DMSO-d6): 184.25 (CHO), 138.29 (ArC), 134.40 (ArCH), 133.29 (ArCH), 128.75 
(ArC), 124.59 (ArCH), 118.09 (ArC), 113.41 (ArCH), 83.89 (ArCI). Mass 
Spectrum HRMS [APCI+] found 271.9572, C9H7INO calculated 271.9572. υ cm-1: 
3155.9, 2929.8, 2863.8, 1767.4, 1628.1, 1515.3, 1480.6, 1456.0, 1424.2, 1383.7, 
1337.4, 1292.1, 1259.3, 1191.3, 1147.9, 1125.7, 1068.9, 1040.9, 897.2, 836.0, 
799.8, 773.8, 764.2, 734.3, 655.2, 609.9, 600.2, 561.7, 487.9. 
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5-Iodoindole-3-carboxaldehyde (30) 
 
 Yield: 95%. mp. 232 - 234 °C (lit. 220 °C)240. δH (400 MHz, DMSO-d6): 12.29 (1 
H, s, NH), 9.92 (1 H, s, CHO), 8.44 (1 H, s, ArCH), 8.30 (1 H, d, J = 2.0, ArCH), 7.54 
(1 H, d, J = 8.5, ArCH), 7.38 (1 H, d, J = 8.5, ArCH). δC (62.5 MHz, DMSO-d6): 
185.10 (COH), 138.84 (ArC, s), 136.11 (ArC, s), 131.49 (ArCH, s), 129.10 (ArCH, 
s), 126.17 (ArC, s), 117.12 (ArCH, s), 114.88 (ArCH, s), 86.55 (ArCI, s). Mass 
spectrum: HRMS (ES-) found 269.9405, C9H5INO calculated 269.9416. υ cm-1: 
2894.6, 1622.8, 1565.9, 1523.0, 1478.7, 1435.3, 1384.2, 1318.1, 1284.4, 1232.3, 
1134.4, 1091.0, 1042.3, 877.5, 795.0, 769.9, 748.3, 661.5, 608.4, 562.2. 
6-Fluoroindole-3-carboxaldehyde (31) 
 
Yield; 77%. mp. 173 - 178 °C (lit. 173 - 174 °C)241. δH (400 MHz, DMSO-d6): 
12.19 (1 H, s, NH), 9.92 (1 H, s, CHO), 8.30 (1 H, d, J = 2.0, ArCH), 8.08 (1 H, dd, J1 
= 9.0, J2 = 2.5, ArCH), 7.32 (1 H, dd, J1 = 9.0, J2=2.5, ArCH), 7.08 (1 H, td, J1=9.0, 
J2=2.5, ArCH). δC (125 MHz, DMSO-d6): 185.42 (CHO), 160.02 (ArCF, d, J = 
236.0), 139.54 (ArCH), 137.64 (ArC, d, J = 12.5), 122.39 (ArCH, d, J = 10.0), 
121.28 (ArC), 118.53 (ArC), 110.90 (ArCH, d, J=25.0), 99.25 (ArCH, d, J=26.5). 
Mass spectrum: HRMS (EI+) found 162.0431, C9H5FNO calculated 162.0433. υ 
cm-1: 3868.5, 3852.1, 3819.8, 3800.0, 3748.0, 3743.2, 3674.2, 3445.7, 3130.9, 
2812.7, 1626.7, 1594.8, 1532.2, 1505.2, 1448.8, 1389.5, 1335.0, 1283.4, 1230.4, 
1149.4, 1117.6, 1082.4, 951.2, 833.1, 812.9, 718.4, 633.5, 620.0, 604.1, 509.6. 
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6-Chloroindole-3-carboxaldehyde (32) 
 
Yield; 96%. mp. 212 - 214 °C (lit. 210 - 211°C)242. δH (400 MHz, DMSO-d6): 12.23 
(1 H, s, NH), 9.94 (1 H, s, COH), 8.40 (1 H, d, J = 2.0, ArCH), 8.08 (1 H, d, J = 8.0, 
ArCH), 7.57 (1 H, s, ArCH), 7.24 (1 H, d, J = 8.0, ArCH). δC (62.5 MHz, DMSO-d6): 
185.06 (CHO), 139.20 (ArCH), 137.49 (ArCH), 127.90 (ArCCl), 122.86 (ArC), 
122.41 (ArCH), 122.05 (ArCH), 117.96 (ArC), 112.97 (ArCH). Mass spectrum: 
HRMS (APCI-) found 178.0055, C9H535ClNO calculated 178.0060. υ cm-1: 3434.1, 
3108.2, 3041.9, 2968.9, 2915.4, 2853.2, 1634.4, 1575.6, 1525.4, 1492.2, 1451.7, 
1430.9, 1384.6, 1327.8, 1278.6, 1243.4, 1145.0, 1132.0, 1090.1, 1061.1, 906.4, 
841.8, 811.4, 752.6, 683.6, 605.5, 504.8. 
6-Iodoindole-3-carboxaldehyde (33) 
 
Yield; 95%. mp. 213 - 215 °C (lit. 216 °C)237. δH (400 MHz, DMSO-d6): 12.19 (1 H, 
s, NH), 9.93 (1 H, s, CHO), 8.27 (1 H, d, J=3.0, ArCH), 7.90 (1 H, d, J = 8.5, ArCH), 
7.88 (1 H, s, ArCH), 7.51 (1 H, dd, J1 = 8.5, J2 = 1.5, ArCH). δC (100 MHz, DMSO-
d6): 185.61 (CHO), 139.31 (ArCH), 138.84 (ArC), 131.02 (ArCH), 123.20 (ArCH), 
121.45 (ArCH), 123.90 (ArC), 118.44 (ArC), 88.20 (ArCI). Mass Spectrum HRMS 
[ES-] found 269.9409, C9H7INO calculated 269.9416. υ cm-1: 3434.6, 2846.9, 
1683.6, 1582.3, 1563.0, 1510.0, 1446.4, 1355.2, 1327.8, 1302.7, 1232.8, 1219.3, 
1141.7, 1129.6, 1073.7, 1054.4, 847.6, 794.1, 774.8, 725.1, 712.1, 679.3, 661.5. 
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7-Fluoroindole-3-carboxaldehyde (34) 
 
Yield; 54%. mp. 136 - 142 °C. δH (400 MHz, DMSO-d6): 12.71 (1 H, s, NH), 9.98 (1 
H, s, COH), 8.37 (1 H, d, J = 3.0, ArCH), 7.91 (1 H, d, J = 7.5, ArCH), 7.20 (1 H, dt, J1 
= 7.5, J2 = 4.5 , ArCH), 7.17 (1 H, dd, J1 = 11.5, J2 = 7.5, ArCH). δC (125 MHz, DMSO-
d6): 185.67 (CHO), 149.53 (ArCF, d, J = 243.5), 139.41 (ArCH), 128.24 (ArC, d, J = 
5.0), 125.26 (ArC, d, J = 12.5), 123.33 (ArCH, d, J = 6.0), 119.26 (ArC), 117.43 
(ArCH, d, J = 4.0), 109.00 (ArCH, d, J = 16.0). Mass Spectrum HRMS [EI+] found 
163.0431, C9H7FNO calculated 163.0433. υ cm-1: 3744.6, 3675.7, 3629.4, 3117.9, 
3035.9, 2877.3, 2362.9, 1617.5, 1529.8, 1499.4, 1467.1, 1400.6, 1344.6, 1282.0, 
1229.9, 1179.7, 1151.3, 1133.0, 1044.3, 966.2, 821.5. 
7-Chloroindole-3-carboxaldehyde (35) 
 
Yield; 89%. mp. 177 - 180 °C (lit. 181 - 182 °C)243. δH (400 MHz, DMSO-d6): 
12.56 (1 H, s, NH), 9.97 (1 H, s, COH), 8.39 (1 H, d, J=3.0, ArCH), 8.06 (1 H, d, J = 
8.0, ArCH), 7.36 (1 H, d, J = 8.0, ArCH), 7.23 (1 H, t, J = 8.0, ArCH). δC (125 MHz, 
DMSO-d6): 185.81 (CHO), 139.61 (ArCH), 134.39 (ArCCl), 126.48 (ArC), 123.79 
(ArCH), 123.54 (ArCH), 120.25 (ArCH), 119.34 (ArC), 117.13 (ArC). Mass 
Spectrum HRMS [EI+] found 179.0134, C9H735ClNO calculated 179.0138. υ cm-1: 
3434.6, 3135.2, 3111.1, 3064.8, 3034.9, 2938.5, 2888.8, 2825.2, 2698.4, 2577.9, 
1938.1 1642.6, 1621.4, 1526.9, 1499.9, 1453.3, 1390.4, 1340.3, 1275.7, 1248.2, 
1206.7, 1160.0, 1130.1, 1111.8, 1048.6, 976.8, 890.5, 848.0, 780.1, 740.5, 658.1, 
610.36. 
 
Materials and Methods  
 
140 
 
7-Bromoindole-3-carboxaldehyde (36) 
 
Yield; 82%. mp. 167 - 170 °C (lit. 171 – 172)237. δH (400 MHz, DMSO-d6): 12.40 
(1 H, s, NH), 9.97 (1 H, s, CHO), 8.38 (1 H, s, ArCH), 8.11 (1 H, d, J = 8.0, ArCH), 
7.50 (1H, dd, J1=8.0, J2 = 1.0, ArCH), 7.23 (1H, t, J = 8.0, ArCH). δC (125 MHz, 
DMSO-d6): 185.93 (CHO), 139.67 (ArCH), 135.92 (ArC), 126.62 (ArCH), 126.23 
(ArC), 124.18 (ArCH), 120.72 (ArCH), 119.34 (ArC), 105.30 (ArCBr). Mass 
Spectrum HRMS [EI+] found 221.9552, C9H779BrNO calculated 221.9554. υ cm-1: 
3434.1, 3143.9, 3034.9, 2929.3, 2881.1, 2358.0, 1638.7, 1617.5, 1568.3, 1522.0, 
1447.3, 1426.6, 1389.9, 1337.9, 1271.3, 1242.9, 1203.9, 1158.5, 1125.3, 1098.8, 
901.6, 879.4, 831.7, 777.7, 740.1, 652.3, 606.0, 561.7, 496.1, 454.2. 
7-Iodoindole-3-carboxaldehyde (37) 
 
Yield; 92%. mp. 104 - 109 °C. δH (400 MHz, DMSO-d6): 12.11 (1 H, s, NH), 9.96 (1 
H, s, CHO), 8.33 (1 H, d, J = 2.5 ArCH), 8.12 (1 H, d, J = 8.0, ArCH), 7.67 (1 H, d, J = 
8.0, ArCH), 7.03 (1H, t, J = 8.0, ArCH). δC (125 MHz, DMSO-d6): 185.98 (CHO), 
139.43 (ArCH), 139.25 (ArC), 132.94 (ArCH), 125.19 (ArC), 124.44 (ArCH), 
121.24 (ArCH), 119.44 (ArC), 78.04 (ArCI). Mass Spectrum HRMS [EI+] found 
270.9490, C9H6INO calculated 270.9494. υ cm-1: 3433.6, 3063.4, 1638.2, 1610.8, 
1558.7, 1522.5, 1488.3, 1442.0, 1384.6, 1331.1, 1277.6, 1237.1, 1204.8, 1149.4, 
1127.2, 1092.5, 872.6, 817.2, 773.8, 736.7, 650.4, 608.0, 554.0. 
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6.1.4 General method for the condensation of aromatic aldehydes with 
rhodanine.188 
(Z)-5-((4-Fluoroindol-3-yl)methylene)-2-thioxothiazolidin-4-one (49) 
 
A suspension of 4-fluoroindole-3-carboxaldehyde (0.40 g, 2.46 mmol), 2-
thioxothiazoolidin-4-one (0.33 g, 2.49 mmol) and sodium acetate (0.59 g, 7.21 
mmol) in glacial acetic acid (5 ml) was heated under reflux for 2 hr. The 
reaction mixture was then cooled to room temperature and water (15 ml) was 
added to the solution. The precipitate that formed was collected by filtration 
under reduced pressure and washed with water (2 × 10 ml). The solid was air 
dried under reduced pressure and washed with diethyl ether (5 ml) to give the 
title compound as a dark red solid (0.54 g, 1.94 mmol, 78%). mp. ~340 °C (dec.). 
δH (400 MHz, DMSO-d6): 13.61 (1 H, s, NH), 12.55 (1 H, s, NH), 7.94 (1 H, s, 
CH=CS), 7.81 (1 H, d, J = 3.5, ArCH), 7.50 (1 H, d, J = 8.0, ArCH), 7.22 (1 H, dt, J = 
8.0, J = 5.0, ArCH), 7.00 (1H, ddd, J1=12.0, J2=8.0, J3= 3.5, ArCH). δC (125 MHz, 
DMSO-d6): 194.63 (CS), 169.08 (CO), 156.49 (ArCF, d, J = 244.5), 138.94 (ArC, d, 
J = 10.0), 129.89 (ArCH), 125.19 (ArCH, d, J = 5.0), 123.89 (ArCH, d, J = 8.0), 
118.95 (ArC), 114.83 (ArC, d, J = 18.0), 109.24 (ArCH, d, J = 4.0), 109.16 (ArC, d, J 
= 3.0), 106.68 (ArCH, d, J = 19.0). Mass spectrum: HRMS (EI+) found 277.9988, 
C12H7FN2OS2 calculated 277.9984. υ cm-1: 3242.2, 1685.0, 1634.4, 1589.5, 
1575.6, 1511.9, 1430.0, 1345.1, 1324.4, 1296.4, 1277.1, 1224.1, 1205.8, 1158.5, 
1148.4, 1033.7, 841.8, 808.0, 777.2, 726.6, 690.9, 670.6, 614.2, 597.8, 576.6, 
556.4, 495.1, 481.6. 
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Benzylidene Derivatives 
(Z)-5-(2-Fluorobenzylidene)-2-thioxothazolidene-4-one (38) 
 
Yield; 92%. mp. 202 - 206 °C. δH (400 MHz, DMSO-d6): 13.93 (1 H, s, NH), 7.58 (1 
H, s, CH=CS), 7.55 (1 H, dt, J1 = 7.5, J2=1.0, ArCH), 7.49 (1 H, dt, J1 = 7.5, J2=1.0, 
ArCH), 7.39 (2H, m, ArCH). δC (125 MHz, DMSO-d6): 195.88 (CS), 169.64 (CO), 
161.12 (ArCF, d, J = 251.5), 133.50 (ArCH, d, J = 10.0), 129.82 (ArCH), 128.58 
(ArC, d, J = 2.5), 126.01 (ArC, d, J = 4.0), 122.77 (ArCH, d, J = 6.5), 121.35 (ArCH, 
d, J = 11.5), 116.73 (ArCH, d, J = 21.5). δF (282 MHz, DMSO-d6): -114.01.  Mass 
spectrum: HRMS (ES-) found 237.9796, C10H5FNOS2 calculated 237.9797. υ cm-1: 
3054.7, 1695.1, 1608.8, 1593.4, 1482.0, 1456.0, 1430.0, 1309.9, 1211.1, 1158.0, 
1068.9, 798.9, 751.1, 677.4, 548.7. 
(Z)-5-(2-Chlorobenzylidene)-2-thioxothazolidene-4-one (39) 
 
 Yield; 22.1%. mp. 189 - 191 °C. δH (400 MHz, DMSO-d6): 13.96 (1 H, s, NH), 7.75 
(1 H, s, CH=CS), 7.64 (1 H, dd, J1 = 8.5, J2 = 1.0, ArCH), 7.52 (3H, m, ArCH). δC (125 
MHz, DMSO-d6): 195.55 (CS), 169.18 (CO), 134.73 (ArCCl), 132.05 (ArCH), 
130.83 (ArC), 130.41 (ArCH), 129.26 (ArCH), 129.11 (ArC), 128.23 (ArCH), 
126.02 (ArCH). Mass spectrum: HRMS (EI+) 254.9586, C10H535ClNOS2 calculated 
254.9579, m/z (ES+): 168.0 (50 % [M-CSNHCO]+). υ cm-1: 3440.9, 3066.7, 
2868.6, 1734.7, 1699.0, 1594.6, 1584.7, 1456.5, 1435.7, 1336.0, 1306.5, 1280.5, 
1239.5, 1197.6, 1161.9, 1069.8, 1041.4, 805.6, 750.2, 723.7, 701.0, 675.5, 632.5, 
532.7, 467.2. 
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(Z)-5-(2-Bromobenzylidene)-2-thioxothazolidene-4-one (40) 
 
 Yield; 93%. mp. 189 - 192 °C. δH (500 MHz, DMSO-d6): 14.00 (1 H, s, NH), 7.88 
(1 H, d, J = 8.0, ArCH), 7.63 (1 H, s, CH=CS), 7.61 (1 H, d, J = 7.0 ArCH), 7.49 (1H, 
t, J1 = 8.0, J2 = 7.0, ArCH). δC (100 MHz, DMSO-d6): 196.02 (CS), 169.50 (CO), 
134.10 (ArCH), 132.91 (ArC), 132.62 (ArCH), 129.79 (ArCH), 129.53 (ArC), 
129.21 (ArCH), 129.18 (ArCH), 126.07 (ArCBr). Mass spectrum: HRMS (APCI-) 
found 297.8987, C10H579BrNOS2 calculated 297.8996. υ cm-1: 3093.7, 2848.9, 
1732.3, 1605.9, 1452.1, 1429.5, 1277.1, 1233.3, 1196.1, 1065.5, 1002.8, 890.5, 
752.6, 724.6, 681.2, 525.5. 
(Z)-5-(2-Iodobenzylidene)-2-thioxothazolidene-4-one (41) 
 
Yield; 71%. mp. 188 - 190 °C. δH (500 MHz, MeOD-d4): 14.00 (1 H, s, NH), 7.75 (1 
H, s, CH=CS), 7.65 (1 H, dd, J1 = 8.0, J2 = 1.0, ArCH), 7.45 (1 H, dd, J1 = 8.0, J2 = 2.0, 
ArCH), 7.40 (1 H, t, J = 8.0, ArCH), 7.24 (1 H, td, J1 = 8.0, J2 = 2.0, ArCH). δC (62.5 
MHz, THF-d8): 195.11 (CS), 168.36 (CO), 140.43 (ArCH), 136.90 (ArC), 134.04 
(ArCH), 131.32 (ArCH), 129.60 (ArC), 128.83 (ArCH), 128.63 (ArCH), 101.98 
(ArCI). Mass spectrum: HRMS (EI+) found 346.8947, C10H5INOS2 calculated 
346.8936.  υ cm-1: 3142.9, 3051.8, 1694.6, 1589.5, 1455.5, 1428.0, 1311.4, 
1281.0, 1230.4, 1198.5, 1068.9, 1014.9, 753.1, 669.2, 651.8, 537.6. 
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(Z)-5-(3-Fluorobenzylidene)-2-thioxothazolidene-4-one (42) 
 
Yield; 68%. mp. 203 - 204 °C. δH (400 MHz, DMSO-d6): 13.91 (1 H, s, NH), 7.63 (1 
H, s, CH=CS), 7.58 (1 H, q, J = 8.0, ArCH), 7.45 (1 H, dd, J1 = 10.0, J2 = 2.0, ArCH), 
7.40 (1 H, d, J = 8.0 ArCH), 7.33 (1 H, dt, J = 8.0, J = 2.0, ArCH). δC (125 MHz, 
DMSO-d6): 195.85 (CS), 169.68 (CO), 162.78 (ArCF, d, J = 245.5), 135.88 (ArC, d, 
J = 8.0), 131.93 (ArCH, d, J = 8.0), 130.51 (ArCH, d, J = 3.0), 127.66 (ArC, s), 
126.39 (ArCH, d, J = 3.0), 117.90 (ArCH, d, J = 21.0), 117.55 (ArCH, d, J = 22.0). δF 
(282 MHz, DMSO-d6): -111.75; Mass spectrum: HRMS (ES-) found 237.9802, 
C10H5FNOS2 calculated 237.9797. υ cm-1: 3445.7, 3193.5, 2360.0, 1705.3, 
1612.2, 1600.6, 1577.0, 1489.7, 1432.9, 1288.2, 1253.5, 1220.7, 952.2, 775.2, 
672.1, 529.4. 
(Z)-5-(3-Chlorobenzylidene)-2-thioxothazolidene-4-one (43) 
 
Yield; 86%. mp. 240 - 242 °C. δH (400 MHz, DMSO-d6): 13.90 (1 H, s, NH), 7.66 (1 
H, s, ArCH), 7.61 (1 H, s, CH=CS), 7.55 (1 H, t, J = 3.0, ArCH), 7.53 (1 H, d, J = 2.0, 
ArCH), 7.50 (1 H, dd, J1 = 6.0, J2 = 2.0, ArCH). δC (125 MHz, DMSO-d6): 195.74 
(CS), 169.61 (CO), 135.57 (ArC), 134.49 (ArCCl), 131.63 (ArCH), 130.66 
(2ArCH), 130.24 (ArCH), 128.57 (ArCH), 127.78 (ArC). Mass spectrum: HRMS 
found (ES-) 253.9500, C10H535ClNOS2 calculated 253.9501. υ cm-1: 3111.1, 
2848.4, 1717.3 1608.3, 1559.7, 1478.7, 1438.6, 1412.6, 1324.4, 1299.8, 1284.8, 
1222.2, 1180.7, 1094.4, 1078.5, 1058.3, 1000.9, 911.2, 895.8, 860.6, 782.0, 
739.1, 704.4, 681.2, 630.1, 547.2, 518.3. 
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(Z)-5-(3-Bromobenzylidene)-2-thioxothazolidene-4-one (44) 
 
 Yield; 86%. mp. 250 - 254 °C. δH (400 MHz, DMSO-d6): 13.92 (1 H, s, NH), 7.80 
(1 H, s, ArCH), 7.68 (1 H, d, J = 8.0, ArCH), 7.61 (1 H, s, CH=CS), 7.48 (1 H, d, 
J=8.0, ArCH), 7.48 (1 H, t, J=8.0, ArCH). δC (125 MHz, DMSO-d6): 195.64 (CS), 
169.53 (CO), 135.77 (ArC), 133.48 (ArCH), 131.77 (ArCH), 130.13 (ArCH), 
128.89 (ArCH), 127.69 (ArC), 122.93 (ArCBr). Mass spectrum: HRMS (ES-) 
found 297.8999, C10H579BrNOS2 calculated 297.8996. υ cm-1: 3422.6, 3108.7, 
2845.0, 1716.8, 1606.4, 1552.9, 1476.2, 1437.7, 1408.7, 1283.4, 1220.2, 1178.3, 
1072.2, 1059.2, 1002.8, 910.2, 881.3, 862.0, 779.6, 737.6, 693.3, 673.0, 627.7, 
546.7, 517.8. 
(Z)-5-(3-Iodobenzylidene)-2-thioxothazolidene-4-one (45) 
 
Yield; 75%. mp. 236 - 239 °C. δH (400 MHz, DMSO-d6): 13.90 (1 H, s, NH), 7.96 (1 
H, s, ArCH), 7.84 (1 H, d, J = 8.0, ArCH), 7.57 (1 H, s, CH=CS) 7.57 (1 H, d, J = 8.0, 
ArCH), 7.32 (1 H, t, J = 8.0, ArCH). δC (100 MHz, DMSO-d6): 195.73 (CS), 169.56 
(CO), 139.31 (2 ArCH), 135.60 (ArC), 131.67 (ArCH), 130.22 (ArCH), 129.27 
(ArCH), 127.27 (ArC), 96.18 (ArCI). Mass spectrum: HRMS (APCI-) found 
345.8861, C10H5INOS2 calculated 345.8857. υ cm-1: 3396.0, 3147.7, 3055.2, 
2847.4, 2349.8, 1690.3, 1600.6, 1563.5, 1550.5, 1472.9, 1437.7, 1404.4, 1310.9, 
1280.5, 1230.8, 1193.7, 1179.3, 1099.2,  1066.9, 1013.9, 992.2, 911.2, 885.6,  
876.0, 864.9, 805.1, 772.8, 714.0, 685.6, 669.2, 626.8, 546.7, 530.3, 429.1, 414.6. 
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(Z)-5-(4-Fluorobenzylidene)-2-thioxothazolidene-4-one (46) 
 
Yield; 88%. mp. 226 – 231 °C. δH (400 MHz, DMSO-d6): 13.86 (1 H, s, NH), 7.66 
(3 H, m, ArCH and CH=CS), 7.37 (2 H, t, J = 8.5, ArCH). δC (125 MHz, DMSO-d6): 
195.45 (CS), 169.26 (CO), 163.01 (ArCF, d, J = 251.5), 132.91 (ArCH, d, J = 9.0), 
130.47 (ArCH), 129.63 (ArC, d, J = 4.0), 125.20 (ArCH), 116.58 (2ArCH, d, J = 
22.0). δF (300 MHz, DMSO-d6): -108.34; Mass spectrum: HRMS (ES-) found 
237.9794, C10H5FNOS2 calculated 237.9797. υ cm-1: 3098.1, 1724.1, 1586.7, 
1508.1, 1446.8, 1290.6, 1228.4, 1179.3, 1160.9, 1063.6, 921.3, 828.3, 794.1, 
748.3, 689.0, 597.3, 549.6, 524.5. 
(Z)-5-(4-Chlorobenzylidene)-2-thioxothazolidene-4-one (47) 
 
Yield; 76%. mp. 233 - 235 °C. δH (400 MHz, DMSO-d6): 13.90 (1 H, s, NH), 7.61 (1 
H, s, CH=CS), 7.58 (4 H, d, J = 8.5, ArCH). δC (125 MHz, DMSO-d6): 195.91 (CS), 
169.90 (CO), 135.80 (ArCCl), 132.48 (2 ArCH), 132.39 (ArC), 130.54 (ArCH), 
129.95 (2 ArCH), 126.92 (ArC). Mass spectrum: HRMS (ES-) found 253.9509, 
C10H535ClNOS2 calculated 253.9501. υ cm-1: 3413.9, 3066.7, 2848.8, 1704.8, 
1596.3, 1582.3, 1558.2, 1487.3, 1444.9, 1404.4, 1293.0, 1281.5, 1232.3, 1187.5, 
1177.3, 1086.7, 1061.6, 1007.6, 917.5, 827.3, 796.9, 756.4, 723.2, 684.1, 572.8, 
545.8, 518.8. 
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(Z)-5-(4-Bromobenzylidene)-2-thioxothazolidene-4-one (48) 
 
Yield; 85%. mp. 243 - 248 °C. δH (400 MHz, DMSO-d6): 13.90 (1 H, s, NH), 7.74 (2 
H, d, J = 8.5, ArCH), 7.62 (1 H, s, CH=CS), 7.53 (2 H, d, J = 8.5, ArCH). δC (125 MHz, 
DMSO-d6): 195.84 (CS), 169.78 (CO), 132.90 (2 ArCH), 132.69 (ArC), 132.64 (2 
ArCH), 130.72 (ArCH), 126.91 (ArCBr), 124.76 (ArC). Mass spectrum: HRMS 
(ES-) found 297.8991, C10H579BrNOS2 calculated 297.8996. υ cm-1: 3403.3, 
3076.9, 2847.9, 1706.2, 1595.8, 1577.5, 1553.9, 1483.5, 1441.5, 1399.1, 1303.6, 
1291.6, 1279.1, 1231.3, 1177.8, 1070.8, 1059.2, 1006.7, 918.0, 825.9, 800.8, 
750.2, 717.9, 686.1, 665.3, 561.7, 540.0, 516.3. 
Indole Derivatives 
(Z)-5-((4-Chloroindol-3-yl)methylene)-2-thioxothiazolidin-4-one (50) 
 
Yield; 86%. mp. ~ 350 °C (dec.). δH (400 MHz, DMSO-d6): 13.62 (1 H, s, NH), 
12.63 (1 H, s, NH), 8.52 (1 H, s, CH=CS), 7.90 (1 H, d, J = 2.5, ArCH), 7.50 (1 H, dd, 
J1 = 7.0, J2 = 2.5, ArCH), 7.24 (2 H, m, 2 x ArCH). δC (125 MHz, DMSO-d6): 195.35 
(CS), 169.70 (CO), 138.54 (ArC), 131.63 (ArCH), 125.99 (ArCH), 125.34 (ArCCl), 
124.43 (ArCH), 123.03 (ArCH), 122.93 (ArC), 119.10 (ArC), 112.61 (ArCH), 
111.24 (ArC). Mass Spectrum HRMS [EI+] found 293.9691, C12H735ClN2OS2 
calculated 293.9688. υ cm-1: 3821.7, 3816.0, 3217.7, 2837.7, 2360.0, 1849.7, 
1833.0, 1692.7, 1616.1, 1578.9, 1513.9, 1487.8, 1443.9, 1421.8, 1349.0, 1340.3, 
1322.9, 1275.2, 1258.3, 1258.3, 1212.0, 1194.2, 1155.6, 1079.5, 1047.2, 1023.5, 
945.4, 936.8, 918.0, 828.3, 801.8, 787.8, 7752, 727.0, 694.7, 648.4, 608.9, 571.3, 
540.5, 506.7, 477.3, 455.6, 420.4. 
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(Z)-5-((4-Bromoindol-3-yl)methylene)-2-thioxothiazolidin-4-one (51) 
 
Yield; 36%. mp. ~350 °C (dec.). δH (400 MHz, DMSO-d6): 12.39 (2 H, s, 2 NH), 
8.48 (1 H, s, CH=CS), 7.75 (1 H, s, ArCH), 7.54 (1 H, d, J = 8.0, ArCH), 7.38 (1 H, d, 
J = 8.0, ArCH), 7.13 (1 H, t, J = 8.0, ArCH). δC (100 MHz, DMSO-d6): 183.92 (CS), 
172.03 (CO), 137.89 (ArC), 129.94 (ArCH), 125.36 (2ArCH), 123.78 (ArCH), 
123.72 (ArC), 120.79 (ArC), 112.97 (ArCBr), 112.33 (ArCH), 112.09 (ArC). Mass 
Spectrum HRMS [EI+] found 337.9186, C12H779BrN2OS2 calculated 337.9183. υ 
cm-1: 3209.5, 3108.2, 2838.2, 1892.8, 1829.6, 1691.8, 1577.0, 1562.5, 1512.9, 
1484.9, 1443.9, 1417.9, 1354.3, 1336.0, 1324.4, 1300.8, 1274.7, 1257.8, 1213.0, 
1192.8, 1155.6, 1082.4, 1045.7, 1021.6, 944.0, 914.1, 797.4, 786.3, 772.4, 726.6, 
694.2, 642.2, 608.4, 564.6, 534.7, 498.5, 472.5, 453.7, 419.9. 
(Z)-5-((4-Iodoindol-3-yl)methylene)-2-thioxothiazolidin-4-one (52) 
 
Yield; 54%. mp. ~ 320 °C (dec.). δH (400 MHz, DMSO-d6): 13.66 (1 H, s, NH), 
12.53 (1 H, s, NH), 8.94 (1 H, s, CH=CS), 7.92 (1 H, d, J = 2.0 ArCH), 7.70 (1 H, d, J 
= 7.5, ArCH), 7.58 (1 H, d, J = 7.5, ArCH), 7.01 (1 H, t, J = 7.5, ArCH). δC (100 MHz, 
DMSO-d6): 194.23 (CS), 169.73 (CO), 137.79 (ArC), 133.64 (ArCH), 132.15 
(ArCH), 126.72 (ArC), 125.30 (ArCH), 125.15 (ArCH), 117.98 (ArC), 113.63 
(ArCH), 112.14 (ArC), 85.36 (ArCI). Mass Spectrum HRMS [ES-] found 384.8966, 
C12H7IN2OS2 calculated 384.8961. υ cm-1: 3434.1, 3236.9, 3041.2, 2851.7, 
1676.8, 1569.8, 1509.5, 1477.2, 1449.2, 1410.2, 1350.9, 1320.0, 1270.4, 1215.9, 
1194.2, 1153.2, 1128.2, 1045.2, 1019.7, 877.9, 783.4, 771.9, 736.2, 694.3, 640.7, 
608.4. 
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(Z)-5-((5-Chloroindol-3-yl)methylene)-2-thioxothiazolidin-4-one (53) 
 
Yield; 79%. mp. ~ 330 °C (dec.). δH (500 MHz, DMSO-d6): 13.57 (1 H, s, NH), 
12.40 (1 H, s, NH), 8.06 (1 H, s, CH=CS), 7.95 (1 H, s, ArCH), 7.86 (1 H, s, ArCH), 
7.51 (1 H, d, J = 8.5, ArCH), 7.26 (1 H, d, J = 8.5, ArCH). δC (125 MHz, DMSO-d6): 
195.13 (CS), 169.47 (CO), 135.34 (ArC), 131.79 (ArCH), 128.52 (ArC), 126.56 
(ArC), 124.66 (ArCH), 123.85 (ArCH), 119.19 (ArC) 118.76 (ArCH), 114.48 
(ArCH), 111.16 (ArCCl). Mass spectrum: HRMS (EI+) found 293.9688, 
C12H635ClN2OS2 calculated 293.9688. υ cm-1: 3259.6, 3110.6, 2837.3, 2360.0, 
1824.3, 1688.4, 1622.8, 1584.2, 1564.0, 1510.0, 1457.0, 1441.1, 1423.2, 1355.7, 
1332.1, 1305.6, 1271.8, 1225.5, 1202.9, 1157.6, 1128.2, 1093.9, 1045.7, 1015.3, 
914.6, 895.7, 864.4, 819.6, 797.9, 766.1, 747.8, 729.4, 693.8, 683.2, 609.9, 571.3, 
558.8, 531.3, 468.2, 418.5. 
(Z)-5-((5-Bromoindol-3-yl)methylene)-2-thioxothiazolidin-4-one (54) 
 
Yield; 86.2%. mp. ~ 300 °C (dec.). δH (400 MHz, DMSO-d6): 13.60 (1 H, s, NH), 
12.44 (1 H, s, NH), 8.23 (1 H, d, J = 2.0, ArCH), 7.96 (1 H, s, CH=CS), 7.86 (1 H, d, J 
= 3.0, ArCH), 7.47 (1 H, d, J = 8.5, ArCH), 7.38 (1 H, dd, J1 =8.5, J2 = 2.0, ArCH). δC 
(100 MHz, DMSO-d6): 195.17 (CS), 169.57 (CO), 135.57 (ArC), 131.36 (ArCH), 
129.11 (ArC), 126.31 (ArCH), 124.90 (ArCH), 121.77 (ArCH), 119.28 (ArCH), 
114.92 (ArCBr), 114.55 (ArCH), 111.04 (ArC). Mass spectrum: HRMS (EI+) 
found 337.9180, C12H679BrN2OS2 calculated 337.9183. υ cm-1: 3254.8, 3109.2, 
3036.9, 2849.3, 2725.9, 1868.2, 1810.8, 1678.7, 1616.1, 1580.9, 1565.9, 1511.4, 
149.2, 1349.0, 1330.2, 1308.0, 1268.5, 1213.5, 1146.5, 1092.0, 1080.0, 1045.2, 
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1019.7, 936.7, 908.3, 886.6, 859.1, 803.2, 772.4, 748.2, 723.2, 702.0, 687.5, 
668.2, 613.7, 595.4, 570.8, 560.2, 542.9, 528.9, 471.0, 461.4, 461.4, 418.0. 
(Z)-5-((5-Iodoindol-3-yl)methylene)-2-thioxothiazolidin-4-one (55) 
 
Yield; 74%. mp. ~ 310 °C (dec.). δH (500 MHz, DMSO-d6): 13.56 (1 H, s, NH), 
12.38 (1 H, s, NH), 8.37 (1 H, s, CH=CS), 7.94 (1 H, s, ArCH), 7.79 (1 H, s, ArCH), 
7.52 (1 H, d, J = 8.0, ArCH), 7.34 (1 H, d, J = 8.0, ArCH).  δC (100 MHz, DMSO-d6): 
195.14 (CS), 169.56 (CO), 135.93 (ArC), 134.31 (ArC), 131.77 (ArCH), 130.90 
(ArCH), 129.75 (ArC), 127.76 (ArCH), 124.93 (ArCH), 115.27 (ArCH), 110.69 
(ArC), 86.13 (ArCI). Mass spectrum: HRMS (EI+) found 385.9038, C12H7IN2OS2 
calculated 385.9045. υ cm-1: 3262.5, 3037.8, 2850.8, 1678.3, 1576.5, 1562.5, 
1510.0, 1447.8, 1349.0, 1327.3, 1305.1, 1269.4, 1212.0, 1147.9, 1076.6, 908.3, 
879.4, 861.5, 802.7, 769.9, 688.0, 609.9, 590.1, 528.9. 
(Z)-5-((6-Fluoroindol-3-yl)methylene)-2-thioxothiazolidin-4-one (56) 
 
Yield; 70%. mp. ~ 330 °C (dec.). δH (400 MHz, DMSO-d6): 13.57 (1 H, s, NH), 
12.30 (1 H, s, NH), 7.94 (1 H, dd J1 = 8.5, J2 = 5.5, ArCH), 7.89 (1 H, s, CH=CS), 7.77 
(1 H, d, J = 3.0, ArCH), 7.27 (1 H, dd. J1 = 9.5, J2 = 2.0, ArCH), 7.41 (1 H, dt, J1=8.5, 
J2 = 2.0, ArCH). δC (100 MHz, DMSO-d6): 194.98 (CS), 169.43 (CO), 160.01 (ArCF, 
d, J = 236.0), 136.72 (ArC d, J = 12.0), 130.78 (ArC), 124.77 (ArCH), 123.82 
(ArC), 120.29 (ArCH, d, J = 10.0), 119.01 (ArCH), 111.32 (ArCH, s), 110.10 (ArCH 
d, J = 25.0), 98.96 (ArCH, d, J = 26.0). Mass spectrum: HRMS (APCI-) found 
276.9900, C12H6FN2OS2 calculated 276.9906. υ cm-1: 3446.2, 3214.3, 3107.7, 
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2851.2, 1811.8, 1678.7, 1626.7, 1599.2, 1573.2, 1516.3, 1497.0, 1448.8, 1438.6, 
1419.8, 1357.6, 1340.8, 1301.2, 1190.4, 1146.5, 1107.9, 1072.2, 1052.9, 1019.7, 
952.7, 909.3, 854.3, 816.7, 806.6, 733.8, 703.9, 691.4, 614.2, 605.1, 594.5, 571.8, 
542.9. 
(Z)-5-((6-Chloroindol-3-yl)methylene)-2-thioxothiazolidin-4-one (57) 
 
Yield; 85%. mp. ~ 350 °C (dec.). δH (400 MHz, DMSO-d6): 13.59 (1 H, s, NH), 
12.35 (1 H, s, NH), 7.94 (1 H, d, J = 8.5, ArCH), 7.88 (1 H, s, CH=CS), 7.82 (1 H, d, J 
= 2.5, ArCH), 7.53 (1 H, s, ArCH), 7.19 (1 H, d, J = 8.5, ArCH). δC (100 MHz, DMSO-
d6): 194.60 (CS), 169.03 (CO), 136.76 (ArCH), 130.66 (ArC), 127.82 (ArCCl), 
125.50 (ArCH), 124.17 (ArCH), 121.50 (ArCH), 120.08 (ArC), 118.91 (ArC), 
112.09 (ArCH), 110.93 (ArCH). Mass spectrum: HRMS (ES-) found 292.9601, 
C12H635ClN2OS2 calculated 292.9610. υ cm-1: 3231.6, 3103.9, 2849.3, 2350.3, 
1676.8, 1584.7, 1570.3, 1513.4, 1488.3, 1437.2, 1416.5, 1353.3, 1333.1, 1295.5, 
1228.0, 1192.8, 1146.5, 1072.2, 1058.3, 1021.1, 931.9, 905.4, 851.9, 798.9, 
785.9, 749.7, 735.2, 688.0, 608.9, 594.5, 575.7, 565.0, 538.0, 467.2, 418.5. 
(Z)-5-((6-Bromoindol-3-yl)methylene)-2-thioxothiazolidin-4-one (58) 
 
Yield; 72%. mp. ~ 320 °C (dec.). δH (400 MHz, DMSO-d6): 13.59 (1 H, s, NH), 
12.34 (1 H, s, NH), 7.91 (2 H, m, ArCH and CH=CS), 7.81 (1 H, d, J = 2.5, ArCH), 
7.67 (1 H, s, ArCH), 7.31 (1 H, d, J = 8.5, ArCH). δC (125 MHz, DMSO-d6): 195.07 
(CS), 169.49 (CO), 137.70 (ArC), 131.70 (ArCH), 126.25 (ArC), 124.55 (2ArCH), 
120.09 (ArCH), 119.47 (ArC), 116.31 (ArC), 115.53 (ArCH), 111.46 (ArCBr). 
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Mass spectrum: HRMS (ES-) found 336.9098, C12H679BrN2OS2 calculated 
336.9105. υ cm-1: 3233.1, 3102.4, 2843.0, 1676.8, 1582.8, 1568.8, 1511.9, 
1484.0, 1436.2, 1355.2, 1330.6, 1295.0, 1227.5, 1194.7, 1147.4, 1072.2, 1049.1, 
1021.1, 931.5, 893.8, 852.4, 797.4, 779.6, 748.2, 687.0, 669.2, 607.5, 587.7, 
570.8, 534.2, 466.7, 418.0. 
(Z)-5-((6-Iodoindol-3-yl)methylene)-2-thioxothiazolidin-4-one (59) 
 
Yield; 69%. mp. ~ 320 °C (dec.). δH (400 MHz, DMSO-d6): 13.59 (1 H, s, NH), 
12.32 (1 H, s, NH), 7.88 (1 H, s, CH=CS), 7.85 (1 H, s, ArCH), 7.78 (1 H, d, J = 6.5, 
ArCH), 7.47 (1 H, d, J = 8.5, ArCH). δC (125 MHz, DMSO-d6): 194.62 (CS), 169.05 
(CO), 137.27 (ArC), 130.27 (ArCH), 129.58 (ArCH), 126.11 (ArC), 124.09 (ArCH), 
120.96 (ArCH), 120.70 (ArCH), 118.89 (ArC), 110.97 (ArCH), 87.43 (ArCI). Mass 
spectrum: HRMS (ES-) found 384.8966, C12H6IN2OS2 calculated 384.8966, m/z 
(ES-): 297.9156 (25 % [M-CSNHCO]-). υ cm-1: 3231.2, 2998.3, 2837.7, 1683.6, 
1581.3, 1568.3, 1509.5, 1479.6, 1445.4, 1354.3, 1327.3, 1302.2, 1232.3, 1218.3, 
1141.2, 1128.6, 1073.2, 1053.9, 1024.0, 887.1, 847.1, 805.1, 793.6, 775.8, 724.6, 
712.1, 678.8, 661.0. 
(Z)-5-((7-Fluoroindol-3-yl)methylene)-2-thioxothiazolidin-4-one (60) 
 
Yield; 54%. mp. ~ 350 °C (dec.). δH (400 MHz, DMSO-d6): 13.59 (1 H, s, NH), 
12.82 (1 H, s, NH), 7.90 (1 H, s, CH=CS), 7.80 (1 H, d, J = 2.5, ArCH), 7.77 (1 H, d, J 
= 7.5, ArCH), 7.35 (1 H, dt, J1 = 7.5, J2 = 5.0, ArCH), 7.21 (1 H, dd, J1 = 11.5, J2 = 8.0, 
ArCH). δC (125 MHz, DMSO-d6): 195.25 (CS), 169.76 (CO), 147.65 (ArCF, d, J = 
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273.5), 130.93 (ArC), 130.71 (ArCH), 124.88 (ArC, d, J = 13.0), 124.51 (ArCH), 
122.33 (ArCH, d, J= 6.0), 120.10 (ArC), 115.21 (ArCH), 112.17 (ArC), 108.67 
(ArC, d, J = 16.0). Mass Spectrum HRMS [ES-] found 276.9901, C12H7FN2OS2 
calculated 276.9906, m/z (ES-): 190.0099 (100 % [M-CONHCS]-). υ cm-1: 3275.5, 
3042.2, 2851.2, 1685.5, 1641.1, 1576.5, 1514.8, 1445.9, 1361.0, 1342.2, 1320.5, 
1295.9, 1256.9, 1229.9, 1216.9, 1171.1, 1141.7, 1113.2, 1063.6, 1051.5, 1019.2, 
975.8, 910.2, 865.4. 
(Z)-5-((7-Chloroindol-3-yl)methylene)-2-thioxothiazolidin-4-one (61) 
 
Yield; 63%. mp. ~ 350 °C (dec.). δH (400 MHz, DMSO-d6): 13.64 (1 H, s, NH), 
12.70 (1 H, s, NH), 7.94 (1 H, d, J = 8.0, ArCH), 7.90 (1 H, s, CH=CS), 7.75 (1 H, d, J 
= 3.0, ArCH), 7.35 (1 H, d, J = 8.0, ArCH), 7.21 (1 H, t, J = 8.0, ArCH). δC (125 MHz, 
DMSO-d6): 195.12 (CS), 169.58 (CO), 133.74 (ArC), 130.68 (ArCH), 129.10 
(ArCCl), 124.44 (ArCH), 123.33 (ArCH), 122.78 (ArCH), 120.19 (ArC), 118.23 
(ArCH), 117.22 (ArC), 112.39 (ArC). Mass Spectrum HRMS [EI+] found 
293.9688, C12H735ClN2OS2 calculated 293.9681. υ cm-1: 3357.9, 3066.7, 2837.7, 
1896.7, 1806.97, 1696.6, 1645.0, 1620.9, 1586.7, 1564.5, 1513.9, 1490.2, 
1436.7, 1358.6, 1339.3, 1313.8, 1295.5, 1247.2, 1218.8, 1194.2, 1149.4, 1134.4, 
1087.2, 1051.0, 1019.7, 899.6, 856.7, 823.9, 785.4, 779.1, 772.8, 734.8, 698.1, 
632.1, 609.9. 
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(Z)-5-((7-Bromoindol-3-yl)methylene)-2-thioxothiazolidin-4-one (62) 
 
Yield; 91%. mp. ~330 °C (dec.). δH (400 MHz, DMSO-d6): 13.64 (1 H, s, NH), 
12.54 (1 H, s, NH), 7.99 (1 H, d, J = 7.5, ArCH), 7.90 (1 H, s, CH=CS), 7.72 (1 H, d, J 
= 3.0, ArCH), 7.50 (1 H, d, J = 7.5, ArCH), 7.16 (1 H, t, J = 7.5, ArCH). δC (125 MHz, 
DMSO-d6): 195.36 (CS), 168.98 (CO), 134.89 (ArC), 129.96 (ArC), 128.45 
(ArCH), 125.79 (ArCH), 123.89 (ArCH), 122.76 (ArCH), 119.73 (ArC), 118.22 
(ArCH), 111.78 (ArC), 104.96 (ArBr). Mass Spectrum HRMS [EI+] found 
337.9184, C12H779BrN2OS2 calculated 337.9183. υ cm-1: 3349.8, 3070.1, 2837.6, 
1695.1, 1584.2, 1560.6, 1512.9, 1487.8, 1434.5, 1356.7, 1336.0, 1312.8, 1295.0, 
1245.3, 1217.8, 1192.4, 1144.6, 1129.6, 1018.2, 882.3, 846.6. 
(Z)-5-((7-Iodoindol-3-yl)methylene)-2-thioxothiazolidin-4-one (63) 
 
Yield; 79%. mp. ~ 320 °C (dec.). δH (250 MHz, DMSO-d6): 13.63 (1 H, s, NH), 
12.24 (1 H, s, NH), 7.97 (1 H, d, J = 7.5, ArCH), 7.86 (1 H, s, CH=CS), 7.67 (1 H, d, J 
= 7.5, ArCH), 7.66 (1 H, s, ArCH), 7.01 (1 H, t, J = 7.5, ArCH). δC (125 MHz, DMSO-
d6): 194.86 (CS), 169.48 (CO), 139.17 (ArC), 132.76 (ArCH), 130.22 (ArCH), 
127.67 (ArC), 124.56 (ArCH), 123.43 (ArCH), 119.95 (ArC), 119.10 (ArCH), 
112.49 (ArC), 78.08 (ArCI). Mass Spectrum HRMS [ES-] found 384.8966, 
C12H7IN2OS2 calculated 384.8967. υ cm-1: 3270.2, 3057.1, 2872.9, 1733.7, 
1672.0, 1590.5, 1576.0, 1556.8, 1509.5, 1484.4, 1464.7, 1440.6, 1425.6, 1351.4, 
1332.1, 1309.0, 1241.0, 1195.7, 1148.9, 1129.1, 1073.2, 1017.3, 876.5, 802.7, 
773.3, 738.6, 707.7, 685.6, 629.2, 584.8, 556.8, 530.8. 
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6.1.5 General method for the preparation of α-mercaptoacrylic acids188 
(Z)-3-(4-Fluoroindol-3-yl)-2-mercaptoacrylic acid (75) 
 
To (Z)-5-((4-fluoroindol-3-yl)methylene)-2-thioxothiazolidin-4-one (0.40 g, 
1.44 mmol) was added 15% aqueous sodium hydroxide (4 ml). The stirred 
reaction mixture was heated under reflux under an N2 atmosphere for 1.5 hr. 
The reaction mixture was then cooled in an ice bath and hydrochloric acid (1 M, 
10 ml) added. The resulting precipitate was collected by filtration under 
reduced pressure and washed with water (2 × 10 ml). The solid was air dried 
under reduced pressure to give the title compound as a light brown coloured 
solid (0.30 g, 1.26 mmol, 88%). mp. 193 - 196 °C. δH (400 MHz, DMSO-d6): 12.12 
(1 H, s, NH), 8.26 (1 H, s, CH=CSH), 7.97 (1 H, d, J = 2.5, ArCH), 7.33 (1 H, d, J = 
8.0, ArCH), 7.17 (1 H, dd, J1 = 5.0, J2 = 8.0, ArCH), 6.92 (1 H, dt, J1 =8.0, J2 = 5.0, 
ArCH), 5.20 (1 H, s, SH). δC (100 MHz, MeOD-d4): 167.00 (COOH), 157.11 (ArCF, 
d, J = 243.5) 138.86 (ArC, d, J = 11.0), 128.64 (ArCH, d, J = 4.5), 127.70 (ArCH), 
123.60 (ArCH, d, J = 8.0), 117.73 (ArC), 115.53 (ArC), 113.47 (ArC), 109.27 
(ArCH), 106.15 (ArCH, d, J = 20.0).  Mass spectrum: HRMS (NSI-) found 
236.0190, C11H7FNO2S calculated 236.0187. υ cm-1: 3428.8, 2932.7, 2792.4, 
2569.7, 1657.0, 1595.8, 1505.2, 1448.8, 1413.1, 1325.3, 1291.6, 1270.9, 1252.5, 
1225.5, 1155.2, 1137.8, 1089.6, 1030.3, 901.6, 841.3, 804.2, 775.7, 727.0, 694.2, 
648.9, 594.0, 547.7, 519.2, 492.2, 418.5. 
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Phenyl Derivatives 
(Z)-3-(2-Fluorophenyl)-2-mercaptoacrylic acid (64) 
 
Yield; 91%. mp. 135 - 140 °C. δH (400 MHz, MeOD-d4): 7.91 (2 H, d, J = 10.0, 
ArCH and CH=CSH), 7.41 (1 H, q, J1 = 7.5, J2 = 6.0, ArCH), 7.29 (1 H, t, J1 = 8.0, J2 = 
7.5, ArCH), 7.18 (1 H, t, J1 = 10.0, J2 = 8.0, ArCH).  δC (125 MHz, MeOD-d4): 166.27 
(COOH), 160.42 (ArCF, d, J = 250.5), 130.46 (ArCH, d, J = 8.0), 129.20 (ArCH, d, J 
= 2.0), 126.49 (ArC), 125.42 (ArCH, d, J = 7.0), 123.83 (ArCH, d, J = 4.0), 123.22 
(ArC, d, J = 12.0), 115.09 (ArCH, d, J = 22.0). Mass spectrum: HRMS (NSI-) found 
197.0074, C9H6O2FS calculated 197.0078. υ cm-1: 2567.3, 1677.8, 1610.3, 
1573.6, 1480.1, 1455.5, 1415.0, 1302.7, 1270.9, 1155.2, 1104.1, 1049.1, 1035.6, 
892.9, 846.1, 801.3, 762.7, 721.6, 669.7, 602.2, 540.5, 527.0. 
(Z)-3-(2-Chlorophenyl)-2-mercaptoacrylic acid (65) 
 
Yield; 63%. mp. 145 - 148 °C. δH (400 MHz, MeOD-d4): 7.96 (1 H, s, CH=CSH), 
7.83 (1 H, dd, J1 = 7.5, J2 = 1.5, ArCH), 7.51 (1 H, dd, J1 = 7.5, J2 = 1.5, ArCH), 7.41 
(1 H, td, J1 = 7.5, J2 = 1.5, ArCH), 7.36 (1 H, td, J1 = 7.5, J2 = 1.5, ArCH).  δC (125 
MHz, MeOD-d4): 166.20 (COOH), 133.80 (ArC), 133.62 (ArCCl), 130.50 (ArCH), 
129.74 (ArCH), 129.48 (ArCH), 129.42 (ArCH), 127.09 (ArC), 126.55 (ArCH). 
Mass spectrum: HRMS (EI+) found 213.9861, C9H7O235ClS calculated 213.9855. υ 
cm-1: 3058.55, 2973.21, 2639.11, 2561.97, 1680.66, 1590.02, 1563.50, 1465.63, 
1437.67, 1411.64, 1295.45, 1260.25, 1212.52, 1049.09, 1034.62, 887.58, 
853.35, 761.26, 743.90, 737.16, 716.91, 686.53, 663.88, 602.16, 534.19, 493.21, 
468.62, 418.96. 
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(Z)-3-(2-Bromophenyl)-2-mercaptoacrylic acid (66) 
 
Yield; 84%. mp. 142 - 145 °C. δH (400 MHz, MeOD-d4): 7.89 (1 H, s, CH=CSH), 
7.77 (1 H, dd, J1 = 8.0, J2 = 1.5, ArCH), 7.69 (1 H, dd, J1 = 8.5, J2 = 1.5, ArCH), 7.45 
(1 H, dt, J1 = 8.0, J2 = 1.5, ArCH), 7.27 (1 H, dt, J1 = 8.0, J2 = 1.5, ArCH). δC (100 
MHz, MeOD-d4) 166.13 (COOH), 135.45 (ArC), 133.00 (ArCH), 132.74 (ArCH), 
129.92 (ArCH), 129.59 (ArCH), 127.16 (ArCH), 127.00 (ArC), 123.94 (ArCBr). 
Mass spectrum: HRMS (EI+) found 257.9344, C9H679BrO2S calculated 257.9350. 
υ cm-1: 3445.7, 2828.6, 2649.7, 2570.7, 2548.0, 2360.4, 1683.1, 1600.2, 1560.1, 
1463.7, 1434.8, 1416.0, 1318.6, 1289.7, 1264.6, 1212.0, 1047.2, 1028.4, 908.3, 
883.2, 850.0, 758.4, 740.5, 733.3, 718.8, 663.4, 600.2, 527.9. 
Benzothiophene-2-carboxylic acid (67) 
 
Yield; 72%. mp. 241 - 244 °C. δH (400 MHz, MeOD-d4): 8.07 (1 H, s, CH=CSH), 
7.94 (2 H, t, J1 = 7.0, J2 = 7.0, ArCH), 7.49 (1 H, td, J1 = 7.0, J2 = 1.5, ArCH), 7.44 (1 
H, dt, J1 = 7.0, J2 = 1.5, ArCH). δC (125 MHz, MeOD-d4): 164.37 (COOH), 142.22 
(ArC), 138.96 (ArC), 130.18 (ArCH), 126.66 (ArCH), 125.21 (ArCH), 124.32 
(ArCH), 122.32 (ArCH), 100.00 (ArC). Mass spectrum: HRMS (NSI-) found 
177.0019, C9H5O2S calculated 177.0016; υ cm-1: 2817.49, 2578.36, 1666.20, 
1593.40, 1557.72, 1521.56, 1460.81, 1439.60, 1415.49, 1338.36, 1318.11, 
1306.54, 1276.16, 1253.02, 1184,08, 1162.87, 1155.15, 1136.35, 1079.46, 
1051.98, 1011.96, 949.77, 924.70, 886.13, 858.17, 761.74, 750.66, 725.10, 
711.60, 584.81, 554.43, 504.29. 
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(Z)-3-(3-Fluorophenyl)-2-mercaptoacrylic acid (68) 
 
Yield; 68%. mp. 137 - 143 °C. δH (400 MHz, MeOD-d4): 7.77 (1 H, s, CH=CSH), 
7.45 (3 H, m, ArCH), 7.10 (1 H, m, ArCH). δC (100 MHz, MeOD-d4): 166.40 
(COOH), 162.72 (ArCF, d, J = 244.5), 137.60 (ArC, d, J = 8.1), 132.55 (ArCH), 
129.98 (ArCH, d, J = 8.0), 125.57 (ArCH, d, J = 3.0), 125.52 (ArC, s), 115.58 
(ArCH, d, J = 22.5), 115.07 (ArCH, d, J = 22.0). Mass spectrum: HRMS (ES-) found 
197.0077, C9H6O2FS calculated 197.0073. υ cm-1: 2567.3, 1677.8, 1610.3, 
1573.6, 1480.1, 1455.5, 1415.0, 1302.7, 1270.9, 1155.2, 1104.1, 1049.1, 1035.6, 
892.9, 846.1, 801.3, 762.7, 724.6, 669.7, 602.2, 540.5, 527.0. 
(Z)-3-(3-Chlorophenyl)-2-mercaptoacrylic acid (69) 
 
Yield; 80%. mp. 141 - 142 °C. δH (400 MHz, MeOD-d4): 7.75 (1 H, s, CH=CSH), 
7.68 (1 H, s, ArCH), 7.59 (1 H, d, J = 7.5, ArCH), 7.44 (1 H, t, J = 8.0, ArCH), 7.37 (1 
H, d, J = 8.0, ArCH). δC (125 MHz, MeOD-d4): 166.36 (COOH), 137.32 (ArC), 
134.17 (ArC), 132.31 (ArCH), 129.71 (ArCH), 128.95 (ArCH), 128.22 (ArCH), 
127.74 (ArCH), 125.77 (ArCCl). Mass spectrum: HRMS (ES-) found 212.9769, 
C9H6O235ClS calculated 212.9777. υ cm-1: 2934.2, 2818.9, 2702.3, 2636.2, 
2558.1, 2510.9, 1675.8, 1587.1, 1558.7, 1480.6, 1423.7, 1347.0, 1294.5, 1268.0, 
1204.8, 1098.3, 1084.3, 1045.7, 932.4, 903.5, 890.0, 779.6, 748.7, 704.4, 675.9, 
658.6, 607.5, 563.6, 495.6, 456.6, 427.6. 
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(Z)-3-(3-Bromophenyl)-2-mercaptoacrylic acid (70) 
 
Yield; 75%. mp. 128 - 135 °C. δH (500 MHz, MeOD-d4): 7.84 (1 H, s, ArCH), 7.73 
(1 H, s, CH=CSH), 7.63 (1 H, d, J = 8.0, ArCH), 7.51 (1 H, d, J = 8.0, ArCH), 7.37 (1 
H, t, J = 8.0, ArCH). δC (125 MHz, MeOD-d4): 166.48 (COOH), 137.65 (ArC), 
132.05 (ArCH), 131.90 (ArCH), 131.13 (ArCH), 129.92 (ArCH), 128.13 (ArCH), 
126.11 (ArC), 122.18 (ArCBr). Mass spectrum: HRMS (ES-) found 256.9270, 
C9H6O279BrS calculated 256.9272.υ cm-1: 2961.6, 2823.8, 2638.1, 2557.6, 
1675.4, 1590.0, 1552.9, 1476.2, 1417.9, 1345.6, 1291.6, 1261.7, 1205.8, 
1093.92, 1074.2, 1042.3, 992.7, 905.4, 889.0, 872.6, 779.6, 737.6, 692.8, 675.4, 
650.4, 604.1, 555.9, 486.9, 451.3. 
(Z)-3-(3-Iodophenyl)-2-mercaptoacrylic acid (71) 
 
Yield; 68%. mp. 147 - 149 °C. δH (500 MHz, MeOD-d4): 8.02 (1 H, s, ArCH), 7.71 
(1 H, d, J = 7.0, ArCH), 7.70 (1 H, s, CH=CSH), 7.66 (1 H, d, J = 8.0, ArCH), 7.22 
(1H, t, J = 8.0, ArCH). δC (125 MHz, MeOD-d4): 166.36 (COOH), 138.03 (ArCH), 
137.53 (ArC), 137.23 (ArCH), 132.20 (ArCH), 129.93 (ArCH), 128.61 (ArCH), 
125.59 (ArC), 93.44 (ArCI). Mass spectrum: HRMS (EI+) found 305.9212, 
C9H6O2IS calculated 305.9212 υ cm-1: 2990.6, 2577.9, 1693.7, 1588.1, 1552.4, 
1473.4, 1414.5, 1345.6, 1285.8, 1251.1, 1207.7, 1067.4, 1042.3, 989.8, 921.8, 
674.0, 644.6, 604.6, 549.1, 488.9, 447.9, 419.0.  
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(Z)-3-(4-Fluorophenyl)-2-mercaptoacrylic acid (72) 
 
Yield; 88%. mp. 138 - 143 °C. δH (400 MHz, MeOD-d4): 7.79 (1 H, s, CH=CSH), 
7.72 (2 H, dt, J1 = 8.5, JHF = 3.5, ArCH), 7.20 (2 H, t, J = 8.5, ArCH). δC (100 MHz, 
MeOD-d4): 167.12 (COOH), 163.57 (ArCF, d, J = 250.5), 145.20 (ArCH), 133.12 
(ArCH, d, J = 8.0), 131.67 (ArCH, d, J = 8.0), 127.88 (ArC), 123.48 (ArC), 115.12 
(ArCH, d, J = 22.0), 114.89 (d, J = 22.0, ArCH). Mass spectrum: HRMS (EI+) found 
198.0152, C9H6O2FS calculated 198.0151.υ cm-1: 2822.8, 2577.4, 1667.6, 1596.8, 
1580.9, 1505.7, 1421.8, 1307.5, 1298.3, 1264.1, 1233.7, 1165.8, 1105.5, 1039.9, 
1014.4, 892.9, 829.2, 798.4, 714.5, 678.3, 621.4, 542.4, 526.0. 
(Z)-3-(4-Chlorophenyl)-2-mercaptoacrylic acid (73) 
 
Yield; 58%. mp. 163 – 173 °C. δH (400 MHz, MeOD-d4): 7.77 (1 H, s, CH=CSH), 
7.66 (2 H, d, J = 8.0, ArCH), 7.46 (2 H, dd, J1 = 6.5, J2 = 2.0, ArCH). δC (125 MHz, 
DMSO-d6): 166.52 (COOH), 134.02 (ArC), 132.63 (ArCH), 130.92 (2ArCH), 
128.37 (2ArCH), 124.70 (ArCCl). Mass spectrum: HRMS (ES-) found 212.9786, 
C9H6O235ClS calculated 212.9777. υ cm-1: 2945.7, 2824.2, 2644.9, 2571.1, 
2506.5, 2346.0, 1665.2, 1586.2, 1559.2, 1489.3, 1422.2, 1400.1, 1349.0, 1309.9, 
1287.7,123.6, 1207.7, 1115.6, 1092.0, 1037.5, 1013.4, 905.4, 887.1, 845.6, 
811.4, 738.1, 702.4, 682.2, 664.8, 623.4, 521.7, 505.3, 446.0.  
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(Z)-3-(4-Bromophenyl)-2-mercaptoacrylic acid (74) 
 
Yield; 82%. mp. 174 – 185 °C. δH (400 MHz, MeOD-d4): 7.75 (1 H, s, CH=CSH), 
7.60 (4 H, d, J = 2.7, ArCH). δC (125 MHz, MeOD-d4): 166.58 (COOH), 134.41 
(ArC), 132.62 (ArCH), 131.40 (2ArCH), 131.13 (2 ArCH), 124.97 (ArC), 122.29 
(ArCBr). Mass spectrum: HRMS (ES-) found 256.9281, C9H6O279BrS calculated 
256.9272. υ cm-1: 3445.2, 2951.0, 2823.8, 2638.6, 2587.0, 2558.6, 1674.4, 
1580.4, 1557.2, 1485.9, 1418.4, 1395.7, 1342.7, 1308.5, 1288.7, 1270.4, 1206.3, 
1181.2, 1115.6, 1077.1, 1037.0, 1009.6, 909.8, 886.6, 850.9, 814.3, 803.2, 768.5, 
750.7, 734.8, 699.6, 677.4, 518.8, 500.0, 446.4. 
Indole Derivatives 
(Z)-3-(4-Chloroindol-3-yl)-2-mercaptoacrylic acid (76) 
 
Yield; 81%. mp. 188 - 192 °C. δH (400 MHz, DMSO-d6): 12.17 (1 H, s, NH), 8.81 (1 
H, s, CH=CSH), 8.06 (1 H, s, ArCH), 7.49 (1 H, m, ArCH), 7.25 (2 H, m, ArCH), 5.20 
(1 H, s, SH). δC (125 MHz DMSO-d6): 167.63 (COOH), 139.90 (ArCH), 137.82 
(ArCCl), 132.05 (ArCH), 125.03 (ArC), 123.63 (ArCH), 123.54 (ArC), 122.71 
(ArCH), 120.71 (ArC), 112.27 (ArCH), 110.85 (ArC). Mass spectrum: HRMS (NSI-
) found 251.9892, C11H735ClNO2S calculated 251.9892. υ  cm-1: 3331.9, 3064.8, 
2563.9, 1668.6, 1538.3, 1513.4, 1485.4, 1404.9, 1339.8, 1280.5, 1240.5, 1190.8, 
1146.0, 1122.4, 1085.2, 1051.5, 1037.5, 938.7, 890.0, 793.1, 776.7, 734.7, 676.9, 
570.3, 505.3, 482.1. 
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(Z)-3-(4-Bromoindol-3-yl)-2-mercaptoacrylic acid (77) 
 
Yield; 71%. mp. 188 - 191 °C. δH (400 MHz, DMSO-d6): 12.22 (1 H, s, NH), 8.94 (1 
H, s, CH=CSH), 8.05 (1 H, d, J = 2.5, ArCH), 7.54 (1 H, d, J = 7.5, ArCH), 7.36 (1 H, 
d, J = 7.5, ArCH), 7.12 (1 H, t, J = 7.5, ArCH), 5.13 (1 H, s, SH). δC (125 MHz DMSO-
d6): 167.69 (COOH), 139.55 (ArCH), 137.80 (ArC), 132.20 (ArCH), 126.10 
(ArCH), 124.81 (ArC), 123.97 (ArCH), 120.49 (ArC), 113.11 (ArCH), 112.76 
(ArC), 111.13 (ArCBr). Mass spectrum: HRMS (NSI-) found 297.9353, 
C11H779BrNO2S calculated 297.9365.  υ  cm-1: 3403.7, 2559.1, 1661.4, 1579.9, 
1558.7, 1509.0, 1481.5, 1403.9, 1335.5, 1281.0, 1238.6, 1188.9, 1142.1, 1080.4, 
1048.6, 913.1, 820.6, 774.3, 734.3, 673.0, 607.0, 563.1, 497.1.  
5H-Thiopyrano[4,3,2-cd]indole-2-carboxylic acid (78) 
 
Yield; 68%. mp. ~ 320 °C (dec.). δH (400 MHz, DMSO-d6): 11.14 (1 H, s, NH), 7.44 
(1 H, s, CH=CS), 7.17 (1 H, d, J = 2.5, C=CHNH), 6.83 (1 H, t, J = 8.0, ArCH), 6.78 (1 
H, d, J = 8.0, ArCH), 6.43 (1 H, d, J = 8.0, ArCH). δC (125 MHz DMSO-d6): 165.21 
(COOH), 135.54 (ArC), 128.33 (ArCH), 128.09 (ArC), 125.87 (ArCH), 125.35 
(ArC), 122.22 (ArCH), 121.97 (ArC), 112.99 (ArC), 112.30 (ArCH), 108.58 
(ArCH). Mass spectrum: HRMS (EI+) found 217.0197, C11H7NO2S calculated 
217.0198.  υ cm-1: 3385.9, 2919.2, 2525.8, 2362.9, 1874.0, 1653.2, 1617.0, 
1595.3, 1559.7, 1517.2, 1487.3. 1420.8, 1383.7, 1329.7, 1296.9, 1254.5, 1215.9, 
1194.2, 1148.9, 1126.2, 1094.4, 1039.9, 1022.1, 948.8, 893.4, 850.0, 825.4, 
785.4, 771.4, 733.8, 717.9, 696.7, 629.6, 614.2, 587.2, 554.4, 494.2, 466.2, 419.0. 
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(Z)-3-(5-Chloroindol-3-yl)-2-mercaptoacrylic acid (79) 
 
Yield; 97%. mp. 196 – 199 °C. δH (400 MHz, DMSO-d6): 12.08 (1 H, s, NH), 8.02 
(1 H, s, CH=CSH), 8.00 (1 H, d, J = 2.0, ArCH), 7.82 (1 H, d, J = 2.0, ArCH), 7.51 (1 
H, d, J = 8.5, ArCH), 7.22 (1 H, dd, J1 =8.5, J2=2.0, ArCH) 5.17 (1 H, s, SH). δC (100 
MHz DMSO-d6): 167.45 (COOH), 138.26 (ArCH), 134.53 (ArC), 132.07 (ArCH), 
129.26 (ArC), 126.09 (ArCCl), 123.03 (ArCH), 121.02 (ArC), 117.86 (ArCH), 
114.30 (ArCH), 110.52 (ArC). Mass spectrum: HRMS (NSI-) found 251.9890, 
C11H735ClNO2S calculated 251.9892; υ cm-1: 3344.0, 3027.7, 2925.5, 2802.1, 
2558.1, 2361.4, 2341.2, 1660.4, 1618.0, 1585.2, 167.8, 1511.0, 1457.9, 1405.8, 
1322.9, 1276.6,1258.3, 1225.5, 1139.7,1117.6, 1054.9, 1034.6, 892.9, 852.34, 
794.5, 737.5, 740.5, 723.2, 683.6, 656.6, 589.1, 498.5, 475.4, 417.5, 372.2, 354.8, 
340.4, 322.1, 313.4. 
(Z)-3-(5-Bromoindol-3-yl)-2-mercaptoacrylic acid (80) 
 
Yield; 89%. mp. 209 - 213 °C. δH (400 MHz, DMSO-d6): 12.05 (1 H, s, NH), 8.05 (1 
H, s, CH=CSH), 8.03 (1 H, d, J = 2.0, ArCH), 8.00 (1 H, d, J = 2.0, ArCH), 7.50 (1 H, 
d, J = 9.0, ArCH), 7.37 (1 H, dd, J1 = 9.0, J2 = 2.0, ArCH). δC (100 MHz DMSO-d6): 
167.05 (COOH), 134.87 (ArC), 129.43 (ArCH), 129.29 (ArC), 125.67 (ArCH), 
125.59 (ArC), 121.05 (ArC), 118.01 (ArCH), 114.56 (ArCH), 113.43 (ArC), 
111.29 (ArCBr). Mass spectrum: HRMS (NSI-) found 297.9359, C11H779BrNO2S 
calculated 297.9365.  υ cm-1: 3377.7, 2925.0, 1656.1, 1615.1, 1579.4, 1563.5, 
1505.7, 1453.6, 1403.4, 1321.0, 1274.2, 1255.4, 1221.7, 1139.2, 1111.3, 1050.5, 
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881.3, 793.6, 768.5, 739.6, 718.8, 645.6, 718.8, 645.5, 593.5, 554.0, 496.6, 468.1, 
414.1.  
(Z)-3-(5-Iodoindol-3-yl)-2-mercaptoacrylic acid (81) 
 
Yield; 29%. mp. 202 – 219 °C. δH (250 MHz, DMSO-d6): 13.00 (1 H, s, COOH), 
12.00 (1 H, s, NH), 8.13 (1 H, s, CH=CSH), 8.01 (1 H, s, ArCH), 7.95 (1 H, s, ArCH), 
7.49 (1 H, d, J = 8.0, ArCH), 7.35 (1 H, d, J = 8.0, ArCH). δC (100 MHz DMSO-d6): 
167.07 (COOH), 135.23 (ArC), 131.94 (ArCH), 130.98 (ArCH), 130.02 (ArC), 
128.87 (ArCH), 127.04 (ArCH), 125.50 (ArC), 114.99 (ArC), 110.95 (ArCH), 
84.74 (ArCI). Mass spectrum: HRMS (APCI+) found 345.9388, C11H9INO2S 
calculated 345.9393. υ cm-1: 3418.2, 2921.2, 2251.5, 1671.0, 1612.2, 1577.0, 
1559.2, 1504.7, 1446.8, 1328.7, 1226.0, 1137.3, 1043.8, 878.9, 795.5, 764.6, 
699.1, 606.1. 
(Z)-3-(6-Fluoroindol-3-yl)-2-mercaptoacrylic acid (82) 
 
Yield; 56%. mp. 194 - 196 °C. δH (400 MHz, DMSO-d6): 11.87 (1 H, s, NH), 8.01 (1 
H, s, CH=CSH), 7.94 (1 H, d, J = 2.5, ArCH), 7.76 (1 H, dd, J1 = 5.5, J2 = 3.5, ArCH), 
7.26 (1 H, dt, J1 =9.5, J2 = 2.5, ArCH), 7.00 (1H, td, J1 = 9.5, J2 = 2.5, ArCH). δC (100 
MHz DMSO-d6): 167.02 (COOH), 159.87 (ArCF, d, J = 236.5), 136.05 (ArC, d, J = 
13.5), 128.76 (ArCH), 125.85 (ArCH), 124.22 (ArC), 119.75 (ArCH, d, J = 10.0), 
117.80 (ArC), 111.65 (ArC), 109.19 (ArCH, d, J = 24.5), 98.58 (ArCH, d, J = 25.5).  
Mass spectrum: HRMS (NSI-) found 236.0190, C11H7FNO2S calculated 236.0187, 
m/z (NSI-). υ cm-1: 3632.8, 3223.9, 1583.3, 1561.6, 1506.1, 1452.1, 1408.8, 
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1333.5, 1298.8, 1256.4, 1228.4, 1144.1, 1069.8, 907.8, 800.8, 783.4, 725.6, 
656.2, 577.6, 491.8.  
(Z)-3-(6-Chloroindol-3-yl)-2-mercaptoacrylic acid (83) 
 
Yield; 52%. mp. 201 - 202 °C. δH (400 MHz, DMSO-d6): 12.93 (1 H, s, COOH), 
11.93 (1 H, s, NH), 8.02 (1 H, s, CH=CSH), 7.99 (1 H, d, J = 2.5, ArCH), 7.78 (1 H, d, 
J = 8.5, ArCH), 7.54 (1 H, t, J = 12.5, ArCH), 7.14 (1 H, d, J = 8.5, ArCH). δC (100 
MHz DMSO-d6): 167.42 (COOH), 138.10 (ArCH), 136.42 (ArC), 131.61 (ArCH), 
127.60 (ArCCl), 126.79 (ArC), 121.55 (ArCH), 121.28 (ArC), 119.90 (ArCH), 
112.36 (ArCH), 110.82 (ArC). Mass spectrum: HRMS (NSI-) found 251.9892, 
C11H735ClNO2S calculated 251.9890. υ cm-1: 3632.8, 3223.9, 1583.3, 1561.6, 
1506.1, 1452.1, 1408.8, 1333.5, 1298.8, 1256.4, 1228.4, 1144.1, 1069.8, 907.8, 
800.8, 783.4, 725.6, 656.2, 577.6, 491.8.  
(Z)-3-(6-Bromoindol-3-yl)-2-mercaptoacrylic acid (84) 
 
Yield; 78%. mp. 193 – 203 °C. δH (400 MHz, DMSO-d6): 13.11 (1 H, s, COOH), 
11.94 (1 H, s, NH), 8.01 (1 H, s, CH=CSH), 7.97 (1 H, d, J = 2.0, ArCH), 7.73 (1 H, d, 
J = 8.5, ArCH), 7.68 (1 H, d, J =1.5, ArCH), 7.27 (1 H, dd, J1 = 8.5, J2 = 2.0, ArCH), 
5.19 (1 H, s, SH). δC (100 MHz DMSO-d6): 166.99 (COOH), 136.98 (ArC), 129.00 
(ArCH), 126.53 (ArC), 125.58 (ArCH), 123.56 (ArCH), 120.43 (ArCH), 118.11 
(ArC), 115.65 (ArCBr), 115.10 (ArCH), 111.71 (ArC).  Mass spectrum: HRMS 
(NSI-) found 295.9378, C11H779BrNO2S calculated 295.9386. υ cm-1: 3432.7, 
2923.1, 2562.5, 1672.0, 1590.5, 1516.3, 1454.1, 1423.7, 1388.0, 1332.6, 1312.8, 
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1297.4, 1268.5, 1141.2, 1111.3, 1071.3, 895.8, 851.9, 811.9, 775.2, 726.6, 678.3, 
517.3, 419.9. 
(Z)-3-(6-Iodoindol-3-yl)-2-mercaptoacrylic acid (85) 
 
Yield; 67%. mp. 185 - 187 °C. δH (400 MHz, DMSO-d6): 13.02 (1 H, s, COOH), 
11.89 (1 H, s, NH), 8.00 (1 H, s, CH=CSH), 7.91 (1 H, s, ArCH), 7.85 (1 H, s, ArCH), 
7.60 (1 H, d, J = 7.5, ArCH), 7.41 (1 H, d, J = 7.5, ArCH). δC (125 MHz DMSO-d6): 
167.42 (COOH), 138.01 (ArCH), 137.45 (ArC), 131.17 (ArCH), 129.59 (ArCH), 
127.42 (ArC), 123.20 (ArC), 121.17 (ArCH), 120.55 (ArCH), 110.87 (ArC), 87.11 
(ArCI). Mass spectrum: HRMS (NSI-) found 343.9241, C11H7INO2S calculated 
343.9241. υ cm-1: 3423.5, 2815.6, 2561.5, 1670.1, 1603.5, 1588.6, 1563.5, 
1512.9, 1449.7, 1419.4, 1385.1, 1329.7, 1312.8, 1295.5, 1267.0, 1230.8, 1144.6, 
1109.8, 1069.8, 1037.0, 901.1, 886.1, 851.9, 808.5, 772.4, 756.0, 742.5, 723.2, 
674.0, 635.4, 622.9. 
(Z)-3-(7-Fluoroindol-3-yl)-2-mercaptoacrylic acid (86) 
 
Yield; 78%. mp. 181 - 183 °C. δH (400 MHz, DMSO-d6): 12.38 (1 H, s, NH), 8.03 (1 
H, s, CH=CSH), 7.95 (1 H, d, J = 2.5, ArCH), 7.59 (1 H, d, J = 8.0, ArCH), 7.09 (3 H, 
m, ArCH). δC (100 MHz DMSO-d6): 167.26 (COOH, s), 149.63 (ArCF, d, J = 244.5), 
138.20 (ArCH), 131.72 (ArC, d, J = 5.5), 131.13 (ArCH), 123.75 (ArC, d, J = 4.0), 
121.75 (ArCH, d, J = 6.5), 121.43 (ArC), 114.45 (ArCH), 111.45 (ArC), 107.94 
(ArCH, d, J = 16.5). Mass spectrum: HRMS (EI+) found 237.0252, C11H8FNO2S 
calculated 237.0260. υ cm-1: 3318.4, 3044.1, 2563.4, 1665.7, 1577.0, 1518.2, 
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1498.4, 1447.3, 1409.2, 1338.4, 1307.5, 1262.2, 1228.9, 1139.2, 1106.0, 1041.9, 
975.8, 896.3, 866.4. 
(Z)-3-(7-Chloroindol-3-yl)-2-mercaptoacrylic acid (87) 
 
Yield; 82%. mp. 179 - 180 °C. δH (400 MHz, DMSO-d6): 12.24 (1 H, s, NH), 8.01 (1 
H, s, CH=CSH), 7.93 (1 H, s, ArCH), 7.76 (1 H, d, J = 8.0, ArCH), 7.31 (1 H, d, J = 8.0, 
ArCH) 7.18 (1 H, t, J = 8.0, ArCH). δC (125 MHz DMSO-d6): 167.64 (COOH), 
139.92 (ArCH), 137.82 (ArC), 132.06 (ArCH), 125.03 (ArC), 123.63 (ArCH), 
123.54 (ArC), 122.72 (ArCH), 120.70 (ArCCl), 112.27 (ArCH), 110.85 (ArC). 
Mass spectrum: HRMS (NSI-) found 251.9887, C11H735ClNO2S calculated 
251.9881. υ  cm-1: 3344.93, 2810.7, 2567.3, 1669.1, 1623.3, 1596.3, 1569.8, 
1518.2, 1491.2, 1435.7, 1422.7, 1405.9, 1338.4, 1306.1, 1265.1, 1243.9, 1200.0, 
1155.2, 1119.0, 1090.1, 1042.3, 894.3, 857.7, 780.5, 751.6, 733.8, 718.8, 682.2, 
582.4, 540.9, 505.3, 488.4. 
(Z)-3-(7-Bromoindol-3-yl)-2-mercaptoacrylic acid (88) 
 
Yield; 86%. mp. 165 - 168 °C. δH (400 MHz, DMSO-d6): 12.09 (1 H, s, NH), 8.01 (1 
H, s, CH=CSH), 7.92 (1 H, d, J = 3.0, ArCH), 7.42 (1 H, dd, J1 = 8.0, J2 = 3.0, ArCH), 
7.10 (1 H, dt, J1 = 8.0, J2 = 3.0, ArCH). δC (125 MHz DMSO-d6): 167.26 (COOH), 
138.09 (ArCH), 134.48 (ArC), 131.34 (ArCH), 129.74 (ArC), 125.69 (ArCH), 
122.66 (ArCH), 121.97 (ArC), 117.97 (ArCH), 111.86 (ArC), 105.29 (ArCBr). 
Mass spectrum: HRMS (EI+) found 296.9466, C11H879BrNO2S calculated 
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296.9459. υ cm-1: 3351.7, 2946.7, 2812.2, 2625.6, 2563.4, 1670.1, 1617.5, 
1594.4, 1563.0, 1515.8, 1487.8, 1434.8, 1420.3, 1403.4, 1335.0, 1304.6, 1262.2, 
1081.4, 1040.9, 881.3, 847.1, 807.6. 
(Z)-3-(7-Iodoindol-3-yl)-2-mercaptoacrylic acid (89) 
 
Yield; 81%. mp. 188 - 189 °C. δH (400 MHz, DMSO-d6): 11.78 (1 H, s, NH), 8.24 (1 
H, d, J = 2.5, ArCH), 8.01 (1 H, s, CH=CSH), 7.59 (1 H, d, J = 8.0, ArCH), 7.45 (1 H, 
d, J = 8.0, ArCH), 6.80 (1 H, t, J = 8.0, ArCH). δC (100 MHz DMSO-d6): 166.94 
(COOH), 137.99 (ArCH), 132.02 (ArC), 128.49 (ArCH), 127.93 (ArC), 125.65 
(ArCH), 122.61 (ArCH), 118.72 (ArC), 118.59 (ArCH), 112.86 (ArC), 77.96 
(ArCI). Mass spectrum: HRMS (NSI-) found 345.9391, C11H9INO2S calculated 
345.9393. υ cm-1: 3384.0, 2920.2, 2571.1, 1679.2, 1588.6, 1555.3, 1514.8, 
1481.1, 1419.8, 1396.2, 1331.6, 1303.2, 1260.7, 1239.0, 1197.1, 1143.1, 1112.2, 
1072.7, 1039.4, 875.5, 780.5, 752.6, 719.3, 675.9, 605.5, 570.3, 522.6. 
6.2 Testing for disulfide formation  
6.2.1 UV-Vis Analysis 
1 μl of a stock solution of (Z)-3-(4-bromophenyl)-2-mercaptoacrylic acid (74), 
100 mM  in DMSO, was added to 1 ml of a 1:1 solution of acetonitrile and 100 
mM KiHPO4 solution (pH 7.4), to create an overall concentration 100 μM. A UV-
Vis spectrum was measured over the range 450 nm to 250 nm at 20 °C and 
every 20 minutes subsequently to that for a total of 300 minutes. A Jasco V-660 
Spectrophotometer (Jasco-UK, Essex, UK) was used with the temperature 
regulated with a Peltier element. To the solution 10 μl of a 1.0 M solution of 
dithiothreitol (DTT) was added and a spectrum was obtained and every 1 
minute subsequently for 5 minutes until the compound was fully reduced, using 
the same wavelength and temperature parameters as above. 
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The same proceedure was applied for the UV-Vis spectroscopy analysis of the 
indole derivative (Z)-3-(7-bromoindol-3- yl)-2-mercaptoacrylic acid (88) 
6.2.2  HPLC Analysis 
HPLC was performed on a Dionex UltiMate 3000 (ThermoFisher, UK) pump 
with an UltiMate 3000 variable wavelength detector. 1.0 mg of 88 was dissolved 
in 0.5 ml of a 1:1 mixture of acetonitrile and 100 mM KiHPO4 (at pH 7.4), 20 μl of 
this solution was injected onto an analytical HPLC column [Acclaim® 120, C18, 
3 μm, 120 Å, 150 × 4.6 mm (ThermoFisher, Surrey, UK)]. The sample was eluted 
using a gradient from 100% water (0.1% TFA) to 100% acetonitrile (0.1% TFA) 
over the course of 60 min - 1 ml a minute. The eluent was analysed at 4 different 
wavelengths (210, 260, 290 and 350 nm). The sample was left to oxidise over 
the course of 5 hours whereupon 20 μl of the sample was injected onto the 
HPLC column and the same analysis was repeated. To the stock solution 10 μl of 
1.0 M of DTT was added, making the total solution to 10 mM DTT, the solution 
was then injected onto the analytical HPLC column and the same analysis was 
repeated once more. 
The same procedure was applied for the HPLC analysis of 74, where 1.5 mg was 
dissolved in 1 ml of a 1:1 solution of acetonitrile and 100 mM KiPO4 (at pH 7.4). 
After 5 hrs the compound had not fully oxidised so the solution was left for a 
further 19 hrs to fully oxidise.  
6.2.3 NMR analysis 
5 mg of 88 was dissolved in 0.6 ml of DMSO-d6 and a 1H NMR spectrum was 
collected immediately. The solution was then left to stand for 5 hrs at room 
temperature. After this time period another spectrum was collected. A third 
spectrum was collected after 24 hrs at room temperature. 
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6.3  Testing of α-mercaptoacrylic acid derivatives (Dr 
C. Parr, Dr E. Robinson and Prof. M. B. Hallett, 
School of Medicine) 
The final α-mercaptoacrylic acid derivatives were tested by Dr Christian Parr, 
Dr Emma Robinson and Prof. Maurice B. Hallett in the School of Medicine at 
Cardiff University (School of Medicine, Heath Hospital, Cardiff University, 
Cardiff, UK). 
6.3.1 Enzymatic assays 
Assay buffer 1 
10 mM HEPES,  10 mM DTT (dithiothreitol), 0.5 mM EDTA 
(ethylenediaminetetraacetic acid) and 0.1% (w/v) bovine serum albumin 
(BSA), at pH 7.2. 
FAM based calpain-I specific fluorogenic assay 
A calpain-I specific substrate; α-fodrin was utilised for this assay, with 
fluorescein amidite (FAM) attached to the N-terminal lysine which is internally 
quenched by 4-([4-(dimethylamino)phenyl]azo)benzoic acid (DABCYL) 
attached to the C-terminal lysine; (H-K(FAM)-EVYGMMK(DABCYL)-OH).206 
Cleavage by calpain-I occurs between the tyrosine and the glycine removing the 
quenching effect of the DABCYL substituent and thereby leading to an increase 
in fluorescence at 520 nm.  
Assays were performed with 25 nM human calpain-I (CalBiochem) and 1 mM 
fluorogenic calpain-I substrate in assay buffer 1 (vide supra). Each assay (100 
μl) was performed at 37 °C within a fluorescent plate reader (BMG Optistar), 
with the excitation wavelength set to 490 nm and emission wavelength 
detected at 520 nm. Potential inhibitors were added as a solution in DMSO (vide 
infra) to the assay mixture prior to the reaction and assays were initiated by 
addition of 5 mM CaCl2. The reaction was incubated for 1 hr at 37 °C and the 
fluorescence emission was detected continuously over that time period. 
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A stock solution of each inhibitor in DMSO (50 mM) was diluted into assay 
buffer to give a range of solutions from 100 nM to 10 mM. In each assay the 
effect of DMSO alone on calpain-I was measured; at lower concentrations no 
effect was observed but at 0.01-0.1% some inhibitory effect was observed. The 
effect of DMSO upon calpain-I was subtracted from the inhibition data collected.  
AMC based fluorogenic assay 
The substrate succinyl-LLVT-7-amido-4-coumarin was used as a non-specific 
calpain fluorogenic substrate for testing with calpain-I and calpain-II. AMC 
fluoresces even when attached to the substrate but upon cleavage the 
fluorescence of AMC increases and is detected at 460 nm.  
Assays (100 μl) were performed with 25 nM human calpain-I or 25 nM porcine 
calpain-II (CalBiochem) and 1 mM fluorogenic AMC substrate in assay buffer 1 
(vide supra). Each assay (100 μl) was performed a 37 °C within a fluorescent 
plate reader (BMG Optistar), with the excitation wavelength set to 390 nm and 
emission wavelength detected at 460 nm. Potential inhibitors were added as a 
solution in DMSO (vide supra) to the assay mixture prior to the reaction and 
assays were initiated by addition of 5 mM CaCl2. The reaction was incubated for 
1 hour at 37 °C and the fluorescence emission was detected continuously over 
that time period through the fluorescence detector in the plate reader 
6.3.2 Cell spreading assay 
Neutrophils were isolated from donated blood,244 and re-suspended in Krebs 
medium at pH 7.4; 120 mM NaCl, 4.9 mM KH2PO4, 1.2 mM MgSO4, 1.2 mM CaCl2, 
1.3 mM KCl, 25 mM HEPES and 0.1% BSA. 100 μl of cell-free Krebs medium was 
placed on an untreated coverslip which was warmed to 37 °C by the heated 
stage of a confocal laser scanning microscope (Leica). 100 μl of the cell 
suspension (~106/ml) was added and the cells were allowed to settle upon the 
glass surface, where upon contact with the surface the cells begin to 
spontaneously spread. ~50 cells were analysed for 3 minutes, following the 
contact with the glass surface. Images were collected with Leica software, the 
boundaries of the cell were identified through contrast enhancement and the 
2D area of the cell was determined with Image J software. 
Materials and Methods  
 
172 
 
To allow the maximum time for the inhibitors to enter the cell and take effect, 
the inhibitors were added to the cell solution prior to addition to the coverslip, 
to give a total concentration of 10 μM, 
6.3.3 Photo-reaction 
Cell spreading assay 
Neutrophils were isolated from donated blood,244 and re-suspended in Krebs 
medium (vide supra). 100 μl of cell-free Krebs medium was placed on an 
untreated coverslip which was warmed to 37 °C by the heated stage of a 
convention phase contrast light microscope (Leica). 100 μl of the cell 
suspension (~106/ml) was added and the cells were allowed to settle upon the 
glass surface. The cells were imaged using a transmitted light (488 nm) and the 
410 nm diode laser (UV laser) restricted to a few cells. The UV laser was 
activated for 1 min and each cell was exposed for 5-15 sec (depending on the 
percentage of the scan zaone occupied by the cell). Formyl-methionyl-leucyl-
phenylalanine (fMLP) was added and the irradiated cells were analysed for 5 
minutes. Images were collected with Leica software and analysed using Image J 
software (NIH, USA). 
Inhibitors or scam addition (equivalent DMSO concentrations) were addad to 
the cell solutions prior to addition to the coverslip (total concentration of 10 
μM). 
AMC based fluorogenic assay 
The substrate succinyl-LLVT-7-amido-4-coumarin was used as a non-specific 
calpain fluorogenic substrate for testing with calpain-I.  
Assays (100 μl) were performed with 20 nM porcine calpain-I (CalBiochem) and 
1 mM fluorogenic AMC substrate in assay buffer 1 (vide supra). Prior to the 
addition to the 96 well plate the two control solutions were kept in the dark, the 
two light samples were irradiated with a 100 W light source with a 360 nm 
band pass filter. Each assay (100 μl) was performed a 37 °C within a fluorescent 
plate reader (BMG Optistar), with the excitation wavelength set to 390 nm and 
emission wavelength detected at 460 nm. Potential inhibitors were added as a 
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solution in DMSO (vide supra) to the assay mixture prior to the reaction and 
assays were initiated by addition of 5 mM CaCl2. The reaction was incubated for 
1 hour at 37 °C and the fluorescence emission was detected continuously over 
that time period. 
6.4  Protein Synthesis 
6.4.1 Materials 
All chemicals were purchased from Sigma Aldrich and Fisher Scientific, unless 
otherwise stated. IPTG and ampicillin were purchased from Melford. All 
restriction enzymes were purchased from New England Biolabs. The genes 
encoding for porcine PEF(S) was purchased from Epoch Gene Synthesis (USA). 
All chemicals were used in accordance with their material safety sheets, COSHH 
and risk assessments. 
6.4.2 Media 
Luria-Bertani medium 
Tryptone (10.0 g), yeast extract (5.0 g) and sodium chloride (10.0 g) were 
dissolved in 1 l of deionised water. The solution was sterilised in an autoclave at 
121 °C, 15 lb in-2 for 20 minutes. 
LB agar 
Tryptone (10.0 g), yeast extract (5.0 g) and sodium chloride (10.0 g) and agar 
(15.0 g) were dissolved in 1 l of deionised water for preparation of culture 
plates. The solution was sterilised in an autoclave at 121 °C, 15 lb.(sq. in)-1 for 
20 minutes. 
6.4.3 Sterile Solutions 
Antibiotics 
Ampicillin was dissolved in deionised water to a concentration of 50 mg/ml and 
used at a working concentration of 0.1 mg/ml. The antibiotic was sterilised 
utilising a 0.2 μm syringe filter, aliquoted and stored at -20 °C. 
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Isopropyl-β-D-1-thiogalactopyranoside (IPTG) 
IPTG (360 mg) was dissolved in 1 ml of deionised water for use at a working 
concentration of 0.12 mg/ml. The solution was sterilised using a 0.2 μm syringe 
filter, aliquoted and stored at -20 °C. 
Competent cell solutions 
Rubidium chloride preparation of ultra-competent cells 
Rubidium chloride solution 1 (Tbf1) was prepared by dissolving potassium 
acetate (0.29 g), rubidium chloride (RbCl) (1.21 g), calcium chloride (CaCl2) 
(0.11 g), manganese(II)chloride (MnCl2) (0.69 g) and glycerol (15 ml) in 100 ml 
of deionised water. The total concentrations within the solution were 30 mM 
potassium acetate, 100 mM rubidium chloride, 10 mM CaCl2, 50 mM manganese 
chloride and 15% v/v glycerol. The pH of the solution was adjusted to 5.8 with 
dilute acetic acid. The solution was sterilised utilising a 0.2 μm syringe filter and 
stored at 4 °C. 
Rubidium chloride solution 2 (Tbf2) was prepared by dissolving 3-(N-
morpholino)propanesulphonic acid (MOPS) (0.21 mg), CaCl2 (0.83 g), RbCl 
(0.12 g) and glycerol (15% v/v) in 100 ml of deionised water. The pH of the 
solution was adjusted to 6.5 with dilute sodium hydroxide and sterilised 
utilising a 0.2 μm syringe filter. The solution was stored at 4 °C.  
Calcium chloride preparation of competent cells 
Calcium chloride solution 1 (Ca1) was prepared by dissolving CaCl2 (1.11 g) in 
100 ml of deionised water, which gave a concentration of 100 mM. The solution 
was sterilised via autoclave at 121 °C (15 lb in-2) for 20 minutes and stored at 4 
°C. 
Calcium chloride solution 2 (Ca2) was prepared by dissolving CaCl2 (1.11 g) and 
glycerol (15 ml) in 100 ml deionised water, which gave concentrations of 100 
mM CaCl2 and 15% w/v glycerol. The solution was sterilised via autoclave at 
121 °C (15 lb in-2) for 20 minutes and was stored at 4 °C. 
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6.4.4 Non-sterile solutions 
Ethidium Bromide 
A 25 mM stock ethidium bromide solution was prepared by dissolving 8.1 g of 
the solid in 100 ml of deionised water. The solution was stored in the dark at 4 
°C. Immediately prior to gel staining, a solution with a working concentration of 
6 μM was prepared by adding 48 μl of the stock solution to 200 ml of deionised 
water. 
10× DNA loading dye 
0.5% (w/v) Bromophenol blue (2 μl) and glycerol (300 μl) were dissolved in 0.7 
ml of deionised water, yielding total concentrations of 0.001% (w/v) 
bromophenol blue and 30% (v/v) glycerol. The solution was stored at room 
temperature. The dye was diluted 1:9 with each DNA sample immediately prior 
to use. 
TAE buffer stock (50×) for agarose gels 
A 0.5 M EDTA solution was prepared by dissolving EDTA (14.61 g) in 100 ml of 
deionised water, the pH of the solution was then adjusted to 8.0 with 5 M NaOH. 
The solution was then immediately used in the preparation of TAE buffer stock 
(50 ×). 
Tris base (242 g), glacial acetic acid (57 ml) and 0.5 M EDTA (100 ml, pH 8.0) 
were dissolved in 1 l with deionised water, which gave total concentrations of 2 
M tris base, 5.7% acetic acid and 50 mM EDTA. The solution was stored at room 
temperature. The solution was diluted 1:49 with deionised water immediately 
prior to use. 
SDS stacking buffer 
Tris base (6.0 g) was dissolved in 100 ml of deionised water to give a total 
concentration of 0.5 M. The pH of the solution was adjusted to 6.8 with 6 M HCl. 
The solution was stored at room temperature. 
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SDS resolving buffer 
Tris base (27.73 g) was dissolved in 150 ml of deionised water, to give a total 
concentration of 1.5 M. The pH of the solution was adjusted to 8.8 and the 
resulting solution was stored at room temperature. 
10% (w/v) Sodium dodecyl sulfate (SDS) 
Sodium dodecyl sulfate (10.0 g) was dissolved in 100 ml of water. The resulting 
solution was stored at room temperature. 
10% (w/v) Ammonium persulfate 
Ammonium persulfate (100 mg) was dissolved in 1 ml of deionised water. The 
solution was freshly made prior to use. 
SDS electrode running buffer (10×) 
Tris base (30.3 g), glycine (144.0 g), SDS (10.0 g) were dissolved in 1 l of 
deionised water, yielding total concentrations of 0.25 M Tris base, 1.92 M 
glycine and 1% (w/v) SDS. The pH (~8.3) of the solution was not adjusted. The 
solution was stored at room temperature. Immediately prior to use the solution 
was diluted 1:9 with deionised water.  
Protein loading dye 
Tris-HCl, (1.25 ml, pH 6.8) (SDS stacking buffer), glycerol (3 ml), bromophenol 
blue (1 ml) and SDS (2 ml) were mixed and the total volume taken to 10 ml with 
deionised water, to make  total concentrations of 0.5 M Tris-HCl, 30% glycerol, 
0.6% (w/v) bromophenol blue, 10% SDS. β-Mercaptoethanol (β-ME) was added 
to a final concentration of 10% prior to use. 
Protein purification buffer A 
Tris base (4.8 g), EDTA (1.3 g) and β-ME (0.7 ml) were dissolved in 2 l of 
deionised water, to yield total concentrations of 20 mM Tris base, 2 mM EDTA 
and 5 mM β-ME. The pH of the solution was adjusted to 8.0 using 5 M HCl. The 
solution was filtered and degassed via vacuum pump and stored at room 
temperature. 
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Protein purification buffer B 
Tris base (4.8 g), EDTA (1.3 g), β-ME (0.7 ml) and NaCl (120 g) were dissolved 
in 2 l of deionised water, which gave total concentrations of 20 mM Tris base, 2 
mM EDTA, 5 mM β-ME and 1 M NaCl. The pH of the solution was adjusted to 8.0 
using 5 M HCl. The solution was filtered and degassed via vacuum pump) and 
stored at room temperature. 
Protein purification buffer C 
Tris base (4.8 g), EDTA (1.3 g), β-ME (0.7 ml) and NaCl ( 18 g) were dissolved in 
2 l of deionised water, which gave total concentrations of 20 mM Tris base, 2 
mM EDTA, 5 mM β-ME and 0.15 M NaCl. The pH of the solution was adjusted to 
8.0 using 5 M HCl. The solution was filtered and degassed via vacuum pump and 
stored at room temperature. 
Dialysis buffer 
KH2PO4 (174.2 g) and K2HPO4 (136.1 g) were separately dissolved in 1 l of 
deionised water for use as 1 M stock solutions. 
The stock solutions were used to prepare the dialysis buffer for the protein. 
12.3 ml of K2HPO4 stock solution and 7.7 ml of KH2PO4 stock solution were 
diluted in 4 l of deionised water, along with 2.6 g of EDTA and 1.4 ml of β-ME to 
give final concentrations of 5 mM, 2 mM and 5 mM respectively. The pH of the 
solution was adjusted to 7.0. The buffer was prepared fresh each time and the 
dialysis was performed at 4 °C. 
DNA miniprep buffers 
Buffer P1 (suspension buffer)  
Tris-HCl (157.6 mg) and EDTA (58.4 mg) and were dissolved in 100 ml of 
deionised water, to give total concentrations of 50 mM and 10 mM. The pH of 
the solution was then adjusted to 8.0. RNAase (50 μg/ml final concentration) 
was dissolved and the solution was stored at 4 °C.  
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Buffer P2 (lysis buffer) 
NaOH (4 g) and SDS (5 g) were dissolved separately in 250 ml of deionised 
water, to give concentrations of 0.4 M and 2% (w/v) these solutions were then 
mixed 1:1. The solution was stored at room temperature. 
Buffer N3 (neutralisation and binding buffer) 
Guanidine hydrochloride (7.6 g) and potassium acetate (981.4 mg) were 
dissolved in 20 ml of deionised water, to give concentrations of 4 M and 0.5 M 
respectively. The pH of the solution was adjusted to 4.2 and was stored at room 
temperature. 
Buffer PB (wash buffer) 
Guanidine hydrochloride (95.5 g) and Tris-HCl (6.3 mg) were dissolved in 125 
ml of deionised water. The pH of the solution was adjusted to 6.6 and 76 ml of 
ethanol was added, to give total concentrations of 5 M and 2 mM. The solution 
was stored at room temperature. 
Buffer PE (wash buffer) 
NaCl (0.117 g) and Tris-HCl (3.1 mg) were dissolved in 20 ml of deionised 
water. The pH of the solution was adjusted to 7.5 and 80 ml of ethanol was 
added, where the total concentrations are 20 mM NaCl and 3 mM Tris-HCl,. The 
solution was stored at room temperature. 
Buffer EB (elution buffer) 
Tris-HCl (32 mg,) was dissolved in 20 ml of deionised water and the pH of the 
solution was adjusted to 8.5, where the concentration of Tris-HCl is 10 mM. The 
solution was stored at room temperature. 
Agarose gel DNA isolation buffers 
Buffer QG (gel solubilisation buffer) 
Guanidine thiocyanate (13.0 g) and Tris-HCl (6.3 mg) were dissolved in 20 ml of 
deioised water, yielding total concentrations of 5.5 M guanidine thiocyanate and 
20 mM Tris-HCl. The pH of the solution was adjusted to 6.6 and stored at room 
temperature. 
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Buffer PE (wash buffer) 
NaCl (0.117 g) and Tris-HCl (3.1 mg) were dissolved in 20 ml of deionised 
water, where the total concentrations are 20 mM NaCl and 2 mM Tris-HCl. The 
pH of the solution was adjusted to 7.5 and 80 ml of ethanol was added. The 
solution was stored at room temperature. 
Buffer EB (elution buffer) 
Tris-HCl (32 mg) was dissolved in 20 ml of deionised water, the total 
concentration was 10 mM Tris-HCl. The pH of the solution was adjusted to 8.5. 
The solution was stored at room temperature. 
6.4.5 E. coli strains and their preparation 
Cloning strains 
XL1-Blue ® Super competent cells (Stratagene, CA, USA) were utilised for the 
preparation of new plasmid constructs since they are highly proficient in 
replicating DNA, creating high concentrations of the desired plasmid, with an 
efficiency of ≥1 × 108 colony forming units per μg.245 
Expression strains 
BL21-CodonPlus(DE3)-RP competent cells and BL21-CodonPlus(DE3)-RIL 
competent cells (Stratagene, CA, USA) were used for the expression of the 
porcine pPEF(S) gene. These two strains of E. coli contain extra genes that 
encode for arginine and proline tRNA in the case of the BL21-CodonPlus(DE3)-
RP cells and with BL21-CodonPlus(DE3)-RIL cells there are genes that encode 
for the tRNA of arginine, isoleucine and leucine.246 The excess tRNA allows for 
the efficient expression of proteins that contain a large quantity of these amino 
acids.246 
Preparation of super-competent cells 
50 μl of cells in calcium chloride solution 2 (Section 6.4.3) was added to 100 ml 
of non-selective LB medium, the culture was incubated overnight at 37 °C. 1 ml 
of this culture was utilised to inoculate 100 ml of fresh non-selective LB media. 
The culture was allowed to grow until an OD of 0.6 at 600 nm was reached after 
which time the cells were chilled on ice for at least 20 min. The cells were 
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harvested by centrifugation (Eppendorf centrifuge 5810R) at 3220 RCF for 10 
min at 4 °C and the supernatant solution was discarded. The pellet was then re-
suspended in 20 ml of Tbf1 solution and incubated on ice for 20 minutes; the 
centrifugation step was then repeated and the supernatant solution was 
discarded once more. The pellet was then resuspended in 5 ml of Tbf2 solution, 
the suspension was then left on ice for 20 min and aliquoted (50 µl) into sterile 
Eppendorf tubes and flash frozen in liquid nitrogen for storage at -80 °C. 
Preparation of competent cells for protein expression 
50 μl of cells in calcium chloride solution 2 (Section 6.4.3) was added to 100 ml 
of non-selective LB medium, the culture was incubated overnight at 37 °C. 1 ml 
of this culture was utilised to inoculate 100 ml of fresh non-selective LB 
medium. The culture was allowed to grow until an OD of 0.6 at 600 nm was 
reached after which time the cells were chilled on ice for at least 20 min. The 
cells were harvested by cenrtrifugation (Eppendorf centrifuge 5810R) at 3220 
RCF for 10 min at 4 °C and the supernatant solution was discarded. The pellet 
was then re-suspended in 20 ml of Ca1 solution and incubated on ice for 20 min, 
the centrifugation step was then repeated and the supernatant solution 
discarded once more. The pellet was resuspended in 5 ml of Ca2 solution and 
the solution was chilled on ice for 20 min. The suspension was then aliquoted 
(50 µl) into sterile Eppendorf tubes and flash frozen in liquid nitrogen for 
storage at -80 °C. 
Transformation protocols and controls 
The appropriate competent cells were allowed to thaw on ice. DNA solution was 
thawed on ice and 1 µl of this solution was transferred into the cell suspension, 
mixing with the pipette tip under sterile conditions. The cell/DNA mixture was 
incubated for 20 minutes on ice, then heat shocked at 40 °C for 40 seconds and 
returned to the ice for a minimum of 2 minutes. Non-selective LB medium was 
added to the solution and the cells were incubated for 1 hour 37 °C. The cells 
were harvested utilising a centrifugation in (Eppendorf centrifuge 5415R) at 
16,100 RCF for 1 minute, the supernatant solution was discarded. The pellet 
was re-suspended in 100 µl of LB medium and plated onto agar plates that 
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contained the appropriate antibiotic. The plated cells were incubated at 37 °C 
overnight. 
A negative control experiment was also carried out, whereby water was 
substituted for the DNA solution. No cells grew on these experiments. 
6.4.6  DNA Manipulation 
Growth and Purification of Plasmid DNA 
A single colony was extracted from the ampicillin selective plate (vide supra) 
and placed into 10 ml LB medium containing ampicillin (1 μg/ml), the culture 
was incubated overnight at 37 °C with shaking at 150 rpm in an Innova® 43 
shaker (New Brunswick Scientific, Hertfordshire, UK). The cells were then 
harvested via centrifugation (Eppendorf centrifuge 5810R) for 10 minutes at 
3220 RCF, the supernatant solution was discarded. The plasmids were isolated 
via the QIAprep spin miniprep kit with the pellet initially re-suspended in buffer 
P1 (250 µl). Cells underwent lysis via the alkaline lysis buffer. Buffer P2 (250 µl) 
was then added, followed by buffer N3 (350 µl) the solution was mixed then 
cells were harvested by centrifugation (Eppendorf centrifuge 5415R) for 10 min 
at 16100 RCF. The supernatant solution was collected and added to a spin 
column where the plasmid then binds to the filter. The centrifugation step was 
then repeated for 1 minute at 16,100 RCF and the flow through solution was 
discarded.  To the spin column PB buffer (0.5 ml) was added and the previous 
centrifugation step repeated, the flow through solution was once again 
discarded. Buffer PE (0.75 ml) was then added to the spin column for the 
washing step, the centrifugation step was repeated, the flow through solution 
was discarded and to ensure all the ethanol was removed the centrifugation 
step was repeated once more. The miniprep filter was then placed in a clean 
Eppendorf tube, EB buffer (50 µl) was added and this was left to stand for a 
minimum for 1 minute, centrifugation was then repeated, during this final step 
the plasmid DNA was washed from the column and collected in an Eppendorf 
tube. The purified DNA solution was then stored at -20 °C. 
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Restriction Digestion of DNA 
For each restriction digest the manufacturer’s guidelines were followed with 
regards to operating buffers, temperatures and denaturation steps. NcoI and 
BamHI were used for the excision of the PEF(S) gene from the pBSK vector. NcoI 
and BamHI were incubated at the same temperature (37 °C) for 3 hours and 4 
hours respectively. The restriction endonucleases were removed by agarose gel 
electrophoresis. 
DNA Visualisation, Isolation and Purification 
The agarose gels were prepared with a w/v ratio of 1% with 1 × TAE buffer 
(vide supra). Gels were run at a constant voltage of 100 V for 60 minutes, they 
were then stained with 6 µM ethidium bromide for 20 minutes whilst stirring. 
The DNA was visualised utilising a Syngene GeneFlash UV light box (Syngene, 
Cambridge, UK), this ensured limited exposure to UV light. The bands that were 
visualised were compared to the 1 kb DNA ladder (0.5 kb, 1.0 kb, 1.5 kb, 2.0 kb, 
3.0 kb, 4.0 kb, 5.0 kb, 6.0 kb, 8.0 kb and 10.0 kb), the desired bands were then 
identified and where appropriate they were cut from the gel with a clean scalpel 
blade and placed into an Eppendorf tube. In order to extract the DNA from the 
agarose gel the QIA gel extraction kit (QIAGEN, Crawley, UK) (Section 6.4.4) was 
used. Initially the gel was suspended in QG buffer the volume of which was 3 
times that of the weight of the gel within the Eppendorf tube. The suspension 
was placed in a heat block for 10 min at 50 °C. After this a volume equal to the 
calculated weight of the gel of isopropanol was added to the Eppendorf tube, 
the solution was then placed into a spin column and centrifuged (Eppendorf 
centrifuge 5415R), for 1 minute at 16,100 RCF, the flow through solution was 
discarded. The DNA that was bound to the membrane was washed with 0.5 ml 
of QG buffer and the centrifuge step repeated followed addition of 0.75 ml of PE 
buffer. The centrifuge step was repeated twice and the DNA bound to the 
membrane was then inserted into a 1 ml Eppendorf tube and 50 µl of EB buffer 
was added and the solution left to stand for 1 minute. The sample was collected 
through centrifugation using the conditions mentioned above and stored at -20 
°C. 
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Cloning of PEF(S) into expression vector pET21d 
The PEF(S) gene in the pBSK vector was subjected to sequential Nco1 and 
BamH1 restriction endonuclease treatment (vide supra). A pET21d vector 
containing a gene encoding for wtAS (wild type Aristolochene Synthase, from 
lab stocks) was also subjected to a sequential NcoI and BamHI restriction 
endonuclease digest. Following each digestion the restriction endonucleases, 
plasmid and insert were separated using agarose gel electrophoresis, the gel 
was then visualised and the bands indicating the expression vector and the 
PEF(S) gene were isolated and purified (vide supra). 
Digested pET21d and the PEF(S) gene were ligated under two different 
conditions indicated in Table 6.1. 
Ligation Component (μl) 
 Plasmid Gene T4 ligase Buffer dH2O T4 Ligase 
A 1 3 1.5 9 1 
B 1 6 1.5 6 1 
 
Table 6.1: Components used for the ligation of the PEF(S) gene and the pET21d expression vector. 
The ligation temperature was varied between 4 °C and 22 °C, with 20 seconds 
for each 1 °C increase and decrease, with 4 cycles in total. Super-competant E. 
coli XL1 Blue cells were then transformed with 5 μl of each ligation mixture. 
DNA Sequencing 
Upon isolation of the plasmid DNA from the appropriate cloning strain using the 
QIA spin miniprep kit (QIAGEN, Crawley, UK) (Section 6.4.4) to give pure DNA 
at a concentration of ~100 ng/µl. DNA sequencing of the plasmid constructs 
was carried out by School of Biosciences, Cardiff University, Cardiff, UK. 
6.4.7 Protein production and purification 
Purification of the protein was carried out utilising an ÄKTA fast protein liquid 
chromatography (FPLC) (GE Healthcare, Buckinghamshire, UK). The pump that 
was used for the buffers was an UP-920 and the buffers were mixed to achieve 
the desired gradient with a M-925 gradient controller. The samples were 
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injected on to the column with an INV-907 injection valve and the UV analysis 
that was carried out with a UPC-900 detector. 
Small scale test-expression of the PEF(S) gene 
A small scale test expression was carried out prior to large scale production of 
protein, this was to ensure that the cells grew to an optical density (OD) of 0.6 
at 600 nm and to ensure that upon induction of the gene, with IPTG, a sufficient 
quantity of protein was produced. To ampicillin (1 μg/ml) selective LB medium 
(500 ml) 5 ml of overnight culture was added of BL21-CodonPlus(DE3)-RP cells 
containing thepET21d-PEF(S) construct. The culture was allowed to reach the 
desired OD at 37 °C. IPTG was used to induce gene expression, which continued 
for 16 hours in total. 1 ml samples were collected prior to induction and every 
hour subsequently, these samples were analysed utilising SDS-PAGE.  
This process was also carried out with the BL21-CodonPlus(DE3)-RIL cells that 
contained the pET21d-PEF(S) construct. 
Large scale expression of the PEF(S) gene 
BL21-CodonPlus-(DE3)-RP competent cells were transformed with the 
appropriate DNA solution and incubated overnight on ampicillin selective agar 
plates at 37 °C. A single colony was retrieved in order to inoculate 100 ml of 
ampicillin selective (1 μg/ml) LB medium, which was incubated overnight at 37 
°C whilst shaking at 150 rpm in an Innova® 43 shaker (New Brunswick 
Scientific, Hertfordshire, UK). 6 × 5 ml of the overnight pre-culture was utilised 
to inoculate 6 x 500 ml of ampicillin selective (1 μg/ml) LB medium. The culture 
was incubated at 37 °C whilst shaking as previously described until an OD of 0.6 
a.u. at 600 nm was reached and IPTG (0.5 mM) was then added and the 
incubation was continued for a further 3 hours. 
After this time period the cells were then harvested via centrifugation in a 
Sorvall RC6 Plus centrifuge (Thermo Fisher Scientific, Inc, MA, USA) using an 
SLA-3000 rotor at 6080 RCF for 15 minutes. The pellets were then stored at -20 
°C. 
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Anion exchange chromatography 
Frozen cell pellets were allowed to thaw on ice. The cells were then re-
suspended in protein purification buffer A (Section 6.4.4) and lysed by 
sonication on ice (5 seconds sonication period followed by 10 seconds off, this 
sequence was run for 3 minutes in total), The solution was clarified through 
centrifugation at 5 °C for 40 minutes at 30310 RCF in a Sorvall RC6 Plus 
centrifuge. The supernatant solution was then removed from the debris and 
filtered with a 0.2 µm syringe tip filter. The supernatant solution was then 
applied to a diethylaminoethyl (DEAE) anion exchange column which was 
attached to a Fast Protein Liquid Chromatography instrument (FPLC) (ÄKTA 
FPLC).  The DEAE column had a column volume (CV) of ~60 ml. The flow-
through was collected and the column was washed with protein purification 
buffer A (Section 6.4.4) until the UV absorbance (280 nm) reached 
approximately the baseline absorbance. A two-stage NaCl gradient was applied 
to the column, with 0.0-0.5 M NaCl (50 % protein purification buffer B, section 
6.4.4) over 4 CV, followed by 0.5-1.0 M NaCl (50-100% protein purification 
buffer B, Section 6.4.4) over 1 CV. The column was washed with protein 
purification buffer B (Section 6.4.4) for 1 CV and then stored under high (1 M) 
salt conditions at 4 °C. The flow rate was set to 10 ml/min throughout the 
purification process. The absorbance was monitored at 280 nm and fractions (6 
ml) were collected from 0-50% buffer B. SDS-PAGE was carried out on each of 
the fractions that demonstrated a high absorbance from the UV monitoring.  
The fractions containing the desired protein as indicated by the SDS-PAGE 
analysis were pooled in preparation for purification with size exclusion 
chromatography (vide infra) 
Size exclusion chromatography 
The eluent from the DEAE column which contained PEF(S) was concentrated 
via Amicon to around 15 ml. The concentrated sample was loaded onto a 
SuperDex 75 column (320 ml column volume) which had been equilibrated 
with protein purification buffer C (Section 6.4.4). The column was eluted with 
1.5 CV (480 ml) of protein purification buffer C (at 2.5 ml/min) and the 
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absorbance was monitored at 280 nm. 10 ml fractions were collected and SDS-
PAGE analysis was used to determine the point of elution of the desired protein. 
The fractions containing the desired protein were then pooled and dialysed 
against 3 changes of 4 l of dialysis buffer 2 (Section 6.4.4) at 4 °C. 
Analytical size exclusion chromatography 
For the calibration of the SuperDex 75 column (26 ml column volume) three 
proteins were used; bovine serum albumin (MW 66,000), trypsin inhibitor from 
soya beans (MW 20,090) and RNAase A (MW 13,700). A 0.5 ml sample 
containing each protein at a concentration of 2.5 mg/ml was loaded onto the 
column which had been equilibrated with protein purification buffer C. The 
column was eluted with 1.5 CV (39 ml) of protein purification buffer C (at 0.5 
ml/min) and the absorbance was monitored at 280 nm.  
A 0.5 ml sample was taken from the eluted fractions of PEF(S) from the 
preparative SuperDex 75 (320 ml) and was loaded on to the analytical 
SuperDex 75 (26 ml), which had been equilibrated with protein purification 
buffer C. The column was eluted with 1.5 CV (39 ml) of protein purification 
buffer C (at 0.5 ml/min) and the absorbance was monitored at 280 nm.  
Protein storage 
The protein was stored in a buffer solution with a final concentration of 5 mM 
KiPO4, 2 mM EDTA and 5 mM βME at pH 7.0. The solution was stored at 4 °C.  
Protein concentration determination 
Potassium phosphate (100 mM, pH 7.0) was filtered and degassed using a 
vacuum pump. The Beer-Lambert law was used to calculate the concentration 
(mg/ml) of the protein solution (Equation 6.1).  
 , and therefore     
Equation 6.1: The equation for measuring the concentration of protein within solution through 
UV-Vis analysis. Where A = absorbance at a given wavelength, ε = extinction coefficient, c = the 
concentration, l = the path length of the cuvette (cm) and df is the dilution factor. 
Average extinction coefficients for proteins at the wavelengths of 210, 215 and 
220nm are 20, 15 and 11.217 These were utilised to determine the concentration 
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of the protein. The measurements were obtained using a Jasco V-660 UV-Vis 
spectrophotometer (Jasco UK, Essex, UK), with the temperature controlled with 
a Peltier cooler. 
The concentrations were converted into micromolar concentrations, this was 
done using the concentration in mg/ml that was obtained from the equation 
was divided by the molecular weight of the protein (19,993 for pPEF(S)), 
multiplied by 106. 
SDS-PAGE protocol 
The gel, composed of two parts, the resolving and stacking solutions were 
prepared as described in Table 6.2. 
Component Resolving solution 
(ml) 
Stacking solution 
(ml) 
H2O 3.4 5.7 
Gel buffer 2.5 2.5 
30% Acrylamide solution 
(with bis-acrylamide) 
4.0 1.7 
10% SDS solution 0.1 0.1 
Table 6.2: Components in the resolving and stacking solutions for SDS-PAGE gel preparation. 
Prior to pouring the resolving solution freshly prepared ammonium persulfate 
solution (APS, 100 μl) (10% w/v in dH2O) and 15 μl of N,N,N’,N’-
tetramethylenediamine (TEMED) were added to the resolving solution, and for 
the stacking solution 100 μl of 10% APS and 20 μl of TEMED. Solutions were 
stirred in order to initiate polymerisation. When the resolving solution was 
poured it was covered with a layer of isopropanol and allowed to polymerise. 
Once the resolving solution had polymerised, the isopropanol was then 
removed with blotting paper, the stacking gel was poured on top and a comb 
was inserted to create the wells for sample loading. 
6.4.8  MALDI-TOF mass spectrometry 
The standard matrix solution used as a carrier for the protein of interest was a 
10 mg/ml solution of sinapinic acid in a 1:3 acetonitrile to water (0.1% 
trifluoroacetic acid). 1.75 µl of the carrier solution was mixed with 1.75 µl of 
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protein solution. Various concentrations of the protein solution were set-up 
from the concentration that was determined from the UV-Vis measurements 
(vide supra), these ranged from 5-100 µM.  
A MALDI-TOF Micro MX spectrophotometer (Waters, Manchester, UK) was used 
in linear mode, positive polarity and the mass range was 5,000-30,000. 
6.4.9 Circular Dichroism spectroscopy 
All circular dichroism spectroscopy was out on the ChirascanTM apparatus 
(Applied Photophysics Limited, UK). 
CD spectroscopy Buffers 
A 10 mM KiPO4 buffer at pH 7.0 was used for the denaturation experiments, the 
buffer was sterilised using a 0.2 µm syringe and it was then degassed under 
reduced pressure. A blank measurement was taken of the buffer alone prior to 
the experiment. 
Calculation of the Mean Residue Ellipticity (MRE) 
In order to calculate the MRE from the signal obtained from the CD experiments 
Equation 6.2 was used. 
          
Equation 6.2: The equation for calculating the mean residue epilicity. Where: Θ = CD signal 
(millidegrees), n = number of back bone peptide bonds (i.e. number of amino acid residues minus 
1), c = molecular concentration and l = the path length of the cuvette used (cm). 
The cuvette that was used had a path length of 0.1 cm and a total volume of 350 
μl. The CD spectra of PEF(S) were collected from 190-350 nm. CD spectra were 
collected at 20 °C and the total concentration of PEF(S) was ~ 20 µm.  
6.4.10 Analysis of protein-inhibitor affinity by fluorsecence spectroscopy 
The fluorescence spectra were obtained with the use of a Perkin-Elmer LS-22 
Luminescence Spectrometer (Perkin-Elmer, Buckinghamshire, UK), which was 
attached to a Julabo F25 water bath (Julabo, Seelbach, Germany). 
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3 ml samples containing; 20 μM TNS (6-(p-toluidino)-2-naphthanlenesulfonic 
acid) in 20 mM Tris.HCl, 0.1 mM EDTA and 20 μM PEF(S) were incubated for 5 
minutes in a fluorescence cuvette at 20 °C (pH 7.4). The incubations took place 
both with and without 1.1 mM CaCl2. The fluorescence spectra were obtained 
with an excitation wavelength of 340 nm and the data collected over a range of 
350 nm to 600 nm, with the slit widths of 15 nm and 5 nm for excitation and the 
emission slits respectively. 5 μl of a 50 mM solution of (Z)-3-(-4-bromophenyl)-
2-mercaptoacrylic acid was added to the solution, which gave an overall 
concentration of 83 μM. The sample was analysed in the fluorimeter with the 
same conditions mentioned previously in order to detect a change. 
6.5 Protein crystallography 
All consumables for the purpose of protein crystallography were purchased 
from Molecular Dimensions Ltd (Suffolk, UK).  
6.5.1  Screening solutions 
General screen solutions 
All general screens were purchased from Molecular Dimensions Ltd (Suffolk, 
UK), these screens were used to obtain the optimum crystallisation conditions 
for PEF(S). The 3 screens that were used were; JCSG-plusTM HT-96, PACT 
premierTM HT-96 and ProPlex HT-96.223, 224, 226 
Crystallisation precipitant 1 
HEPES (1.19 g), 1.4 M sodium citrate  (20.59 g) with 20 mM CaCl2 (0.11 g) was 
dissolved in 50 ml of deionised water resulting in concentrations of 0.1 M 
HEPES, 1.4 M sodium citrate and 20 mM CaCl2. The pH of the solution was 
adjusted to 7.0 with 1 M NaOH. The solution was filtered with a syringe tip filter 
(0.2 μm) and stored at 20 °C. 
Crystallisation precipitant 2 
Sodium cacodylate (0.54 g), PEG6000 (6.25 g) and CaCl2 (0.11 g) were dissolved 
in 50 ml of deionised water, resulting in final concentrations of 50 mM sodium 
cacodylate, 12.5% (w/v)PEG6000 and 20 mM CaCl2. The pH of the solution was 
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adjusted to 7.4 with 5 M NaOH. The solution was filtered with a 0.22 μm syringe 
tip filter and stored at 20 °C. 
6.5.2 Protein preparation 
Protein solution 1 
The protein was purified and dialysed into dialysis buffer 1 (Section 6.4.4), then 
concentrated in an Amicon with a MW cut-off of 10,000, until the concentration 
became at least 5 mg/ml. 
Protein solution 2 
Sodium cacodylate (1.07 g), EDTA (0.65 g), β-ME (350 μl) and CaCl2 (0.11 
g)were dissolved in 1 l of deionised water, resulting in the final concentrations 
of 5 mM  sodium cacodylate, 2 mM EDTA, 5 mM β-ME and 1 mM CaCl2 . The pH 
of the solution was adjusted to 7.0 with 5 M NaOH. The solution was then stored 
at 20 °C. 
PEF(S) was purified (Section 6.4.7) and concentrated using a protein spin 
column with a molecular weight cut-off of 10,000. The protein was then washed 
(4 times) with the protein solution 2 (vide supra), to ensure that the buffer was 
fully exchanged. The protein was concentrated to ~10 mg/ml.  
6.5.3 Crystal plate set-up 
General screen setup 
An Art-Robbins Phoenix dispensing robot (Alpha Biotech, Glasgow, UK) was 
used in the process of setting up the screens. The robot was initially cleaned 
with 0.5 M NaOH which is followed by a washing step with deionised water. A 
40 µl aliquot of protein sample was placed into a 200 µl Eppendorf tube, the 
solution was centrifuged at 3381 RCF for 30 seconds. The protein sample was 
then placed in the robot, along with the general screen solutions (Section 6.5.1) 
and a 96 well Intelliwell II crystallisation plate. 60 µl volumes of the broad 
screen solutions were placed into each deep well of the crystallisation plate and 
0.2 µl of the broad screen solution was placed into the sitting drop depression. 
The protein solution was dispensed in 0.2 µl aliquots into each of the sitting 
drop wells on the crystallisation plate. The plate was then removed from the 
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robot and sealed with Easy Seal DWB sheets (Molecular Dimensions Ltd, 
Suffolk, UK).  
Before the crystal plate was stored in an incubator at 20 °C each drop 
photographed with a microscope at a magnification of 3.0 (Leica Microsystems, 
Buckinghamshire UK) equipped with a camera (Leica Microsystems, 
Buckinghamshire UK). The plates were scanned 24 hrs after set-up and every 
48 hrs subsequently to that until crystals formed. 
Crystallisation plate set-up 1 
Using a 48 well sitting drop plate (Molecular Dimensions Ltd, Suffolk, UK), 300 
µl of crystallisation precipitant 1 (Section 6.5.1) was manually added to the 
deep well and 1 µl of crystallisation precipitant 1 (Section 6.5.1) in the sitting 
drop, in each well of the 48 well crystallisation plate. To each drop, 1 µl of 
protein solution 1 (Section 6.5.2) was added. The plate was then sealed with 
Easy Seal DWB sheets (Molecular Dimensions Ltd, Suffolk, UK). The plates were 
viewed under a microscope (Zeiss Vert.A1. AX10 (Cambridge, UK)) at 5 × 
magnification straight after set-up. The plates were stored at 20 °C and viewed 
24 hrs after set-up and every 48 hrs subsequently, until crystals form. 
Crystallisation plate set-up 2 
The EasyXtal 24 well plates (Qiagen, Crawley, UK) were set-up using the 
hanging drop vapour diffusion method. 1 ml of crystallisation precipitant 2 
(Section 6.5.1) was placed in the well. The drops contained 3 μl of the 
crystallisation precipitant 2 (Section 6.5.1), 1 μl of deionised H2O and 3 μl of 
protein solution 2 (Section 6.5.2) onto the screw cap lid. The lid of the wells 
were sealed and the plate stored at 20 °C until crystals formed. The plates were 
viewed under a microscope (Zeiss Vert.A1. AX10 (Cambridge, UK)) at 5 × 
magnification straight after set-up (images were collected with a Ziess Axio Cam 
MRm camera (Cambridge, UK)). The plates were stored at 20 °C and viewed 24 
hours after set-up and every 48 hours subsequently, until crystals form.The 
crystals normally took 3 days to appear within the hanging drop.  
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6.5.4 Soak set-up 
Soaks of the crystals formed in crystallisation precipitant 1 
Concentation of the 
ligand/mM 
Volume
/μl 
Concentration of the 
protein/mM 
Ratio 
/Ligand:PEF(S) 
0.5 0.5 0.25 2:1 
0.75 0.75 0.25 3:1 
1.0 1 0.25 4:1 
 Table 6.3: The concentrations of the inhibitor used in the soaking expreriments of the inhibitors 
into the crystallised PEF(S), using a stock solution of 2 mM of the ligands. 
50 mM stock solutions (1 ml) of the mercaptoacrylic acid derivatives (Section 
6.1.5) in DMSO were used to make the solutions for soaking the protein. The 
stock solution was diluted with crystallisation precipitant 1 to 2 mM. The screw 
caps were removed and the diluted stock solutions were added to the sitting 
drop containing the crystals in the concentrations listed in Table 6.3. The soaks 
were carried out both with and without 10 mM DTT. 
Soaks of the crystals formed in crystallisation precipitant 2 
With crystallisation precipitant 2 the stock solutions were diluted to 8 mM. The 
screw caps were then removed from the wells containing crystals and 1 μl of 
the solution was added to the 7 μl drop containing the crystals, taking the total 
concentration of the inhibitor to 1 mM. Therefore the ratio of PEF(S) to the 
ligand was 1:2, as the concentration of the protein in the drop solution was 
~200 μM (~4 mg/ml). The wells were re-sealed and the plates were stored at 
20 °C for 16 hours until the crystals were collected. 
6.5.5 Crystal harvesting and data collection 
Crystal collection 
The cover was removed from each well where crystals were found, 100 to 300 
µm loops were used to harvest the crystals. Each crystal collected by the loop 
was then flash frozen in liquid nitrogen and placed into a position in the 
transport puck. The puck contains spaces for 16 samples and was kept in liquid 
nitrogen until the samples reached the synchrotron (Diamond Light Source, 
Oxford, UK). 
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Data collection and refinement  
Data was collected at Diamond Light Source (Oxfordshire, UK) at 100 K; all data 
were collected at 0.976 Å with a Pilatus pixelated detector. The raw diffraction 
images were processed through the xia2 data-reduction system. The data were 
scaled, reduced and analysed using the Scala program from the CCP4i package 
(Collaborative Computational Project number 4).227  
Molecular replacement was done with Phaser (CCP4i) with a model derived 
from the structure of PEF(S)(PDB: 1NX2 and 1ALV).81, 186, 228 The model 
obtained was adjusted with the COOT program (Crystallographic Object-
Oreinted Toolkit) for molecular model building, and completion, the model was 
refined further with the Refmac5 refinement program.229, 230   
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